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Zusammenfassung
Mitglieder der Familie der vaskulären endothelialen Wachstumsfaktoren (VEGF) und
ihre Rezeptoren (VEGFR) spielen eine wesentliche Rolle in der Entstehung und
Aufrechterhaltung des physiologischen Blut- und Lymphgefässystems. Desweiteren werden
die fünf bis anhin in Säugetieren entdeckten VEGFs, VEGF-A, -B, -C, -D und der plazentare
Wachstumsfaktor (PlGF), während der Tumorigenese hochreguliert und sind an der
Tumorangiogenese und -lymphangiogenese beteiligt. VEGF-A als zentraler angiogener
Wachstumsfaktor fördert die Tumorangiogenese und damit das Tumorwachstum und die
–progression durch Aktivierung von VEGFR-1 und –2, die auf Blutgefässendothelzellen
exprimiert werden. Im Gegensatz dazu führt die Hochregulierung des lymphangiogenen
Wachstumsfaktors VEGF-C, einem Liganden für den lymphatischen VEGFR-3 sowie für
VEGFR-2, zur Neubildung von tumorassoziierten Lymphgefässen und fördert damit die
passive Metastasierung von Tumorzellen zu regionalen Lymphknoten. Über die
Auswirkungen von tumoralem VEGF-B und PlGF, zwei selektiven Liganden für VEGFR-1,
sowie VEGF-D, dem zweiten lymphangiogenen Wachstumsfaktor und Liganden von
VEGFR-3 und -2, ist hingegen wenig bekannt. Desweiteren macht die kürzliche Entdeckung
von selektiven Liganden für VEGFR-2 und –3, namentlich VEGF-E und VEGF-C156S, eine
Untersuchung der spezifischen Rolle dieser Rezeptoren möglich.
Um die Funktionen von VEGF-D unter physiologischen Bedingungen zu studieren
habe ich transgene Mäuse analysiert, die VEGF-D spezifisch in β-Zellen der pankreatischen
Langerhans’schen Inseln exprimieren (Rip1VEGF-D). Die transgene Expression von VEGF-
D im endokrinen Pankreasgewebe dieser transgenen Mäuse induziert die Neubildung von
grossen lymphatischen Lakunen um einen Grossteil der Inseln. Häufig enthalten diese
Gefässe Anhäufungen von Immunzellen, die wahrscheinlich infolge der Dysfunktion einiger
peri-insulären Lymphgefässe entstehen. Als Folge von Blut-Lymphgefäss-Verbindungen
enthalten lymphatische Lakunen auch häufig Erythrozyten und Blutungen, die bis in die
regionalen Lymphknoten drainiert werden und damit indirekt die Funktionalität der meisten
neugebildeten Lymphgefässe beweisen. Um den Einfluss von tumorexprimiertem VEGF-D
auf die Tumorigenese zu erforschen, habe ich diese Mäuse mit Rip1Tag2 Mäusen gekreuzt,
einem etablierten transgenen Mausmodell für β-Zell Karzinogenese. Wie in der zuvor
beschriebenen einzel-transgenen Maus fördert das durch Rip1Tag2 Tumorzellen produzierte
VEGF-D das Wachstum von peri-tumoralen Lymphgefässen, die häufig
Immunzellanhäufungen und Blutungen enthalten. Gleichzeitig weisen diese doppel-
transgenen Mäuse eine hohe Inzidenz von Metastasen in regionalen Lymphknoten als auch in
der Lunge auf. Da die Expression von VEGF-D das invasive Verhalten der Tumoren nicht
direkt beeinflusst und da alle Metastasen gut differenziert sind, fördert VEGF-D die
lymphogene Metastasierung sehr wahrscheinlich durch die Neubildung von Lymphgefässen.
Interessanterweise bewirkt die Expression von VEGF-D eine signifikante Hemmung der
Tumorangiogenese und des Tumorwachstums durch einen bislang unbekannten
Mechanismus. Eine kürzlich publizierte Studie über die Auswirkungen von VEGF-C auf die
Rip1Tag2 Tumorigenese berichtet, dass die Expression dieses Wachstumsfaktors die
Metastasierung zu regionalen Lymphknoten, jedoch nicht in die Lunge, durch die
Stimulierung von tumor-assoziierter Lymphangiogenese fördert. Überdies weisen diese
Mäuse keine intra-tumoralen Immunzellanhäufungen oder Blutungen auf, und die
Tumorangiogenese und das Tumorwachstum werden durch die Expression von VEGF-C
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nicht beeinflusst. Die Anwendung des Rip1Tag2 Tumormodells hat es mir ermöglicht, nicht
nur Ähnlichkeiten sondern auch signifikante funktionelle Unterschiede von VEGF-C und
VEGF-D zu ermitteln. Interessanterweise führte die syngene und allogene Tranplantation von
VEGF-D produzierenden Rip1Tag2 Tumorzellinien in die Haut von transgenen Mäusen zur
Bildung von Tumoren, die dichte intra- jedoch keine peri-tumorale Lymphgefässnetzwerke
aufweisen. Überdies beeinflusst die Expression von VEGF-D auch die Angiogenese dieser
Tumoren nicht Diese Beobachtungen zeigen, dass das tumorumgebende Milieu die von
VEGF-D induzierten Effekte grundlegend beeinflusst.
Da VEGF-C und –D sowohl VEGFR-3 als auch –2 binden können, ist bislang nicht
erforscht, ob die selektive Aktivierung von VEGFR-3 ausreicht um Tumor
Lymphangiogenese und dadurch die lymphogene Metastasierung zu fördern. Daher habe ich
transgene Mäuse generiert, die VEGF-C156S im endokrinen Pankreas exprimieren und habe
diese Mäuse mit Rip1Tag2 Mäusen gekreuzt. Die Analyse der einzel- und doppel-transgenen
Mäuse hat ergeben, dass VEGF-C156S VEGF-C in allen untersuchten Parametern imitiert
und beweist damit, dass die Aktivierung von VEGFR-3 genügt, um tumor-assoziierte
Lymphangiogenese und lymphogene Metastasierung zu fördern. Die Hemmung von VEGFR-
3 könnte daher durchaus zur Hemmung der Metastasenbildung beitragen.
Um die spezifischen Rollen von VEGFR-1 und –2 unter physiologischen als auch
malignen Bedingungen besser zu verstehen, habe ich transgene Mäuse hergestellt, in denen
die VEGFR-1-spezifischen Liganden VEGF-B167 und PlGF-1 sowie der VEGFR-2-
spezifische Ligand VEGF-ED1701 im endokrinen Pankreas exprimiert werden (Rip1VEGF-
B167, Rip1PlGF-1, und Rip1VEGF-ED1701 Mäuse). Diese einzeltransgenen Mäuse wurden vor
allem auf Veränderungen der Blutgefässmorphologie und –dichte untersucht. In einem
zweiten Schritt habe ich einzeltransgene Mäuse mit Rip1Tag2 Tumormäusen gekreuzt. Diese
doppelttransgenen Mäuse, die VEGF-B167, PlGF-1 oder VEGF-ED1701 in Tumorzellen
exprimieren, wurden auf Veränderungen der Tumorangiogenese, des Tumorwachstums und
der Tumorprogression untersucht. Die vorläufigen Daten zeigen, dass die β-zell-spezifische
Hochregulierung von VEGF-B167 das physiologische Blutgefässsystem nicht beeinflusst,
jedoch die Blutgefässdichte in Tumoren von doppelttransgenen Mäusen signifikant erhöht.
Das Tumorwachstum wird hierdurch jedoch nicht begünstigt. Im Gegensatz dazu führt die
Expression von PlGF-1 in einzeltransgenen Mäusen zu einer deutlichen Dilatation der
Inselblutkapillaren, was sehr wahrscheinlich die Folge einer signifikanten Erniedrigung von
gefässstabilisierenden Perizyten ist. Desweiteren hemmt die tumorale Produktion von PlGF-1
die Tumorangiogenese und das Tumorwachstum, was bedeuten könnte, dass dieser
Wachstumsfaktor ein natürlicher Inhibitor der pathologischen Angiogenese ist. Obgleich
VEGF-B167 und PlGF-1 denselben Rezeptor binden, bewirken sie entgegengesetzte Effekte
auf das tumorale Blutgefässystem, was bei der Entwicklung von Angiogenese-Hemmstoffen,
die auf der Inhibierung von VEGFR-1 beruhen, bedacht werden sollte. Der Phänotyp der
VEGF-B167- und PlGF-1-exprimierenden Rip1Tag2 Mäuse unterscheidet sich wesentlich von
den kürzlich beschriebenen VEGF-A165 transgenen Rip1Tag2 Mäusen, die infolge
beschleunigter Tumorangiogenese und rascherem Tumorwachstum frühzeitig versterben. Die
Analyse der VEGF-ED1701-exprimierenden Mäuse und damit der spezifischen VEGFR-2
Signalwege wird zur Zeit in die Wege geleitet.
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Summary
Members of the vascular endothelial growth factor (VEGF) family and their receptors
(VEGFR) play an essential role in the development and maintenance of the blood and
lymphatic vasculature. To date, five VEGFs have been identified in the mammalian genome,
VEGF-A, -B, -C, -D, and placental growth factor (PlGF), which display distinct binding
affinities for VEGFR-1, -2, and -3. In addition to their central function in physiological
angiogenesis and lymphangiogenesis, VEGFs and VEGFRs are upregulated during
carcinogenesis and are involved in the remodeling of the tumoral blood and lymphatic
vasculature. By activating VEGFR-1 and –2, which are both expressed on blood endothelial
cells, VEGF-A promotes the formation of new tumoral blood vessels and thereby accelerates
tumor growth. In contrast, upregulation of VEGF-C, a ligand for lymphatic endothelial
VEGFR-3 as well as for VEGFR-2, induces the formation of tumor-associated lymphatic
vessels and thus promotes the passive metastatic dissemination of tumor cells to regional
lymph nodes. Much less is known about the functional consequences of tumor-expressed
VEGF-B and PlGF, two selective ligands for VEGFR-1, as well as VEGF-D, the second
VEGFR-3- and -2-binding lymphangiogenic VEGF family member. Also, the biological
effects of selective VEGFR-1, -2 or -3 signaling on tumor angiogenesis and tumor growth as
well as tumor lymphangiogenesis and metastasis are incompletely studied. Only recently, the
identification of VEGF-E, a selective ligand for VEGFR-2, as well as the generation of
VEGF-C156S, a specific ligand for VEGFR-3, has enabled the study of the distinct roles of
these receptors.
To investigate the function of lymphangiogenic VEGF-D under physiological
conditions, I analyzed transgenic mice, in which expression of VEGF-D is specifically
targeted to β-cells of pancreatic islets of Langerhans (Rip1VEGF-D mice). In these mice,
expression of VEGF-D induces the formation of large lymphatic lacunae surrounding most
islets. A few of these lymphatic vessels may be dysfunctional, which causes intra-lymphatic
accumulations of immune cells. Moreover, lymphatic lacunae often contain erythrocytes,
which may result from blood-lymphatic vessel shunts found in the vicinity of some islets.
However, the fact that erythrocytes are drained to regional lymph nodes demonstrates the
draining capacity of the de novo formed lymphatic vessels. To address the impact of VEGF-D
on tumorigenesis and metastasis, I crossed Rip1VEGF-D with Rip1Tag2 mice, a well-
characterized transgenic model of poorly metastatic multistage β-cell carcinogenesis.
Tumoral expression of VEGF-D in Rip1Tag2 mice promotes the growth of peri-tumoral
lymphatic vessels that frequently contain leucocyte clusters and hemorrhages. Concomitantly,
these double-transgenic mice exhibit a high incidence of regional lymph node and distant
lung metastases. Since expression of VEGF-D does not significantly affect the invasiveness
of tumors and all metastases are well differentiated, these data indicate that VEGF-D
promotes lymphogenous metastasis by upregulating tumor-associated lymphangiogenesis.
Interestingly, the presence of VEGF-D significantly represses tumor angiogenesis and tumor
growth, yet the mechanisms of this inhibition are thus far uncharacterized. Notably, syngenic
and allogenic subcutaneous transplantation of VEGF-D-producing Rip1Tag2 tumor cell lines
results in the formation of tumors exhibiting a dense intra-tumoral lymphatic network but
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lacking peri-tumoral lymphatic vessels. In these transplanted tumors, no immune cell clusters
or hemorrhages are formed in tumor-associated lymphatic vessels and tumor angiogenesis is
unaffected by the expression of VEGF-D. These results demonstrate that the tumor
microenvironment critically modulates VEGF-D-elicited effects. It has been recently shown
that transgenic expression of VEGF-C during Rip1Tag2 tumorigenesis promotes metastasis to
regional lymph nodes but not to the lungs by inducing peri-tumoral lymphangiogenesis.
Tumor-associated lymphatic vessels of these mice neither contain immune cell accumulations
nor hemorrhages, and tumor angiogenesis and tumor growth are not affected by the
production of VEGF-C. Thus, by employing the Rip1Tag2 tumor model, I was able to
identify not only similarities but also significant differences between VEGF-D and –C
function.
Since VEGF-C and –D can bind both VEGFR-3 and –2, it is not fully established
whether selective activation of VEGFR-3 is sufficient to induce tumoral lymphangiogenesis
and to promote lymphogenous metastasis. Therefore, I established transgenic mice expressing
VEGF-C156S in the endocrine pancreas and crossed these mice with Rip1Tag2 animals. The
analysis of single and double transgenic mice revealed that VEGF-C156S phenocopies
VEGF-C in all investigated aspects. These results indicate that VEGFR-3 may be the
predominant receptor mediating VEGF-C-elicited effects in Rip1Tag2 mice and that selective
activation of VEGFR-3 is sufficient to promote tumor-associated lymphangiogenesis and
metastasis. Hence, VEGFR-3 might represent a valuable target for future anti-metastatic
strategies.
To further understand the specific roles of VEGFR-1 and –2 signaling in physiological
angiogenesis as well as in tumorigenesis, I established transgenic mouselines, which express
the VEGFR-1-specific ligands VEGF-B167 and PlGF-1 as well as the selective VEGFR-2
ligand VEGF-ED1701 in β-cells of pancreatic islets (Rip1VEGF-B167, Rip1PlGF-1, and
Rip1VEGF-ED1701 mice). These single transgenic mice were analyzed with regard to islet
blood vessel morphology and density. In a second set of experiments, I crossed single-
transgenic animals with Rip1Tag2 mice. These double-transgenic mice expressing either
VEGF-B167, PlGF-1 or VEGF-ED1701 in tumor cells, were analyzed for changes in tumor
angiogenesis, tumor growth, and tumor progression. The preliminary data provide evidence
that β -cell-specific upregulation of VEGF-B167 does not critically affect physiological
angiogenesis of single-transgenic mice but results in a significant increase in the tumor
microvessel density of double-transgenic animals. However, tumor growth and tumor
progression are not promoted by the stimulation of tumor angiogenesis. In contrast,
overexpression of PlGF-1 in single-transgenic mice leads to a prominent dilation of blood
capillaries, which may at least in part be caused by a significant reduction of stabilizing blood
vessel-associated pericytes. Furthermore, tumoral expression of PlGF-1 significantly inhibits
tumor angiogenesis and tumor growth, suggesting that this growth factor might be a natural
inhibitor of pathological angiogenesis. Hence, although binding to the same receptor, VEGF-
B167 and PlGF-1 elicit opposing effects on the tumor blood vasculature. These results suggest
that the two growth factors induce distinct signaling pathways via VEGFR-1, which might be
considered when designing inhibitors of angiogenesis involving VEGFR-1. Importantly, the
phenotype of VEGF-B167- and PlGF-1- expressing Rip1Tag2 mice is different from the
Summary
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recently described VEGF-A165 transgenic Rip1Tag2 mice, which exhibited accelerated tumor
growth and early death. The analysis of VEGF-ED1701-expressing mice and effects induced by
selective activation of VEGFR-2 signaling is currently underway.
General Introduction
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1. General Introduction
1.1. The two vascular systems
1.1.1. The cardiovascular system
Large multicellular organisms use carrier molecules to deliver oxygen and nutrients
to distant organs and to remove and manage metabolic waste products, thereby ensuring
homeostasis of the body. In vertebrates, a closed cardiovascular system consisting of the
heart, arteries, blood capillaries, and veins guides the transport of these molecules via the
bloodstream to and from tissues. By repeated rhythmic contractions, the heart ventricles exert
a pressure to pump the blood through arteries into organ capillaries and to return it via veins
to the heart (Figure 1A). In addition to supplying tissues with oxygen and nutrients, the
vascular system and blood are critically involved in the regulation of the body temperature
and the systemic pH (reviewed in [1]).
According to their distinct functions, blood vessels display characteristic structural
properties. Arteries and veins typically consist of three layers: an intima composed of
endothelial cells, a media of smooth muscle cells, and an adventitia of fibroblasts, matrix, and
elastic laminae. The adventitial layer has its own blood supply (vasa vasorum). Smooth
muscle cells and elastic laminae contribute to the vessel tone and mediate the control of
vessel diameter and blood flow. Arteries participate in establishing a high arterial pressure,
why their media consists of multiple sheets of smooth muscle cells. In contrast, veins
constitute the low-pressure section of the vascular system and therefore display only few
layers of smooth muscle cells, which accounts for their much thinner vessel wall and
commonly larger lumina. Extravasation of macromolecules and cells from the blood stream
typically occurs from postcapillary venules. Since blood capillaries are specialized for the
exchange of nutrients and oxygen with the surrounding tissue, their vessel wall is only
composed of one layer of tightly coherent endothelial cells and a continuous basement
membrane. Four types of capillary endothelium are discerned, which are typically found in
distinct organs: (i) endothelia that include tight junctions are impermeable to various
molecules and are found in the blood-brain and blood-retina barrier, (ii) continuous
endothelium occurs for instance in the muscle, (iii) fenestrated endothelium is composed of
endothelial cells exhibiting pores, thereby facilitating molecular exchange for instance in
endocrine glands, (iv) sinusoidal or discontinuous capillaries display inter-cellular gaps,
enabling the trans-capillary transport of macromolecules for example in the liver [2]. Most
though not all capillaries are further stabilized by scaffolding cells such as pericytes, which
are embedded in the basal membrane [3].
1.1.2. The lymphatic system
As a result of the high arterial pressure, plasma leaks from the capillaries into the
extracellular space and becomes interstitial fluid. About 90% of this extravasated fluid is
reabsorbed by post-capillary venules driven by osmotic forces [4]. The remaining 10% are
drained by a second vascular system, the lymphatic system, and returned to the blood
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circulation. Unlike the cardiovascular system, the lymphatic system is not closed, has no
central pump in mammals, and exhibits a unidirectional proximal lymph flow due to valves
(Figure 1A). Through its draining function, the lymphatic system counteracts the
accumulation of interstitial fluid in tissues and thus the formation of edema. Lymphatic flow
starts by diffusion of interstitial fluid into blind-ended lymphatic capillary networks that are
present in most body tissues. Once in the lymphatics, the fluid is called lymph but has almost
the same composition as the original interstitial fluid. The lymph is propulsed under low
pressure mostly due to the milking action of skeletal muscles and rhythmic contractions of
nearby blood vessel walls. Moreover, large lymphatic ducts containing valves can contract
themselves. The lymph is transported to progressively larger lymphatic vessels and passes
through one or several interposed lymph nodes into large ducts, which drain the fluid back
into the blood circulatory system at the right and left subclavian veins. Besides its crucial role
in maintaining tissue fluid homeostasis, the lymphatic system constitutes an important
component of the immune system. About 50% of the plasma proteins and cells pass through
lymphatics and lymph nodes every day. Lymph nodes harbour antigen-presenting cells, B and
T lymphocytes, which elicit an immune response in case pathogens are passing the lymph
nodes. Another important function of the lymphatic system is the intestinal absorption and
transport of long chain dietary triglycerides and lipophilic compounds such as fat-soluble
vitamins (reviewed in [5]).
Structurally, the lymphatic capillaries are rather distinct from blood capillaries. They
consist of a layer of extremely attenuated endothelial cells that also form microvalves and
lack a continuous basal lamina and pericytes. Adjacent endothelial cells are extensively
overlapping and lack inter-cellular adhesion devices in many areas. In these regions,
lymphatic endothelial cells maintain a close relationship with the adjoining interstitium by
anchoring filaments, which interact with components of the extra-cellular matrix (ECM). As
shown in Figure 1B, an increase in interstitial fluid exerts tension on fibers of the ECM,
which is transmitted via the anchoring filaments to endothelial cells and forces them to
distend from each other, thereby facilitating the entry of fluid, macromolecules, and cells [6].
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Figure 1. The blood and the lymphatic vascular systems
(A) The two vascular systems (modified from D. Sheer, J. Butler and R. Lewis, Hole’s Human
Anatomy and Physiology, 2003) (B) Regulation of interstitial fluid absorption into lymphatic
capillaries upon increase in tissue pressure. Extra-cellular fibers are drawn in brown,
anchoring filaments in black, black arrows indicate pulling forces, red arrows symbolize
interstitial fluid flow into capillaries.
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1.2. Molecular players of vascular development
1.2.1. Early blood vascular development
The cardiovascular system is the first organ that develops during embryogenesis. In
an initial phase, angioblast precursors and primitive hematopoietic cells develop from a
common mesodermal precursor, the so-called hemangioblast (Figure 2). In the process of
vasculogenesis, the de novo-forming angioblasts aggregate in the embryo and yolk sac into a
primitive network of simple endothelial tubes called primary vascular plexus. In parallel, the
primitive hematopoietic cells form the first blood islands in the visceral yolk sac [7, 8]. The
primary capillary plexus is remodeled into organized vessels by proliferation, intussusceptive
growth (division of large vessels into smaller ones), and sprouting of new vessels from
existing ones - the process of angiogenesis [2, 9].
In this early phase of vasculogenesis and angiogenesis, the first identified member of
the vascular endothelial growth factor (VEGF) family of glycoproteins, VEGF-A, and its
receptors vascular endothelial growth factor receptor (VEGFR)-1 and VEGFR-2 play a
crucial role, since knock-out mice for either of these molecules result in embryonic lethality.
Embryos deficient for the receptor tyrosine kinase VEGFR-2 or one or both alleles of VEGF-
A fail to develop blood islands, endothelial cells, and major vessel tubes [10-12]. In contrast,
in mice lacking VEGFR-1, vessels do form but exhibit excess levels of endothelial cells,
which obstruct the lumina of abnormal vascular channels [13]. Thus, although both VEGFR-1
and VEGFR-2 are expressed on hematopoietic stem and blood endothelial cells, only
VEGFR-2 is absolutely critical for the earliest stages of vasculogenesis, while VEGFR-1
becomes involved only later, acting as a negative regulator of VEGF-A activity during early
angiogenesis. Remarkably, mutant mice containing a form of VEGFR-1 that lacks only its
tyrosine kinase domain exhibit normal vascular development, indicating that only the binding
portion of this receptor may be necessary to support its major actions during vascular
development [14]. Detailed studies confirmed that VEGF-A is a critical growth factor during
vasculogenesis as well as early and adult angiogenesis by promoting endothelial cell
proliferation, migration, tubule-formation, sprouting, and the maintenance of the mature
vasculature (reviewed in [15]). A third VEGFR, VEGFR-3, which is not a receptor for
VEGF-A but for the lymphangiogenic growth factors VEGF-C and VEGF-D, is also
expressed on blood vessels during embryogenesis, but becomes largely restricted to lymphatic
vessels in the adult. Notably, mice deficient for VEGFR-3 display early embryonic lethality
due to defects in the organization of large vessels prior to the emergence of lymphatics,
suggesting an early role of this receptor for blood vessel development [16].
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Figure 2. Involvement of VEGF family members in blood and lymphatic vessel
development
(modified from Achen, J Exp Path, 1998)
1.2.2. Specification of blood vessels into arteries and veins
Artery and vein-specific markers are expressed on arterial and venous endothelial
cells before establishment of the circulation, indicating that arterial and venous fate may be
intrinsically specified early during development [15]. Although the process of arterial and
venous specification is not well understood at the molecular level, there is increasing
evidence that sonic hedgehog (Shh), VEGF-A, Notch4, ephrinB2, and neuropilin (NP)
signaling may be important triggers of arterial/venous specialization. Shh is a transcription
regulating protein, which is expressed in the notochord of developing embryos and acts as a
morphogen involved in patterning many organ systems. Recent studies suggest that Shh
induces the expression of VEGF-A in nearby somites of embryos, which in turn acts on
adjacent angioblasts that activate the Notch pathway [17, 18]. Expression of the receptor
Notch4 and the ligand Delta4 is restricted to developing endothelium and is artery-specific
[19]. Mice exhibiting a mutation of Notch1/4 exhibit vascular defects in mid-gestation, and
studies in zebrafish have revealed that Notch plays a critical role in specification of the dorsal
aorta and the cardinal veins. Conversely, activation of the Notch pathway represses venous
markers and activates expression of arterial markers, like ephrinB2, in the posterior cardinal
vein [20, 21]. The Eph receptors and their membrane-bound ligands, the ephrins, can induce
forward signaling through the Eph receptors as well as reverse signaling through the ephrinB-
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type ligands [22]. EphrinB2 and EphB4 are specifically expressed in arterial and venous
endothelial cells, respectively. Bidirectional signaling involving arterial ephrinB2-positive
and venous EphB4-positive endothelial cells is not required for vasculogenesis but critical for
angiogenesis of arteries and veins as well as the maintenance of artery-vein separation [23-
25]. Thus, the sequential activation of Shh, VEGF-A, and Notch may activate downstream
artery-specific genes such as ephrinB2 in distinct angioblasts, whereas remaining angioblasts
take up a vein identity.
Another mechanism was proposed by studies of the NP receptors. These are involved
in the development of the neural and cardiovascular systems and are co-receptors for VEGFs.
In chick embryos, expression of endothelial NP-1 is mostly restricted to arteries, whereas NP-
2 primarily marks veins [26]. Although the precise mechanisms are not elucidated yet, a
recent study suggests that NP-1 and NP-2 act as major determinants for arterial/venous fate,
since the sinus vein of the extra-embryonic blood vascular plexus formed from blood islands
that expressed NP-2 but not NP-1. Moreover, these observations suggest that the identity of
vessels may not depend on blood flow and may be determined already before vessel
formation [27].
1.2.3. Maturation of blood vessels
The maturation of newly formed sprouts into differentiated blood vessels involves the
recruitment of mural cells, the development of the surrounding matrix and elastic laminae,
and organ-specific specialization of endothelial cells. Pericytes stabilize nascent blood vessels
by providing a scaffolding support and furthermore communicate with endothelial cells by
direct physical contact and paracrine signaling [3]. The platelet-derived growth factor
(PDGF)-B/PDGF receptor (PDGFR)-β and angiopietin (Ang)/Tie2 signaling systems are
important regulators of blood vessel maturation. Presumably in response to VEGF-A, PDGF-
B is secreted by endothelial cells and pericytes and activates PDGFR-β-positive pericytes to
proliferate and migrate during vascular maturation [28]. In contrast, Ang proteins may not be
“instructive” but permissive molecules. Pericyte-secreted Ang-1 acts in a paracrine fashion on
its receptor Tie2, which is specifically expressed in endothelial cells. Thereby, Ang-1
mediates an appropriate interaction between endothelial cells and pericytes, which enables
responsiveness of endothelial cells and pericytes for further cues [29]. Ang-1 signaling is
required also for the maintenance of mature blood vessels and is therefore constitutively and
widely expressed also in the adult. In contrast, Ang-2 is expressed only at sites of vascular
remodeling in the adult tissue and predominantly acts as an antagonist of Ang-1/Tie-2
signaling [30]. It exerts a dual role on blood vessels depending on the presence or absence of
VEGF-A. When VEGF-A is co-expressed with Ang-2, the latter facilitates VEGF-A-
mediated vascular remodeling and angiogenesis by partly destabilizing mature vessels. In the
absence of VEGF-A, Ang-2 promotes plain regression of blood vessels. Thereby, both
PDGF-B/PDGFR-β and Ang/Tie2 signaling systems act in a coordinated and complementary
fashion together with VEGF-A (reviewed in [22]). In addition, sphingosine-1-phosphate
(S1P), its receptor, S1P1/endothelial differentiation gene (EDG1), and transforming growth
factor (TGF)-β have been shown to be involved in the recruitment and differentiation of
pericytes (reviewed in [2]).
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1.2.4. Lymphatic vessel development
To date, experimental data from mice support the hypothesis proposed in 1909 by
Florence Sabin that lymphatic endothelial cells arise by sprouting from embryonic veins
(Sabin, F. R. (1909). The lymphatic system in human embryos, with a consideration of the
morphology of the system as a whole. Am J Anat 9, 43–91). Around embryonic day 10, the
homeobox transcription factor Prox1, a ‘master gene’ in the program specifying lymphatic
endothelial cell fate, is expressed in a subpopulation of vein endothelial cells and promotes
their transdifferentiation into lymphatic endothelial cells [31] (Figure 2). Subsequently,
VEGFR-3 gets expressed and activated by VEGF-C, which acts as an essential chemotactic
and survival factor for nascent lymphatic endothelial cells and stimulates the migration of
such to form primary lymph sacs and the primary lymphatic plexus [32]. Recent findings
have also implicated exogenous signals from hematopoietic cells in promoting the separation
of the vascular and lymphatic system. Mice lacking the hematopoietic signaling molecule Syk
or its substrate SLP-76 fail to show proper separation of vascular and lymphatic systems [33].
Thus, exogenous and endogenous signals interact to maintain vascular and lymphatic integrity
and to prevent aberrant flow between the two systems. Postnatal remodelling of the lymphatic
vasculature includes sprouting of lymphatic capillaries from the primary lymphatic plexus,
whereas deeper lymphatic vessels recruit smooth muscle cells and develop lymphatic valves,
thereby acquiring a collecting vessel phenotype. These processes have been recently shown to
depend on NP-2, Ang-1/Ang-2/Tie2 as well as ephrinB2 signaling [6, 34]).
A second theory proposes that lymphatic vessels can also form by fusion of
mesenchymal lymphatic endothelial precursor cells or lymphangioblasts (Figure 2). Although
in birds, such mechanism of lymphatic vessel development has been demonstrated,
convincing evidence is still missing for mammals [35]. Recently, two unique populations of
stem and progenitor cells have been identified in human blood that either coexpress VEGFR-
3, CD133, and CD34 or VEGFR-3, CD31, and CD14. Both cell types were shown to
differentiate into lymphatic endothelial cells in vitro, indicating that lymphatic endothelial
precursors might also contribute to lymphangiogenesis in humans [36, 37].
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1.3. VEGF family members and their receptors
1.3.1. VEGFs
The VEGF family constitutes part of a cystine knot motif-containing superfamily of
growth factors, which also includes PDGF-BB and TGFβ [38]. To date, five VEGF members
are identified in mammals, VEGF-A, -B, -C, -D, and PlGF, which are active as dimeric
glycosylated proteins [39-43]. VEGFs act relatively specifically on blood and lymphatic
endothelial cells due to the distinct expression pattern of their receptors VEGFR-1, -2, and –3
as well as NP co-receptors. While VEGFR-1 and VEGFR-2 are mainly found on blood
endothelial cells, VEGFR-3 is largely restricted to lymphatic endothelium (see also next
section). VEGF-A, the to date best-studied VEGF family member, binds to both VEGFR-1
and VEGFR-2, whereas VEGF-B and PlGF are selective ligands for VEGFR-1. Notably,
although binding to the same receptor, VEGF-A and PlGF were recently shown to induce
distinct intra-cellular signaling pathways [44]. VEGF-C and –D are the only known ligands
for VEGFR-3 but can also bind VEGFR-2. Thus, according to their affinities for VEGFR-1
and -2, VEGF-A, -B, and PlGF exert angiogenic activities, while VEGF-C and –D
predominantly act as lymphangiogenic growth factors by activating VEGFR-3 (Figure 3)
[45].
VEGF-A homologs have been identified also in the genome of parapoxviruses and in
the venom of different pit vipers, being generally termed VEGF-E and snake venom VEGF
(svVEGF), respectively (reviewed in [46, 47]). In particular VEGF-E represents an important
complementary tool in elucidating our understanding of distinct VEGFR-2-induced biological
activities since this factor is the only known ligand that exclusively activates VEGFR-2 but
not VEGFR-1 or –3.
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Figure 3. VEGFs and VEGF receptors
Cells expressing the distinct VEGFRs are shown in boxes of the respective receptor color.
Arrows indicate affinities of VEGF family members to VEGFRs, dashed arrows indicate weak
affinity depending on proteolytical processing of VEGF-C and VEGF-D. BEC, blood
endothelial cell; flk, fetal liver kinase; flt, fms-like tyrosine kinase; KDR, kinase insert domain
receptor; LEC, lymphatic endothelial cell; PlGF, placental growth factor; sVEGFR-1 and -2
indicate the respective soluble receptor forms.
As indicated in the summary Table I at the end of this section, all VEGF members
share the highly conserved VEGF homology domain (VHD), which contains VEGFR binding
sites, the cysteine knot motif composed of eight characteristically spaced cysteine residues, as
well as heparin and NP binding sites [48]. Yet, angiogenic and lymphangiogenic VEGFs are
structurally distinct and display different molecular properties. Alternative splicing of human
angiogenic VEGFs gives rise to different isoforms, which display characteristic receptor
affinities as well as interactions with the ECM through the heparin binding sites. Notably,
VEGF-A165b is a natural VEGF-A antagonist, which binds VEGFR-2 with the same affinity as
VEGF165, but does not stimulate downstream signalling pathways [49]. The affinity for
heparin affects the bioavailability of these growth factors, since heparin-binding isoforms are
mostly sequestered to heparansulfate-proteoglycans of the ECM and at the cell surface and
are only active once released by the activity of heparinases, matrix metalloproteases, plasmin
or urokinase [50]. By contrast, the non-heparin binding isoforms are freely diffusible [48].
Angiogenic VEGFs form covalently linked anti-parallel homodimers via intra- and inter-
chain disulfide bonds among residues of the cysteine knot motif. Notably, both isoforms of
VEGF-B as well as PlGF-1 are capable of forming heterodimers with VEGF-A165, which may
have important biological implications in VEGF-A-mediated angiogenesis by modulating the
affinity of VEGF-A for its receptors [51, 52].
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Based on their distinct structural features and biological function, the
lymphangiogenic growth factors VEGF-C and –D constitute a subfamily of VEGFs. Both
growth factors are produced as homodimeric pre-propeptides, in which the VHD is flanked by
long N- and C-terminal peptide extensions (Figure 4 and Table I). In the C-terminus,
numerous cystein residues constitute a Balbiani ring 3 protein-like motif (BR3P), which may
be involved in intermolecular interactions [41, 53]. VEGF-C and –D are proteolytically
processed by the intra-cellular secretory proprotein convertases (PC)5, PC7, furin, as well as
extra-cellular plasmin and other thus far unknown proteases. As depicted in Figure 4, the
sequential cleavage of C- and N-termini gives rise to the partially processed ΔC propeptides
and the fully processed ΔNΔC peptides consisting of the homodimeric VHD only [45]. This
maturation process critically modulates the receptor affinities of VEGF-C and –D and thereby
their biological function. While the unprocessed forms bind to VEGFR-3 only, mature
VEGF-C and -D display increased affinity for lymphangiogenic VEGFR-3 and are moreover
capable of binding and activating blood vessel VEGFR-2, thereby mediating also angiogenic
signals (Figure 3, Table I) [45]. Therefore, site-specific expression levels of VEGF-C, -D,
VEGFR-3, VEGFR-2 as well as the status of VEGF-C and D processing in a given tissue
determine the lymphangiogenic and angiogenic activities of these growth factors.
Figure 4. Processing of VEGF-
C and VEGF-D
Arrows indicate cleavage sites of
pre-protein convertases. SS,
signal sequence; –S-S-, disulfide
bonds; VHD, VEGF homology
domain. The VHD is drawn in
yellow, the N- and C-terminal
peptide extensions in black, the
plasma membrane in blue
(modified from A. Stacker, J Biol
Chem, 1999).
In contrast to angiogenic VEGFs, the fully processed VEGF-C and -D homodimers
are linked exclusively via non-covalent interactions [54]. Also, only one human isoform of
both VEGF-C and –D has been reported. Another dissimilarity in comparison to angiogenic
VEGFs is that no affinity for heparin has been demonstrated for both lymphangiogenic
growth factors.
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Recently, a mutant form of VEGF-C termed VEGF-C156S has been generated by
replacing the second of the eight conserved cysteine residues (Cys156) of the VHD with a
serine. In contrast to VEGF-C, fully processed VEGF-C156S is a selective agonist of
VEGFR-3 but not VEGFR-2 and has therefore enabled the study of VEGFR-3-specific
biological functions (Figure 3, Table I) [55].
Table I. Structure, interactions and binding properties of VEGF family members
1.3.2. VEGFRs
The receptor tyrosine kinases VEGFR-1 (also known as fms-like tyrosine kinase (flt)-
1), VEGFR-2 (also fetal liver kinase flk-1 or kinase insert domain receptor (KDR)), and
VEGFR-3 (also fms-like tyrosine kinase (flt)-4) are the main signaling receptors for VEGF
family members [56-58]. VEGFR-3 is present in two isoforms that differ in their C-termini
through alternative splicing of the human VEGFR-3 gene [59]. In addition to the
transmembrane receptors, VEGFR-1 and VEGFR-2 are also produced as alternatively spliced
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soluble forms consisting of only the extra-cellular domains [60, 61]. sVEGFR-1 can act as a
competitive inhibitor by sequestering VEGF-A, VEGF-B, and PlGF. Moreover, it may bind
and inactivate membrane-bound VEGFR-1 and -2 through heterodimerization [60]. As such,
the role of sVEGFR-1 has been studied both as a surrogate marker for disease progression
and/or as a potential inhibitor of tumor angiogenesis in variety of cancers as well as for its
possible contribution to diseases such as preeclampsia [62, 63]. The functional significance of
sVEGFR-2 is unknown thus far.
The extra-cellular portion of transmembrane VEGFR-1 and -2 consists of seven
immunoglobulin (Ig)-like domains, whereas the soluble forms contain only six (Figure 5).
Also VEGFR-3 contains only six Ig-like domains since the fifth domain is proteolytically
cleaved soon after biosynthesis and the resulting polypeptide chains remain linked via a
disulfide bond (Figure 3)[45]. The second and third Ig-like domain of VEGFR-1 is involved
in binding to VEGF-A and PlGF, whereas the third and fourth domain mediate interactions
with NP-1 [64, 65]. The intra-cellular part of VEGFRs consists of a consensus tyrosine kinase
sequence that is interrupted by a kinase-insert domain (Figure 5) [56].
Figure 5. Schematic representation of
the VEGFR-2 structure
VEGFR-1 is similar in most structural
aspects, while the fifth Ig-like domain of
VEGFR-3 is cleaved and held together by
disulfide bonds. Flk, fetal liver kinase; Ig,
immunoglobulin; KDR, kinase insert
domain receptor
Activation of receptors by their cognate ligands results in VEGFR homo-
dimerization, cross-phosphorylation of distinct tyrosine residues in the tyrosine kinase
domains and the subsequent triggering of intra-cellular signaling pathways. Furthermore,
VEGFR-1 can trans-phosphorylate VEGFR-2, which leads to an enhancement of VEGF-A-
mediated biological functions [44]. Recent studies also demonstrated the formation of
VEGFR-1/-2 as well as VEGFR-2/-3 heterodimers. Whereas there is evidence that VEGFR-
1/-2 heterodimers may be more active than the respective homodimers, the biological
implications of VEGFR-2/-3 heterodimerization remains to be elucidated [44, 66].
As mentioned above, all VEGFRs are essential for the development of blood and
lymphatic vessels, since mice deficient for either receptor are embryonically lethal before or
during the development of the primary blood vascular plexus (see above and [47]). As shown
in Figure 3, VEGFR-1 is predominantly expressed on blood endothelial cells but can be found
also on many non-endothelial cells. During embryonic development, this receptor acts
primarily as negative regulator of vasculogenesis and angiogenesis since mice lacking
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VEGFR-1 exhibit uncontrolled endothelial cell proliferation, which results in the obstruction
of vessel lumina [13]. Interestingly, expression of only the extra-cellular portion of VEGFR-1
is sufficient to rescue the phenotype [14]. The negative regulatory role of VEGFR-1 may be
explained by the 10-fold higher affinity for VEGF-A but only weak tyrosine kinase activity
when compared to VEGFR-2 [47]. In the adult, VEGFR-1 can provide growth and survival
signals for blood endothelial cells and pericytes via the phospholipase C (PLC)-γ and mitogen
activated protein kinase (MAPK) signaling pathway as well as migratory signals for
macrophages [48, 67]. Importantly, VEGFR-1 is upregulated on pathological blood
endothelium and is substantial for angiogenesis under ischemic, inflammatory, and malignant
conditions [48, 68]. Furthermore, VEGFR-1 is involved in the preparation of the metastatic
niche. VEGFR-1-positive haematopoietic progenitor cells were shown to colonize tumor-
specific pre-metastatic sites prior to the arrival of tumor cells [69].
In contrast, VEGFR-2 is an essential mediator of the earliest steps of vasculogenesis.
Similarly to VEGFR-1, VEGFR-2 is found on blood endothelium but also on hematopoietic
precursor and other cells, and as mentioned above, embryos lacking VEGFR-2 fail to develop
blood islands, endothelial cells, and major vessel tubes [10-12]. These and other experiments
have demonstrated that VEGFR-2 is essential for growth, survival, and differentiation of
endothelial cell progenitors and is the major mediator of mitogenic, angiogenic and
permeability-enhancing effects of VEGF-A also in the adult [48]. While proliferative signals
of VEGFR-2 are mainly transmitted via the PLC-γ and MAPK pathway, survival is provided
via the phosphoinositide-3 kinase (PI3K)/Akt signaling cascade. PI3K-Rac, Cdc42-
p38MAPK, and focal adhesion kinase FAK are involved in mediating migration, however,
the mechanisms of PI3K and FAK activation are unknown so far [67]. Importantly, also
lymphatic endothelial cells express VEGFR-2 to some extent, which may be one explanation
for the recently reported lymphangiogenic activity of VEGF-A [70].
Also VEGFR-3 plays an essential role in early embryonic blood vessel development
prior to the formation of lymphatic vessels [16]. Although being first expressed on blood
endothelial cells early during development, this receptor becomes largely confined to
embryonic and adult lymphatic endothelium and is the main mediator of lymphangiogenic
signals induced by VEGF-C and –D. VEGFR-3-mediated proliferation is dependent on the
proteine kinase C (PKC) and MAPK pathways, whereas survival signaling is mediated via
PKB/Akt activation [67]. Nevertheless, VEGFR-3 is still expressed on fenestrated blood
endothelium and can become re-expressed on blood vessels of tumors, thereby possibly also
mediating VEGF-C and –D-induced angiogenic signals [45]. Interestingly, two
subpopulations of macrophages and dendritic cells were recently described, which co-
expressed immune cell markers and VEGFR-3 [37, 71]. Such cells could thus represent
immune cells that were trans-differentiating into lymphatic endothelial cells, yet, such
alternative mechanism of lymphangiogenesis remains to be further confirmed.
1.3.3. Neuropilins
NP-1 and –2 are transmembrane glycoproteins and have been first identified as co-
receptors for axon guidance factors of the class-3 semaphorin subfamily, mediating repulsive
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signals during neuronal axon guidance. The essential role of NPs in vascular development and
maintenance as co-receptors for VEGF family members was discovered only later. NPs are
expressed on neuronal, endothelial, and smooth muscle cells as well as monocytes [72]. In
addition to semaphorins, NP-1 binds VEGF-A, VEGF-B, and PlGF-2, while NP-2 binds
VEGF-A, VEGF-C, and PlGF-2 (Table I) [73]. Since semaphorins and VEGFs use the same
binding site in the extra-cellular NP domain, they may compete for the receptor. Indeed such
activity was shown for semaphorin-3A, which inhibited VEGF-A-induced sprout formation in
an in vitro model of angiogenesis [74]. Yet, whether semaphorins modulate angiogenesis in
vivo remains to be demonstrated.
The extracellular part of NPs contains two complement-binding domains that mediate
interactions with semaphorins and VEGFs, two coagulation factor V/VIII homology domains
involved in heparin binding and adhesion, and a MAM (meprin, A5, mu) domain, which is
important for homo- and hetero-dimerization of NPs (Figure 6) [75, 76]. Although the
cytoplasmic tail is short and contains no known signaling motif or homology domain, it
probably plays an important, yet uncharacterized role. NPs may primarily modulate binding
of VEGFs to VEGFRs and thereby VEGFR signaling rather than induce intrinsic signaling
pathways [77]. Both NPs are expressed in several splice forms including soluble forms, which
consist of only the extra-cellular domains and may act as natural inhibitors [78].
Figure  6 .  Schemat ic
represen-tation of the NP-1
structure
Ligands and functions are as
indicated. MAM, meprin a5
mu; NP, neuropilin.
As mentioned above, NP-1 and -2 are involved in determining arterial/venous
segregation and NP-2 is essential for lymphatic vessel development. Moreover, by associating
with VEGFR-2, NP-1 enhances VEGF165-induced migration of endothelial cells [79, 80]. A
balance in these NP activities is essential, since transgenic mice in which NP-1 is expressed
under the control of the ubiquitous actin promoter exhibit cardiac malformations, excessive
blood vessels, and hemorrhages [81]. Conversely, inactivation of the NP-1 gene causes
disorganized and insufficient vasculogenesis, transposition of large vessels as well as defects
in cardiac development and neural vascularization [82]. In contrast, while exhibiting a severe
reduction of small lymphatic vessels and capillaries, NP-2-deficient mice develop a normal
blood vasculature [34]. Interestingly, combined NP-1/-2 knock-out mice resemble the
phenotype of VEGF-A and VEGFR-2 gene-targeted mice [83]. In conclusion, NPs are
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essential for VEGFR-1 and –2 to efficiently transduce VEGF-A-mediated signals in early
development. Furthermore, NP-1 may also act as a heterologous cell adhesion molecule by
interacting with L1-CAM via the b1 and b2 domains [84, 85]. Although the functional
consequences of a possible NP-1-mediated adhesion remain to be investigated, it can be
speculated that this activity may be also important for angiogenesis.
1.4. The role of VEGF family members in tumor angiogenesis and
lymphangiogenesis
1.4.1. VEGFs and VEGFRs in tumor angiogenesis
In industrialized countries, cancer is presently responsible for about 25% of all
deaths, therewith representing the second-most cause of death after cardiovascular diseases
[86]. Like normal tissues, tumors require supply of oxygen and metabolites in order to grow
beyond a size of 1-2 mm3 [87]. Therefore, they are dependent on a concomitantly growing
blood vessel network, which forms like during vascular development by vasculogenesis and
angiogenesis. Angiogenesis is orchestrated by a fine-tuned balance between secreted pro- and
anti-angiogenic factors. Under physiologic conditions of the adult, blood endothelial cells are
quiescent since anti-angiogenic factors such as thrombospondin and endostatin outweigh pro-
angiogenic forces, including VEGF-A, PlGF, fibroblast growth factor 2, interleukin-8, TGF-
β , PDGF and others. During carcinogenesis but also tissue regeneration and chronic
inflammatory conditions, angiogenic factors are upregulated, which is commonly referred to
as angiogenic switch, and become dominant over anti-angiogenic activities [88]. Importantly,
not only tumor cells themselves but also cells of the tumor stroma such as endothelial cells,
tumor-associated macrophages (TAMs), and carcinoma-associated fibroblasts (CAFs) secrete
angiogenic growth factors. Furthermore, TAMs and CAFs produce matrix metalloproteases
that activate latent or sequestered forms of these growth factors and modulate the ECM [89].
Notably, tumor blood vessels differ from the physiological vascular bed by their large size,
tortuous shape, an only fragmented basement membrane, the presence of only few pericytes,
and leakiness, which may result from an imbalance of angiogenic factors and inhibitors
within a tumor. Particularly VEGF-A is known to induce the formation of disorganized and
leaky vessels [90]. Moreover, many tumor vessels are not lined with endothelial but with
tumor cells, which is termed vascular mimicry [91].
Numerous studies have established VEGF-A as a key angiogenic player in cancer
(reviewed in [92]). VEGF-A is expressed in most tumors and its expression correlates with
tumor microvessel density and growth. Tumoral expression of VEGF-A can be induced by a
variety of stimuli, including genomic alterations such as mutant p53 and ras, erbB-2/Her2,
activated epidermal growth factor receptor, bcr-abl fusion gene products, but also nitric oxide
(NO) and other growth factors [47]. Due to hypoxia inducible factor (HIF)-regulated elements
of its gene, VEGF-A is also strongly induced in hypoxic tumor areas [93]. In addition to
mediating directly angiogenesis, VEGF-A also stimulates the recruitment of TAMs and CAFs
(reviewed in [89]). Increasing data from clinical studies demonstrate that also expression of
the VEGFR-1-selective ligands VEGF-B and PlGF is upregulated during tumorigenesis.
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Moreover, a correlation between expression levels and tumor angiogenesis has been found in
several of these reports, suggesting that both VEGF-B and PlGF might be involved in tumor
angiogenesis and tumor growth [94-98]. In contrast to VEGF-A, the regulation of VEGF-B
and PlGF gene expression as well as the impact of these growth factors on tumor
angiogenesis is still incompletely understood. Furthermore, analysis of xenograft tumor
models has revealed that VEGF-C and -D can also drive tumor angiogenesis and accelerate
tumor growth, potentially as a result of VEGFR-2 activation [99, 100]. Yet, their significant
contribution to angiogenesis in human tumors remains to be demonstrated.
VEGFR-2 is the main angiogenic signaling transducer of VEGF-A during tumor
angiogenesis. Yet, unlike in physiological angiogenesis, VEGFR-1 signaling plays an
important role in angiogenesis under pathological conditions including cancer, which is in
line with the involvement of its ligands VEGF-B and PlGF in pathological angiogenesis [68,
101]. Similarly to VEGF-A, expression of VEGFR-1 but not VEGFR-2 or –3 is upregulated
by hypoxia [102, 103]. In addition to mediate tumor angiogenesis, VEGFR-1 is involved in
the induction of MMPs and in the paracrine release of growth factors from endothelial cells.
Furthermore, in some cases VEGFR-1 is expressed by tumor cells and may mediate a
chemotactic signal, thus potentially promote tumor cell migration and invasion [104].
Due to the essential role of angiogenesis for tumor growth, VEGF-A - and possibly
also VEGF-B and PlGF - as well as its receptors have emerged as important targets for anti-
cancer strategies. An advantage of anti-angiogenic treatment is that in contrast to the
heterogenic and genetically unstable tumor cells that frequently develop resistance to
chemotherapy, tumor endothelial cells are proliferating but remain genetically stable.
Moreover, animal models have demonstrated that long-term inhibition of VEGF-A activity
does not affect the physiological vasculature but significantly reduces tumor angiogenesis and
induces even regression of tumor blood vessels, resulting in growth arrest of primary and
secondary tumors [105, 106]. Detailed overviews of angiogenesis inhibitors and anti-
angiogenic therapy and can be found in [104, 107, 108].
1.4.2. VEGFs and VEGFRs in tumor-associated lymphangiogenesis
The fatality of cancer predominantly results from the dissemination of primary tumor
cells to distant sites and the subsequent formation of metastases. Cancer cells spread via
lymphatic or blood vessels or seed directly to body cavities. In the case of lymphogenous
metastasis, cancer cells are passed through lymph nodes and may there form the first
metastases. In patients with solid tumors, lymph node metastases are recognized for over 200
years [109]. Some of the most frequent tumor types, including melanoma, breast, lung, and
gastrointestinal tract cancer, preferably spread via lymphatics, and sentinel lymph node
biopsy of patients with these tumors is routinely used for refinement of prognostic and
therapeutic measures. Since the lymphatic vasculature is specialized for entry and transport of
immune cells, lymphogenous spread is more efficient than that via blood vessels. As
mentioned above, lymphatic capillaries are larger than blood capillaries, display an only
fragmented basal lamina, and display a special endothelial cell arrangement facilitating
intravasation of cells. Moreover, the composition of lymph is similar to that of interstitial
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fluid and flow velocities are low, thus allowing better cell viability as compared to the serum
toxicity and shear stress encountered in the bloodstream [110]. In the past few years, tumor-
associated lymphangiogenesis has gained increasing attention due to the discovery of
lymphangiogenic growth factors, such as VEGF-C and –D, and specific markers for
lymphatic endothelium, including VEGFR-3, LYVE-1, Podoplanin, and Prox-1. Recent
clinical correlation studies have confirmed the proposed notion that the presence of lymphatic
vessels in the vicinity of tumors favors lymphogenous metastatic dissemination of cancer
cells [111, 112]. In contrast, contradictory results about the functionality and presence of
intra-tumoral lymphatic vessels do not yet allow a clear conclusion with regard to their role in
lymphogenous metastasis. Although there has been some debate whether preexisting
lymphatic vessels are sufficient for lymphogenic metastasis, data from animal models and
clinical studies combined clearly demonstrate a significant promotion of lymphogenic
metastasis by tumor-induced lymphangiogenesis (reviewed in [89]).
Tumoral expression of VEGF-C emerges as a reliable marker for ongoing tumor
lymphangiogenesis and increased risk of regional lymph node metastasis in many carcinomas
[61, 113]. Data for VEGF-D are less consistent, suggesting that its ability to promote
metastatic spread via lymphatics depends on the investigated tumor type and/or grade [114-
116]. It is still unknown whether VEGF-C and D alter adhesive properties of tumor and
endothelial cells and modify functional features of lymphatic vessels, which would actively
enhance tumor cell adhesion to and intravasation into lymphatics. In addition, VEGF-C and D
may activate lymphatic endothelial cells to secrete chemotactic factors for tumor cells [110].
Since expression of VEGF-C is stimulated by inflammatory mediators such as
interleukin-1, tumor necrosis factor-α , COX-2, and COX-2-induced prostaglandins,
lymphangiogenesis might be stimulated at sites of chronic inflammation to counteract
inflammation-associated edema [117, 118]. This mechanism may also contribute to
upregulation of VEGF-C in cancer, since tumors are known to be infiltrated by immune cells.
Moreover, VEGF-A may also trigger expression of VEGF-C, thus, at sites of vessel
remodeling or growth, lymphangiogenesis is stimulated in parallel to angiogenesis to
maintain tissue fluid homeostastis [118]. VEGF-D, originally identified as c-fos-induced
growth factor, is inducible by the AP-1 transcriptional activation pathway [42]. Moreover, it
can be enhanced by cadherin-11-mediated cell-cell contacts, interleukin-7, and nitric oxide,
whereas VEGF-D mRNA stability is downregulated by cytosolic β-catenin [119, 120]. β-
catenin exists in different cellular pools, either associated with cadherins at the cell membrane
contributing to cell adhesion, or in the cytoplasm, where it may participate in the canonical
Wnt signaling pathway [121]. Repression by cytosolic β-catenin and upregulation in response
to cadherin-11 suggests that expression of VEGF-D seems to depend on stable cellular
interactions with the surrounding environment, which may have implications for the secretion
of lymphangiogenic growth factors by migrating cells [118].
Recent data have demonstrated that the inhibition of tumor lymphangiogenesis with
use of inhibitory anti-VEGFR-3 antibodies can suppress regional and distant metastasis in a
mouse model of breast cancer [122]. The combined administration of anti-VEGFR-2 and –3
antibodies was even more potent and may represent a particularly promising approach for
controlling metastasis. One might think that targeting tumor-associated lymphangiogenesis
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might not be a promising anti-metastatic tool, since a large proportion of human tumors have
already metastasized by the time of diagnosis. However, in addition to possibly prevent the
occurrence of tumor cell dissemination in patients who display no detectable metastases at the
timepoint of diagnosis, such therapy could also be of benefit for cancer patients already
exhibiting local lymph node metastases. The “bridgehead concept of metastases” postulates
that lymph node metastases form a reservoir of successfully metastasized tumor cells. These
may already possess many of the properties required for further metastatic spread and may
therefore disseminate more frequently to peripheral sites than cells from the primary tumor
[123]. According to this hypothesis, inhibition of de novo lymphangiogenesis may therefore
be of benefit even for cancer patients already suffering from local but not systemic lymph
node metastases.
1.5. The Rip1Tag2 transgenic mouse tumor model
Mouse models of cancer enable the study of complex interactions between tumor cells
and the tumor stroma as well as processes involved in tumor angiogenesis,
lymphangiogenesis and metastatic disease in vivo. One approach of generating tumor-bearing
mice is the introduction of highly oncogenic viral genes into the mouse genome. By use of
tissue-specific promoters, expression of these oncogenes can be targeted to distinct organs,
which are subsequently subject to malignant transformation. Using this technique, the
Rip1Tag2 transgenic mouse model of β-cell carcinogenesis was established twenty years ago.
In these mice, the early region of large T antigen (Tag) of simian virus 40 is expressed under
the control of the rat insulin gene promoter (Rip) and thereby targeted to the insulin-
producing β-cells of the endocrine pancreas [124]. Tag displays direct transforming functions
and disrupts cell cycle control by sequestering and inactivating the tumor suppressor genes
p53 and pRb [125]. Together, these activities induce malignant transformation and
uncontrolled proliferation of β-cells resulting in the sequential formation of insulinomas over
a period of 12-14 weeks.
The murine pancreas contains approximately 400 islets of Langerhans, which together
constitute the endocrine part of the organ. Islets consist of several types of hormone-
producing cells, including α-, β-, δ-, and PP cells, the most abundant being β-cells (80%). In
Rip1Tag2 mice, β-cells start to express the transgene at embryonic day 8.5 (Figure 7).
Hyperplastic islets begin to appear at around 4 weeks of age, and although all islets express
Tag, only about 50% of the islets become hyperplastic at 10 weeks [126]. The onset of an
angiogenic switch in a subset of hyperplastic islets triggers the formation of new blood
vessels, resulting in the sequential emergence of angiogenic islets at 6 weeks and solid tumors
at 9 to 10 weeks of age [127]. At 12 to 14 weeks, 2-4% of all initial islets have progressed
into well-encapsulated, non-invasive benign tumors or adenomas and about 0.5% of islets into
malignant, invasive carcinomas, the latter having the potential to metastasize [128].
Importantly however, metastases are very rarely encountered in Rip1Tag2 mice because the
animals succumb already at 12-14 weeks of age to hypoglycemia caused by the massive
tumoral production of insulin. The predictability and reproducibility of Rip1Tag2
tumorigenesis allows the study of distinct molecular events that may influence tumor growth
and progression as well as tumor angiogenesis, lymphangiogenesis and metastasis.
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Figure 7. Multistep β-cell carcinogenesis in Rip1Tag2 transgenic mice
As indicated, islets (small brown circles) sequentially progress into hyperplastic islets (large
brown circles), angiogenic islets (red circles), benign adenoma (large red shapes), and
malignant carcinoma (magenta shape). Percentages indicate the subset of initial islets that
have developed into a specific tumor grade at 12-14 weeks of age. The exocrine pancreatic
tissue is drawn in light brown, the foregut in green. E8.5, embryonic day 8.5 (modified from
G. Christofori, Mol Endocrinol, 1995).
1.6. Aim of the study
The objective of this study was to investigate and to compare side-by-side the
biological effects elicited by different VEGF family members in vivo under physiological
conditions as well as during carcinogenesis. Therefore, transgenic mice were generated
expressing the VEGFR-1-specific ligands VEGF-B167 and PlGF-1, the VEGFR-2-specific
ligand VEGF-ED1701, the VEGFR-2 and –3 ligand VEGF-D, as well as the VEGFR-3-specific
ligand VEGF-C156S in β-cells of pancreatic islets of Langerhans. These single transgenic
mice were analyzed with regard to different parameters including angiogenesis and
lymphangiogenesis. In a second step, single transgenic mice were crossed with Rip1Tag2
mice, which resulted in the generation of double transgenic tumor mice expressing the
respective ligand in tumor cells. The analysis of tumor angiogenesis and lymphangiogenesis,
tumor progression, as well as metastasis allowed the identification of significant modulatory
functions of the distinct VEGFs during tumorigenesis. Furthermore, the presented data
demonstrate that activation of the same receptor by different VEGFs can elicit diverse or even
opposing biological effects and that the same ligand can exert distinct functions depending on
the encountered tumor microenvironment.
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2. General Materials and Methods
Mouse tissue processing
Animal care was in accordance with Swiss Animal Protection Ordinance issued by
the Swiss Federal Veterinary Office. Single transgenic Rip1VEGF-B167, Rip1VEGF-C156S,
Rip1VEGF-D, Rip1VEGF-ED1701, and Rip1PlGF-1 mice were sacrificed between 12 and 13
weeks if not indicated otherwise. Generation and phenotypic characterization of Rip1Tag2
mice was as described previously [124]. Tumor-bearing Rip1Tag2;Rip1VEGF-B167,
Rip1Tag2;Rip1VEGF-C156S, Rip1Tag2;Rip1VEGF-D, Rip1Tag2;Rip1VEGF-ED1701, and
Rip1Tag2;Rip1PlGF-1 double transgenic and Rip1Tag2 littermate control mice were
sacrificed between 12 and 13 weeks of age. Tumor incidence per mouse was determined by
counting all macroscopically apparent pancreatic tumors with a minimal diameter of 1mm.
The tumor volume was defined as total tumor volume per mouse in mm3. The volume of each
macroscopically visible tumor was calculated by measuring the tumor diameter assuming a
spherical shape of the tumors.
Tumors and pancreata were either embedded in OCT (Tissue Tek, Torrance, CA) and
freshly snap frozen in liquid nitrogen or fixed overnight in 4% paraformaldehyde in PBS,
dehydrated in a Microm Spin Tissue Processor STP-120 (Microm, Volketswil, Switzerland)
and paraffin-embedded. 5 µm fresh frozen sections were methanol-fixed for 10 min at –20°C
or fixed in 70% ethanol for 2 min at room temperature prior to storage at –80°C. 5 µm
paraffin-embedded tissue sections were deparaffinized and rehydrated prior to usage
according to standard procedures.
Histopathological analysis
Histologic sections were analyzed by hematoxylin and eosin staining,
immunohistochemistry and immunofluorescence. The following antibodies were used for
immunohistochemistry or immunofluorescence on paraffin sections: goat anti-human VEGF-
B167/189 (R&D Systems, Minneapolis, MN), rabbit anti-rat VEGF-C (Reliatech, Braunschweig,
Germany), rabbit anti-rat VEGF-D (Reliatech, Braunschweig, Germany), guinea pig anti-
insulin (DakoCytomation, Glostrup, Denmark), rabbit anti-mouse LYVE-1 (Reliatech,
Braunschweig, Germany), hamster anti-mouse podoplanin (8.1.1; Developmental Studies
Hybridoma Bank, Iowa University, Iowa City, Iowa), rat anti-mouse CD31 (PharMingen,
Franklin Lakes, NJ), mouse anti-mouse smooth muscle actin (Boehringer Mannheim,
Germany), rabbit anti-mouse NG-2 (Chemicon, Hampshire, UK), biotinylated mouse anti-
BrdU (Zymed, South San Francisco, CA) for detection of proliferating cells, In Situ Cell
Death Detection Kit, POD (terminal deoxynucleotidyl transferase-mediated nick end labeling
(TUNEL); Roche, Basel, Switzerland) for visualization of apoptotic cells. All biotinylated
secondary antibodies for immunohistochemistry (Vector, Burlingame, CA) were used at a
1:200 dilution, and positive staining was visualized with the ABC horseradish peroxidase kit
(Vector) and DAB Peroxidase Substrate (Sigma Chemical Co., St. Louis, MO) according to
the manufacturer’s recommendations. For analysis of tissue morphology, slides were slightly
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counterstained with hematoxylin or eosin. Alexa Fluor 568- and 488-labeled secondary
antibodies (Molecular Probes, Eugene, OR) diluted 1:400 were used for immunofluorescence
analysis. 6-Diamidino-2-phenylindole (DAPI) was used for nuclear staining in
immunofluorescence stainings. All paraffin-embedded sections were subject to antigen
retrieval with 10 mM citrate buffer (microwave) except for VEGF-D and insulin (10 min in
0.2% Triton X-100 in PBS), CD31 (10 min 0.1% Proteinase K (Fluka) in PBS at 37°C), BrdU
(1h in 2N HCl and subsequently 1 h 1x trypsin at room temperature), and TUNEL (10 min
2µg/ml Proteinase K (Fluka) at room temperature). Rabbit anti-VEGF-E (#1384 and #1385,
kindly provided by Prof. C. Dehio, Division of Molecular Microbiology, Biozentrum, Basel,
Switzerland), rat anti-mouse CD45, CD4, CD8, CD45R/B220 (all from BD Biosciences, San
Jose, CA), rat anti-mouse F4/80 (Serotec, Oxford, UK), rabbit anti-mouse Prox1 (a gift from
K. Alitalo, Molecular/Cancer Biology Laboratory, Biomedicum, University of Helsinki,
Helsinki, Finland), rat anti-mouse flt-4 (eBioscience, San Diego, CA) and double stainings for
CD-31 and LYVE-1 were exclusively performed on frozen sections and by
immunofluorescence. For each staining, sections of control mice or respective serial sections
of transgenic mice without primary antibody incubation were used as negative control.
Stained sections were viewed on a Axioskop 2 plus light microsope (Zeiss, Feldbach,
Switzerland) using the axiovision 3.1. software (Zeiss, Feldbach, Switzerland) or a Nikon
Diaphot 300 immunofluorescence microscope (Nikon, Egg, Switzerland) using the Openlab
3.1.7. software (Improvision, Coventry, England).
For BrdU labeling, 100 µg BrdU (Sigma Chemical Co., St. Louis, MO) per gram
body weight were injected 90 min before sacrificing the mice. To determine tumor cell
proliferation/apoptotic indices, BrdU-/TUNEL-positive nuclei were counted per randomly
chosen 40x magnification field of tumor tissue, respectively. Approximately 10 fields/mouse
were counted.
Accordingly, tumoral blood vessel density was assessed by counting the CD31-
positive vessels per 40x magnification field of tumor tissue if not otherwise indicated.
Lymphangiogenesis was quantified by assessing the extent by which LYVE-1-
positive lymphatic vessels surrounded the tumor perimeter. Tumors from all mice of a
genotype were grouped into three classes: tumors that were not in contact with any lymphatic
vessel (0%), tumors that were surrounded less than 50% (<50%), and tumors that were
surrounded more than 50% of the tumor perimeter by lymphatics (>50%).
The blood vessel density of islets as well as Rip1Tag2;Rip1PlGF-1 and ectopic
subcutaneous Rip1Tag2 and Rip1Tag2;Rip1VEGF-D tumors was determined upon
immunofluorescence staining with anti-CD31 antibody and subsequent analysis with the
ImageJ software of the National Institutes of Health (http://rsb.info.nih.gov/ij/). The islet
diameter was measured on pictures of HE-stained slides using the Axiovision software 3.1.
Intra-insular NG-2-positive pericytes as well as intra-tumoral CD45-positive immune cells,
F4/80-positive macrophages, B220-positive B lymphocytes, and CD4- and CD8-positive T
lymphocytes were visualized by immunofluorescence on serial sections and quantified with
the ImageJ software.
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Lectin Perfusion
For analysis of functional blood vessels, mice were inhalation-anesthetized with
isoflurane (Minrad Inc., Buffalo, NY) and tail vein-injected with 100 µ l of 1 mg/ml
fluorescein-labeled lycopersicon esculentum lectin (Vector, Burlingame, CA). After 5 min,
mice were heart-perfused with 10 ml of 4% paraformaldehyde followed by 10 ml PBS.
Isolated pancreata were immersed in ascending concentrations of sucrose (12%, 15% and
18%, for 1 h each), embedded in OCT and snap frozen in liquid nitrogen.
Tumor grading
All tumors found on a representative pancreatic section of a given mouse genotype
were categorized into following sub-classes: normal/hyperplastic islet (including normal as
well as enlarged islets), adenoma (larger than 1 mm in diameter, well differentiated tumor
cells, encapsulated tumor, no invasive tumor edges), carcinoma grade I (well differentiated
and homogenous appearance of tumor cells, tumor capsule partially absent, one invasive
tumor edge), carcinoma grade II (partially dedifferentiated and heterogenous appearance of
tumor cells, tumor capsule largely absent, more than one invasive tumor edge), carcinoma
grade III or anaplastic tumor (complete loss of tumor cell differentiation, very heterogenous
tumor appearance). In statistical tables, normal/hyperplastic islets and adenomas were
summarized as benign, all carcinomas as malignant tumors.
Collagen Gel Assay
For collagen gel assays, islets from single transgenic Rip1VEGF-D and Rip1PlGF-1
mice as well as tumors from 8-10 week-old Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice
were isolated by retrograde perfusion of the common bile duct with a collagenase/DNase
solution as described (Collagenase Type IV and DNase I from Worthington, Lakewood,
NJ) [129]. Human umbilical vein endothelial cells (HUVECs) were cultured in Medium199
supplemented with 20% FBS, 4 mM glutamine, 40 µg/ml bovine brain extract, 80 units/ml
heparin, and 100 U/ml penicillin (all cell culture articles were purchased from Sigma
Chemical Co., St. Louis, MO). HUVECs were trypsinized, resuspended in 10% FBS RPMI,
and co-cultured with islets/tumors in a three-dimensional collagen matrix (Vitrogen from
Nutacon, Leimuiden, Netherlands) as described  [127]. After 2–3 days, the response of
endothelial cells to islets and tumors was scored. Approximately 30 islets/tumors were
analyzed per genotype.
Electron microscopy
For light and transmission electron microscopy, mice were perfused with PBS
followed by Karnovski solution. In collaboration with Prof. V. Djonov, isolated pancreata
were postfixed in osmium tetroxide, block-stained using uranyl acetate, dehydrated through
ascending concentrations of ethanol, and embedded in epoxy resin. Semithin sections were
obtained at a nominal thickness of 1 µm, stained with toluidine blue, and viewed under a
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Leica light microscope. Ultrathin sections were obtained at 80-90 nm, counterstained with
lead citrate, and viewed on a Philips EM-300 microscope.
Corrosion cast analysis
In collaboration with Prof. V. Djonov, Mercox (Japan Vilene Co) vessel casts were
prepared of pancreata from Rip1VEGF-D J97 and C57BL/6 mice. The vasculature was
perfused with a solution of 0.9% sodium chloride containing 1% heparin (Liquemine; Roche
Pharma AG, Reinach, Switzerland) and 1% procaine followed by a freshly prepared solution
of Mercox containing 0.1 mL accelerator per 5 mL resin according to [130]. After 2 to 4
weeks of tissue dissolution in 15% KOH, casts were dehydrated in ethanol and dried in a
vacuum desiccator. Samples were glued onto stubs with carbon, spattered with gold, and
examined with a Philips XL 30 FEG scanning electron microscope.
VEGF-D promotes metastasis VEGF-D
29
3. Generation and analysis of transgenic mice expressing lymphangiogenic VEGF
family members during Rip1Tag2 tumorigenesis
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3.1.1. Abstract
Metastasis is the foremost cause for cancer death. In many human carcinomas,
expression of the lymphangiogenic factor vascular endothelial growth factor-D (VEGF-D)
correlates with regional lymph node metastasis. This study addressed the effect of VEGF-D
on tumor lymphangiogenesis and metastasis. Therefore, Rip1VEGF-D transgenic mice were
generated, expressing the transgene in β-cells of pancreatic islets of Langerhans. Whereas
wildtype islets were not associated with lymphatics, RipVEGF-D islets were surrounded by
lymphatic vessels, often containing leucocyte accumulations and hemorrhage. These mice
were crossed with Rip1Tag2 mice, a well-characterized transgenic model of poorly metastatic
pancreatic β-cell carcinogenesis. Rip1Tag2;Rip1VEGF-D mice formed tumors surrounded by
lymphatics and frequently developed lymph node and lung metastases. Tumor
hemangiogenesis was significantly reduced in vivo and in vitro. In contrast, tumors resulting
from subcutaneous injection of Rip1Tag2;Rip1VEGF-D cells exhibited intra-tumoral
lymphangiogenesis, while hemangiogenesis was unaffected. Our results demonstrate that
VEGF-D-induced lymphangiogenesis promotes metastasis to lymph nodes and lungs and that
VEGF-D-elicited effects are dependent on the tumor microenvironment. Furthermore, the
comparison of Rip1Tag2;Rip1VEGF-D with the previously described Rip1Tag2;Rip1VEGF-
C mice revealed unexpected functional differences between VEGF-D and VEGF-C.
3.1.2. Introduction
VEGF-D and -C, the only known ligands for VEGFR-3, belong to the VEGF family of
ligands (reviewed in [45]. Proteolytic processing of human VEGF-D and -C by proprotein
convertases, plasmin and other (thus far unknown) proteases generates the mature ∼40 kDa
homodimers, which display increased affinity for VEGFR-3 but also for VEGFR-2 that is
predominantly expressed on blood endothelium [131, 132]. While VEGF-C exhibits the same
binding properties in mice, processed mouse VEGF-D (VEGF-DΔNΔC) exclusively activates
mouse VEGFR-3 [133]. Mature human VEGF-D however activates both mouse VEGFR-2
and 3 (K. Alitalo, unpublished observations). VEGF-C binds also to the co-receptor NP-2,
which is expressed on lymphatic endothelium and is essential for normal lymphatic vessel
development [34]. The binding capacity of VEGF-D to NP-2 remains to be investigated.
Recent mouse knock-out studies have shown that VEGF-D is dispensable for the
development of a lymphatic system during embryogenesis and cannot compensate for absent
VEGF-C in VEGF-C-/- mice, which fail to develop functional lymphatic vessels [32, 134].
Nevertheless, the lymphangiogenic and angiogenic potency of VEGF-D has been clearly
demonstrated. Ectopic expression of mouse VEGF-D in the skin of K14-VEGF-D transgenic
mice induced dermal lymphangiogenesis, and adenoviral delivery of human VEGF-D into
rabbit skeletal muscle, adventitia of rabbit carotid arteries, and porcine hearts induced both
lymphangiogenesis and angiogenesis [135-138].
The role of VEGF-D in tumor metastasis has been recently addressed in several clinical
and animal studies. In a number of human cancers, including papillary thyroid, gastric,
pancreatic, colorectal, breast, ovary and endometrial carcinoma, an elevated tumoral VEGF-D
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 expression correlates with an increased incidence of regional lymph node metastases [113,
114, 139-142]. In three of these studies, a concomitant increase in peri-tumoral
lymphangiogenesis as the underlying mechanism of enhanced lymphogenous metastasis has
been reported [139, 140, 143]. Moreover, xenotransplantation of human carcinoma-derived
cell lines expressing VEGF-D into immunocompromised mice resulted in enhanced
lymphogenous metastasis via induction of tumor-associated lymphangiogenesis [100, 144,
145]. Together, these studies indicate that tumoral overexpression of VEGF-D may promote
tumor-associated lymphangiogenesis and thereby lymphogenous metastasis.
To investigate the effect of VEGF-D on tumor development and metastasis, we have
generated Rip1VEGF-D transgenic mice, in which the expression of human VEGF-D is
driven by the rat insulin promoter (Rip1) and thereby is specifically targeted to β-cells of
pancreatic islets of Langerhans. Rip1VEGF-D mice were subsequently crossed to Rip1Tag2
tumor mice, a transgenic mouse model of poorly metastatic β-cell carcinogenesis [124], and
tumor lymphangiogenesis, angiogenesis, and metastasis were analyzed in double-transgenic
Rip1Tag2;Rip1VEGF-D mice. We furthermore aimed to compare this newly established
mouse model with the previously described Rip1VEGF-C and Rip1Tag2;Rip1VEGF-C mice,
where VEGF-C has been shown to promote peri-tumoral lymphangiogenesis and lymph node
metastasis [146]. The side-by-side comparison of effects elicited by these two highly related
lymphangiogenic growth factors revealed not only similarities but also fundamental and
unexpected differences with regard to tumor growth and metastatic dissemination.
3.1.3. Materials and Methods
Transgenic Mouse Lines
Rip1VEGF-D transgenic mice were generated by M. Jeltsch and T. Veikkola
(Molecular/Cancer Biology Laboratory, Biomedicum, University of Helsinki, Helsinki,
Finland) according to standard procedures [147]. The cDNA encoding the 1065 bp coding
region of human VEGF-D (nucleotides 411-1475, Acc. No. AJ000185) was cloned between
the 704 bp BamHI/XbaI fragment of the rat insulin gene II promoter (Rip1; [124]) and a 436
bp fragment containing SV40 introns and polyadenylation signal sequences.
Genotypes were confirmed by Southern blot and PCR analysis. Routine PCR
screening of Rip1VEGF-D heterozygotes was performed using a primer pair specific for the
t ransgene ( forward  pr imer  located  in  the  Rip1 sequence:  5 ' -
TAATGGGACAAACAGCAAAG; reverse primer located in the human VEGF-D sequence:
5'-TCCAAACTAGAAGCAGCCCTGATCT), starting from standard toe or tail genomic
DNA preparations. PCR cycles were: 94°C, 5 min (x1); 94°C, 30 sec, 58°C, 30 sec, and
72°C, 30 sec (x34); and 72°C, 7 min (x1). PCR products were analyzed in 1.5% agarose gels.
Glucose measurements
Blood glucose levels of mice were measured by tail vein blood sampling using the
Accu-Chek Comfort device and test stripes (Roche Diagnostics Corporation, Indianapolis,
IN). Basal glucosemy was assessed on mice fasting for six hours. Intra-peritoneal glucose
tolerance tests (IPGTT) were performed on 8 to 21 week-old mice with a body weight
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between 25 and 35 grams. Mice were starving for 16 hours and subsequently i.p. injected with
1 gram D-(+)-Glucose anhydrous (Sigma Chemical Co., St. Louis, MO)/kg body weight.
Blood glucose levels were measured 0, 20, 40, 70 and 100 min after injection. The maximum
measurable blood glucose concentration was 34 mmol/l, and mice were considered
hyperglycemic when fasting blood glucose levels were >6 mmol/l or peak glucose levels
during the IPGTT were >13 (which was the maximum measurement for wildtype littermate
controls). Data represent mean ± standard deviation.
Immunoblotting
The processing status of VEGF-D expressed by Rip1VEGF-D islets,
Rip1Tag2;Rip1VEGF-D and Rip1Tag2 tumors as well as of cell lines established from
Rip1Tag2;Rip1VEGF-D and Rip1Tag2 tumors was assessed by immunoblotting. Protein
lysates of tumors from twelve week-old Rip1Tag2;Rip1VEGF-D and Rip1Tag2 mice were
obtained by homogenization of isolated tumors with a polytron tissue grinder in lysis buffer
and subsequent centrifugation. Islets of Rip1VEGF-D mice were resuspended in standard
sample buffer and sonicated for five min. 40 µg of tumor and cell line protein and the total
islet lysate were resolved by 12% SDS-PAGE, transferred to Immobilon-P membranes
(Millipore) and probed with 5 µ l/ml rabbit anti-rat VEGF-D antibody (Reliatech,
Braunschweig, Germany) using the Uptilight chemiluminescence system (Uptima,
Montluçon, France). 10 ng of recombinant human VEGF-D (R&D Systems, Minneapolis,
MN) were used as positive control.
Cell culture
Tumor cell lines were established from insulinomas of tewlve week-old Rip1Tag2
and Rip1Tag2;Rip1VEGF-D mice. Therefore, tumors were excised from pancreata and
single-cell suspended in cold PBS. The suspension was mixed 1:1 with DMEM supplemented
with 10% fetal bovine serum, 10 % horse serum, 2 mmol/L glutamine and 100 units/mL
penicillin. After 1 minute of sedimentation at room temperature, the supernatant was
transferred to a new tube, re-mixed 1:1 with medium and let sediment another 10 min at room
temperature. The pellet containing the tumor cells was resuspended and cells were plated on
24-well plates for further expansion. 106 cells were injected subcutaneously into the two
flanks of mice anesthetized with isoflurane (Minrad Inc., Buffalo, NY).
ELISA
We determined tumor-derived circulating human VEGF-D levels in sera of 12 week-
old C57BL/6, Rip1VEGF-D, Rip1Tag2, and Rip1Tag2;Rip1VEGF-D mice by using the
Human VEGF-D Quantikine ELISA Kit (R&D Systems, Minneapolis, MN) according to the
manufacturer’s protocol. Blood was derived by heart puncture of mice inhalation-anesthetized
with isoflurane. Sera were obtained by clotting of punctured blood for 1 hour at room
temperature and subsequent centrifugation for 20 min at 3000 rpm.
For histopathological analysis, lectin perfusion, electron microscopy, and vascular
cast analysis refer to General Materials and Methods
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3.1.4. Results
Peri-insular lymphangiogenesis in Rip1VEGF-D transgenic mice
To generate transgenic mice expressing human VEGF-D specifically in β-cells of
pancreatic islets of Langerhans, a cDNA comprising the full-length coding sequence of
human VEGF-D (hVEGF-D) was cloned between the rat insulin II gene promoter fragment
(Rip) and the human growth hormone introns and a polyadenylation signal (Figure 1).
Injection of the transgene into fertilized C57BL/6 oocytes resulted in seven viable and fertile
founder lines exhibiting stable germline transmission.
Figure 1. Cloning of the
Rip1VEGF-D construct
The blunted EcoRII-
hVEGF-D was ligated to
the XbaI/HindIII-opened
Rip1 vector.
Immunohistochemical and immunofluorescence analysis of pancreatic sections
revealed that transgenic founder lines expressed VEGF-D specifically in islets of Langerhans,
whereas no VEGF-D expression was detectable in islets of wildtype littermate mice (Figures
2A and B). No VEGF-C expression could be detected in Rip1VEGF-D mice by
immunohistochemistry (data not shown). The founder line Rip1VEGF-D J97 exhibited the
most intense β-cell-specific signal for VEGF-D and was used for phenotypical analysis. The
founderlines Rip1VEGF-D B12 (only weakly expressing VEGF-D) and Rip1VEGF-D E2
(exhibiting strong VEGF-D expression) served as controls in several experiments. In the
following, Rip1VEGF-D refers to the Rip1VEGF-D J97 founderline if not otherwise noted.
To investigate morphological changes elicited by transgenic VEGF-D expression, we
analyzed pancreata of Rip1VEGF-D and littermate control mice by histology,
immunohistochemistry, immunofluorescence, and electron microsopy. Hematoxylin and
eosin stainings as well as toluidine blue-stained semi-thin sections of pancreata revealed that
most islets of Rip1VEGF-D mice were separated from the surrounding exocrine tissue by
large endothelium-lined clefts, whereas islets of wildtype mice were completely embedded in
the exocrine pancreas (Figures 2C-F). Based on immunoreactivity for the lymphatic
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endothelium marker LYVE-1, peri-insular lacunae were identified as lymphatic vessels
(Figure 2H).
Figure 2. Histological
analysis of pancreata from
C57BL/6 control  and
transgenic Rip1VEGF-D
mice
(A , B) Immunohistochemical
staining for VEGF-D (grey)
(C, D) Hematoxylin and eosin
staining (E, F) Toluidine blue-
stained semi-thin sections.
Note the intra-lymphatic
lymphocytes and the smaller
size of the transgenic islet,
which lacks blood capillaries
on this section (see also
quanti f icat ion of  is le t
microvessel density below) (G,
H ) Immunohistochemical
staining for LYVE-1 (brown).
Dashed lines demarcate islets,
arrows in (B) indicate intra-
lymphatic blood vessels,
arrowheads in (F) indicate
endothelial lining, arrowhead
in (H) indicates immune cells;
A, artery; C, blood capillary;
Ex, exocrine tissue; L,
lymphatic lacuna; V, vein.
Scale bars (A-H): 100µm.
Analysis by transmission electron microscopy (TEM) revealed that peri-insular lacunae
displayed typical features of lymphatic endothelium. As shown in Figure 3A, the endothelial
cells lacked fenestrations and cells were in part overlapping (black arrowheads). Moreover,
the basement membrane was discontinuous or even absent and the abluminal endothelial
surface was closely associated with collagen fibrils (asterisks) produced by the adjacent
fibroblasts (white arrowheads). However, no lymphatic vessels were observed in the islets
themselves. Thus, similarly to VEGF-C in the previously characterized Rip1VEGF-C mice
[146], VEGF-D exerts a lymphangiogenic function by promoting peri-insular
lymphangiogenesis in Rip1VEGF-D mice.
In contrast to the previously described Rip1VEGF-C mice, the newly formed
lymphatic vessels of Rip1VEGF-D mice contained immune cells, which accumulated with
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increasing age of the mice and filled the entire lacuna (Figure 3A-G). These cells were readily
detectable by hematoxylin and eosin staining, and characterization using immunofluorescence
staining revealed that most of the leucocytes were CD4-positive T helper and B220-positive
B lymphocytes as well as F4/80-positive macrophages. CD8-positive cytotoxic T
lymphocytes were absent from the clusters. Some leucocytes were also found in islets
themselves by immunofluorescence analysis (Figure 3D and 3F).
Figure 3. Intra-lymphatic immune
cell accumulations in Rip1VEGF-D
mice
(A ) TEM showing a peri-insular
l ympha t i c  lacuna  containing
lymphocytes. The inset is a higher
magnification of the boxed area as
indicated. Asterisks indicate collagen
fibrils in the abluminal space of the
lacuna, black arrowheads indicate
overlapping lymphatic endothelial
cells, white arrowheads indicate
fibroblasts
(B) Hematoxylin and eosin staining of
a pancreatic section from a six
month-old Rip1VEGF-D mouse (C)
Immunohistochemical analysis of a 12
moth-old Rip1VEGF-D pancreas with
anti-LYVE-1 antibody (brown,
counter-staining with hematoxylin).
The dashed line delineates the islet
(D-G) Double immuno-fluorescence
analysis with anti-LYVE-1 (green)
and (D ) anti-CD45 (red) (E) anti-
B220 (red) (F) anti-CD4 (red) and
(G) anti-CD8 antibody (red) of a 12
week-old Rip1VEGF-D mouse. Nuclei
are counterstained with DAPI. C,
blood capillary; E, endothelial cells;
En, endocrine tissue; Ex, exocrine
tissue; Ly, lymphocytes. Scale bars:
(A) 15µm, (B, C) 100µm, (D-G)
50µm.
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Generation of transgenic mice using the Rip1 vector construct has repeatedly resulted
in the induction of an immune cell-mediated diabetic phenotype (G. Christofori, personal
communication). Also mice deriving of one of the Rip1VEGF-D founderlines, namely
Rip1VEGF-D E2, exhibited typical symptoms of diabetes including polyuria and died within
few months of age. To investigate, whether immune cell accumulations observed in
Rip1VEGF-D J97 mice resulted from an immune response of the mouse immune system to
the human transgene, we compared the pancreatic histology of Rip1VEGF-D J97 with that of
Rip1VEGF-D E2 mice and performed several blood glucose measurements. As shown in the
right panel of Figure 4A, accumulations of immune cells were found around but also actively
infiltrating islets of 14 week-old Rip1VEGF-D E2 mice. Probably as a result of immune cell-
mediated destruction of β-cells, only few islets were detectable on a given pancreatic section.
In contrast, pancreatic sections of age-matched Rip1VEGF-D J97 mice harbored comparable
numbers of islets as control mice. Also, on common hematoxylin and eosin-stained sections
and upon immunohistochemical stainings counterstained with hematoxylin, immune cell
accumulations were found to surround a subset of islets but were never found to infiltrate
such (left panel of Figure 4A). Furthermore, repeated fasting glucose measurements revealed
pathologically elevated blood glucose levels and thus diabetes in Rip1VEGF-D E2 but not
Rip1VEGF-D J97 mice (data not shown). Even a more sensitive intraperitoneal glucose
tolerance test demonstrated a normal glucose metabolism in Rip1VEGF-D J97 mice
comparable to that of Rip1VEGF-D B12 and C57BL/6 control mice, whereas again,
Rip1VEGF-D E2 mice exhibited pathologically elevated blood glucose levels (Figure 4B).
Together, these data eliminate an auto-immune reaction as cause of immune cell
accumulations found around islets of Rip1VEGF-D J97 mice. In comparison, in Rip1VEGF-
C mice, immune cells in peri-insular lymphatic vessels were not detectable on common
histologic sections and no clusters were observed [146].
Figure 4. Islet-associated
immune cells and intra-
peritoneal glucose tolerance
tests of Rip1VEGF-D transgenic
founderlines B12, E2 and J97
(A )  Immunohis tochemical
staining with anti-Podoplanin
antibody on pancreata of
R i p 1 V E G F - D  J 9 7  a n d
Rip1VEGF-D E2 mice (B )
dynamics of serum glucose levels
of two Rip1VEGF-D B12, three
Rip1VEGF-D J97,  three
Rip1VEGF-D E2 and three
C57BL/6 mice upon glucose
challenge at timepoint 0. Data
represent means ± SD. Dashed
lines delineate islets, Scale bars:
50µm.
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Surprisingly, we found that many lymphatic lacunae and regional lymph nodes of
Rip1VEGF-D mice contained erythrocytes, which were never found in lymphatic vessels or
lymph nodes of control and Rip1VEGF-C mice (Figure 5A-D) [146]. This finding implies
that in transgenic mice, red blood cells were drained from the de novo peri-insular lymphatic
vessels via preexisting pancreatic lymphatics to the lymph nodes, which suggests a functional
linkage between newly formed and inherent lymphatic vessels. Using vascular casting
experiments and lectin perfusion, we assessed whether erythrocytes reached the lymphatic
vasculature via blood-lymphatic vessel shunts or whether our observations resulted from
artifacts. To prepare blood vascular corrosion casts, we injected a synthetic resin into the
thoracic artery and the portal vein of anesthetized mice and perfused the pancreatic blood
vasculature. After digestion of the organic material, we obtained pancreatic blood vascular
corrosion casts. Scanning electron microscopy (SEM) of the casts visualized the dense blood
capillary network of wildtype islets of Langerhans as shown in Figure 5E. However, in
Rip1VEGF-D mice, also some of the islet-surrounding lymphatic lacunae were filled with the
injected resin (asterisk in Figure 5F), obscuring the blood capillaries of such islets. In a
second assay, we injected a fluorophore-labeled tomato lectin into the tail vein of anesthetized
mice. This naturally occurring glycoprotein interacts with carbohydrates of blood
endothelium. Also by this technique, the functional blood vessels are perfused and can be
visualized by microscopy. As shown in Figure 5G and H, the i.v. injected lectin decorated the
blood capillaries of control and transgenic pancreata. Interestingly, islets of Rip1VEGF-D
mice were only poorly vascularized, often even appearing devoid of blood capillaries on
several serial sections (see also quantification of islet microvessel density below). However,
we could not detect any lectin on the endothelium of peri-insular lymphatic lacunae.
The vascular casting experiment confirmed the presence of blood-lymphatic vessel
shunts in the vicinity of some Rip1VEGF-D islets. The lack of lectin-labeled lymphatic
lacunae in transgenic mice can be explained by a smaller affinity of the lectin for
carbohydrates on lymphatic endothelium. Alternatively it is possible that on the sections
examined, no intra-lymphatic hemorrhage and thus no blood-lymphatic vessel shunts were
present. Furthermore, these data revealed that transgenic islets appeared smaller and exhibited
less blood capillaries than control islets.
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Figure  5 .  Per i - insular
hemorrhage and blood-
lymphatic vessel shunts in
Rip1VEGF-D mice
 (A, B) Hematoxylin and eosin
staining of islets (C, D)
Hematoxylin and eosin staining
showing lymph nodes. (E, F)
SEM of blood vascular casts from
pancreata showing islets of
Langerhans from a C57BL/6 and
a Rip1VEGF-D mouse. (G, H)
The functional pancreatic blood
vasculature visualized by
perfusion with lectin (yellow).
Note the large blood capillary
heading from the exocrine tissue
through the lymphatic lacuna
towards the transgenic islet.
Nuclei are counterstained with
DAPI (blue).
Fine dashed lines delineate islets,
large dashed lines indicate the
peri-insular lymphatic lacuna,
arrows indicate hemorrhages;
the asterisks indicates the resin-
filled peri-insular lymphatic
lacuna. Ex, exocrine tissue; Scale
bars: (A-H) 100µm.
Together, our results indicate that transgenic expression of VEGF-D promotes the
growth of peri-insular lymphatic vessels. Nevertheless, as described, we detected clear
qualitative differences between VEGF-D-induced lymphatic vessels and those induced by
transgenic VEGF-C in Rip1VEGF-C mice.
Repressed islet angiogenesis and reduced islet size in Rip1VEGF-D transgenic mice
The fully processed form of human VEGF-D (VEGF-DΔNΔC) has been repeatedly
shown to activate VEGFR-2 and to thereby promote angiogenesis [133, 136-138].
Rip1VEGF-D islets expressed large amounts of VEGF-DΔNΔC as revealed by immunoblot
analysis of isolated islets (see below, Figure 7B). Therefore, we quantified the islet
microvascular density (MVD) by immunohistochemical staining with anti-CD31 antibody.
However, confirming our observations from the semi-thin sections, vascular casts, and lectin
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perfusion experiments mentioned above, the MVD of Rip1VEGF-D islets was significantly
reduced in comparison to littermate controls (Table I).
Next, we tested islets of Rip1VEGF-D mice for their angiogenic properties using an in
vitro collagen gel assay, in which isolated islets or tumors were co-cultured with human
umbilical vein endothelial cells (HUVECs) [127, 148]. Wildtype islets do not display any
angiogenic activity, whereas Rip1VEGF-A transgenic islets as well as Rip1Tag2 tumors have
been reported to induce angiogenic responses in co-cultured HUVECs [148]. In keeping with
previous studies, 74% of positive controls (tumors of Rip1Tag2 mice, see also below) were
angiogenic and stimulated HUVECs to form tubule-like structures (see inset in Figure 6).
Notably, all islets of Rip1VEGF-D transgenic mice failed to induce any angiogenic response
(Figure 6).
Figure 6. Collagen gel assay
with Rip1VEGF-D islets
Islets and tumors derived from
9 week-old Rip1VEGF-D
(n=29, N=2) and Rip1Tag2
control mice (n=35, N=4),
respectively. Representative
examples of non-angiogenic
and angiogenic islets are
shown. Results are indicated as
percentages of islets or tumors
in the respective angiogenesis
class above the bars.
We hypothesized that impaired vascularization of transgenic islets might counteract
islet growth and assessed the islet diameter on hematoxylin and eosin-stained histological
sections. Indeed, measurement of islet diameters revealed that Rip1VEGF-D transgenic islets
were significantly smaller than control islets (Table I).
Table I. Islet size and microvessel density (MVD) in control versus Rip1VEGF-D mice
Results VEGF-D
40
These results demonstrate that VEGF-D does not exert any angiogenic activity in
Rip1VEGF-D mice. Rather, islet vascularization is reduced, resulting in impaired islet
growth. These results contrast with the observations from Rip1VEGF-C mice, in which
expression of VEGF-C does not affect islet vascularization and growth [146].
VEGF-D promotes peri- and intra-tumoral lymphangiogenesis
To assess the role of VEGF-D in tumor angiogenesis, lymphangiogenesis, and
metastasis, we crossed Rip1VEGF-D with Rip1Tag2 mice, a transgenic mouse model of
poorly metastatic pancreatic β -cell carcinogenesis [124]. Rip1Tag2 control and
Rip1Tag2;Rip1VEGF-D double transgenic mice were sacrificed between 12 and 14 weeks of
age, a time-point, when these mice succumb to hypoglycemia caused by excessive tumoral
insulin production.
Immunohistochemical analysis for VEGF-D revealed that in Rip1Tag2;Rip1VEGF-D
mice, most β-cells of small adenomas and carcinomas expressed VEGF-D, whereas in larger
adenomas and carcinomas, the staining pattern was more heterogenous with areas devoid of
VEGF-D expression (Figure 7A). Immunoblot analysis for VEGF-D showed the abundant
and predominant presence of the fully processed (human) VEGF-DΔNΔC as well as small
amounts of partially processed VEGF-DΔC and full length VEGF-D in lysates of most
Rip1Tag2;Rip1VEGF-D tumors. Small amounts of full length mouse VEGF-D and VEGF-
DΔC were occasionally detected in Rip1Tag2 control tumors (Figure 7B). To assess, whether
the secreted VEGF-D protein can be found in the circulation and may potentially also act at
distant organs, we performed an enzyme-linked immuno-sorbent assay (ELISA) on serum
samples derived from Rip1VEGF-D and Rip1Tag2;Rip1VEGF-D as well as control mice. As
depicted in Figure 7C, no elevation of circulating VEGF-D levels was observed in VEGF-D
transgenic when compared to control mice, indicating that VEGF-D might be sequestered
locally. However, thus far, no heparin-binding activity was reported for both VEGF-C and
VEGF-D.
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Figure 7. Expression of VEGF-D in Rip1Tag2 control and Rip1Tag2;Rip1VEGF-D
tumors and Rip1VEGF-D islets
(A) Immunohistochemical staining with anti-VEGF-D antibody (grey) on pancreatic sections
of twelve week-old Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice (B) Immunoblot analysis with
anti-VEGF-D antibody on lysates of twelve week-old Rip1Tag2 (n=3, N=2) tumors,
Rip1Tag2;Rip1VEGF-D tumors (n=5, N=2), and Rip1VEGF-D islets (n=200, N=4).
Recombinant hVEGF-DΔNΔC (10 ng) served as positive control (C) ELISA for circulating
VEGF-D on sera of control and transgenic mice as indicated (left panel) standard curve
(right panel) VEGF-D serum levels. Dashed lines delineate tumors; Ex, exocrine tissue; T,
tumor; VEGF-DΔC, partially processed VEGF-D; VEGF-DΔNΔC, fully processed VEGF-D.
Scale bars (A): 100µm.
To assess the lymphangiogenic activity of VEGF-D in tumor mice, we analyzed
pancreatic sections of twelve week-old Rip1Tag2 control and Rip1Tag2;Rip1VEGF-D mice
with different antibodies specific for lymphatic endothelium, such as LYVE-1, VEGFR-3,
Podoplanin, and the transcription factor Prox-1. In agreement with previous publications,
analysis of Rip1Tag2 pancreata by immunofluorescence staining for LYVE-1 revealed that
lymphatic vessels were only rarely found in close association with tumors. In contrast, most
tumors of Rip1Tag2;Rip1VEGF-D mice were partially or completely surrounded by
lymphatic vessels (Figure 8). Collapsed and non-collapsed lymphatic vessels were also found
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on the edge and occasionally in the center of larger adenomas and carcinomas of
Rip1Tag2;Rip1VEGF-D mice (Figure 8D). Peri-tumoral lymphatics were immunoreactive for
all markers tested (Figures 8 C-F). As expected, the Prox-1 expression was more pronounced
in developing peri-tumoral lymphatic vessels than in quiescent lymphatics of the exocrine
pancreas (Figures 8F)[149]. Consistent with previous reports, β-cells also expressed low
levels of Prox-1 (Figure 8F) [150, 151].
To quantify peri-tumoral lymphangiogenesis, we assessed the extent by which
LYVE-1-positive lymphatic vessels surrounded the tumor perimeter. Thereby we found that
only 14% of control tumors were closely associated with lymphatics, while more than 60% of
VEGF-D-expressing tumors were completely surrounded by lymphatic vessels (Figure 8G).
Together, these results indicate that VEGF-D promotes peri- and, to some extent, also intra-
tumoral de novo lymphangiogenesis.
Figure 8. Peri-tumoral lymphangiogenesis in Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice
(A, B) Hematoxylin and eosin staining (C, D) Double-immunofluorescence for the blood
endothelium marker CD31 (red) and LYVE-1 (green) (E) Immunofluorescence analysis with
anti-VEGFR-3 antibody (red) (F) Double-immunofluorescence analysis for Podoplanin (red)
and Prox-1 expression (green). The inset is a magnification of the boxed area as indicated.
(G) Quantification of peri-tumoral lymphangiogenesis as described in the text. Results are
indicated as percentages of tumors in a given class above the bars. 490
Rip1Tag2;Rip1VEGF-D tumors (N=22) and 159 Rip1Tag2 tumors (N=9) were analyzed. (C-
F) Nuclei are counterstained with DAPI (blue). Dashed lines delineate tumors; Ex, exocrine
tissue, Tu, tumor. Scale bars: 100 µm. Arrowheads in (B) indicate endothelial lining; dashed
lines delineate tumors; Ex, exocrine tissue; T, tumor. Scale bars (A-F): 100µm.
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Above we have demonstrated the presence of blood-lymphatic vessel shunts in the
vicinity of VEGF-D-expressing islets. In analogy to these observations, also 32% of the
tumor-associated lymphatic vessels of Rip1Tag2;Rip1VEGF-D mice (n=522, N=20) were
filled with profuse hemorrhage (Figure 9). Occasionally, erythrocytes were also found next to
Rip1Tag2 tumors but never inside of lymphatic vessels. We speculate that also in double-
transgenic tumor mice, shunts between blood and lymphatic vessels account for the intra-
lymphatic hemorrhages. Furthermore, we found erythrocytes in regional lymph nodes of
Rip1Tag2;Rip1VEGF-D but not of Rip1Tag2 mice, which indirectly illustrates the draining
capacity of newly formed peri-tumoral lymphatic vessels (data not shown).
Figure 9. Hemorrhage in lymphatic vessels associated with Rip1Tag2;Rip1VEGF-D
tumors
(A and B) Hematoxylin and eosin stainings of pancreatic sections. Ex, exocrine tissue; H,
hemorrhage; Ic, immune cells; T, tumor. Scale bars: 100 µm.
Impaired tumor angiogenesis and reduced tumor growth in Rip1Tag2;Rip1VEGF-D
mice
As mentioned above, the fully processed form of human VEGF-D (VEGF-DΔNΔC)
has been repeatedly shown to activate VEGFR-2 and to thereby promote angiogenesis [133,
136-138]. Since we detected high levels of VEGF-DΔ N Δ C in tumors of
Rip1Tag2;Rip1VEGF-D mice, we quantified tumor angiogenesis in Rip1Tag2;Rip1VEGF-D
and control mice. The measurment of tumor blood vessel density is commonly used to assess
tumor-induced angiogenesis (reviewed in [152]). Therefore, we stained pancreatic sections of
the two genotypes using the blood endothelial marker CD31 and counted intra-tumoral blood
vessels. In analogy to the impaired angiogenesis in islets of Rip1VEGF-D mice, the tumor
microvessel density was significantly lower in Rip1Tag2;Rip1VEGF-D when compared to
control mice. Concomitantly with the reduced tumor angiogenesis, we observed a reduction
of tumor volumes in Rip1Tag2;Rip1VEGF-D in comparison to control mice. In accordance
with a limited blood supply, VEGF-D-expressing tumors contained less proliferating and
significantly less apoptotic cells than control tumors, suggesting a lower turn-over of cancer
cells. The tumor incidence was unaffected by the expression of VEGF-D (Table II).
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Table II. Phenotypical analysis of Rip1Tag2 and Rip1Tag2;Rip1VEGF-D tumors
During our analysis of tumor blood vessels, we observed that not only the quantity but
also the quality of CD31-positive tumoral blood vessels was affected by the expression of
VEGF-D. In many tumors of Rip1Tag2;Rip1VEGF-D mice, blood vessels were dramatically
enlarged and more irregularly distributed within the tumor when compared with control
tumors. Since it is known that dilated blood vessels can result from insufficient stabilization
of blood vessels by pericytes, we stained Rip1Tag2 and Rip1Tag2;Rip1VEGF-D tumors with
anti-smooth muscle actin and anti-NG-2 antibody, two markers for pericytes [3]. However,
the blood vessels of both control and Rip1Tag2;Rip1VEGF-D tumors were comparably
coated by smooth muscle cells and pericytes (Figure 10A).
To test the angiogenic capacity of tumor cell-secreted VEGF-D in vitro, we performed
a collagen gel assay with tumors from 9 week-old Rip1Tag2 and Rip1Tag2;Rip1VEGF-D
mice as described above. In line with our histological observations, we found that
Rip1Tag2;Rip1VEGF-D tumors induced markedly less angiogenic response in co-cultured
HUVECs than control tumors (Figure 10B). In fact, most of the tumors of 9-week old
Rip1Tag2;Rip1VEGF-D mice were very small and lacked the typical reddish color of
angiogenic tumors. The reduced angiogenic activity of Rip1Tag2;Rip1VEGF-D tumors
demonstrates that expression of VEGF-D directly or indirectly inhibits angiogenesis in our
mouse model. Again, these observations strongly contradict the results of previous studies
where VEGF-DΔNΔC induced angiogenesis.
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Figure 10. Pericyte-
coating of intra-
tumoral blood vessels
and angiogenic activity
of  Rip1Tag2;Rip1
VEGF-D tumors
(A ) Double immuno-
fluorescence staining
with anti-CD31 (green)
and anti-NG-2 (red)
antibody. Nuclei are
counterstained with
DAPI. (B) Collagen gel
assay. Islets and tumors
were derived from 9
week -o ld  Rip1Tag2;
Rip1VEGF-D (n=29,
N=4) and Rip1Tag2
control mice (n=35,
N = 4 ) .  Representative
examples  of  non-
angiogenic and angio-
genic responses are
shown. Results are
indicated as percentages
of islets or tumors in the
respective angiogenesis
class above the bars.
Dashed lines delineate
tumors. Ex, exocrine
tissue; T, tumor. Scale
bars: 50 µm.
VEGF-D promotes metastasis to regional lymph nodes and the lungs
Evidence from clinical and experimental studies suggests that the close association of
tumors with lymphatic vessels might promote lymphogenous spread of tumor cells, which
may follow routes of natural drainage and subsequently form metastases in regional lymph
nodes. To assess whether VEGF-D-induced peri-tumoral lymphangiogenesis promotes the
lymphogenous dissemination of cancer cells, hematoxylin and eosin-stained pancreatic
sections of Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice were screened for metastatic
insulinoma cells. Consistent with previous reports, β-cells were only occasionally found to
disseminate in lymphatic vessels of Rip1Tag2 pancreata, which may account for the fact that
only 15% of the investigated control mice displayed metastases in pancreatic lymph nodes. In
contrast, all investigated double-transgenic Rip1Tag2;Rip1VEGF-D mice exhibited tumor
cell clusters circulating in lymphatic vessels located next to insulinomas and in the exocrine
pancreas (data not shown). In 61% of these mice, β-cells were drained to the regional lymph
nodes and formed secondary tumors (Figure 11A). Furthermore, 86% of
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Rip1Tag2;Rip1VEGF-D mice analyzed for peripheral metastases exhibited such in the lung
parenchyma and/or surface, the latter being already visible upon macroscopical inspection
(Figure 11C). Tumor cells retained their well-differentiated morphology, since all metastases
were immunoreactive for insulin, confirming their derivation from primary β-cell tumors
(Figures 11B and D). Also, a comparative analysis of tumor grades demonstrated that
expression of VEGF-D did not significantly affect the ratio of benign adenoma versus
malignant carcinoma (Table III).
Figure 11. Regional lymph
node and distant lung
metastases in 12 week-old
Rip1Tag2;Rip1VEGF-D
double transgenic mice
(A ) Hematoxylin and eosin
staining of a pancreatic lymph
node (B) Immunofluorescence
analysis of lymph node
metastasis with anti-insulin
antibody (red). (C) Hematoxylin
and eosin staining of a lung
section (D )  Immunofluo-
rescence analysis of a lung
metastasis with an anti-insulin
antibody (red). (B and D)
Nuclei are counterstained with
DAPI (blue). Ex, exocrine
tissue; GC, germinal center;
LN, lymph node; M, metastasis.
Scale bars: 100 µm.
Table III. Tumor progression and metastatic phenotype of Rip1Tag2;Rip1VEGF-D mice
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To assess whether lung metastases originated from hematogenous tumor cell spread,
we analyzed the livers of five Rip1Tag2;Rip1VEGF-D mice displaying lung metastases by
hematoxylin and eosin and immunofluorescence stainings with anti-insulin antibody. No
hepatic metastases were found, suggesting a primarily lymphogenous spread of insulinoma
cells (data not shown). In accordance to the vast literature on Rip1Tag2 mice, we did not
detect any peripheral metastases in single-transgenic Rip1Tag2 mice. Notably, transgenic
expression of VEGF-C similarly promoted regional lymph node metastasis in
Rip1Tag2;Rip1VEGF-C mice [146]. However, neither the previous study nor our analysis of
Rip1Tag2;Rip1VEGF-C mice unveiled any lung metastases.
Since VEGF-D expression did not significantly affect the transition from benign
adenoma to invasive carcinoma and metastases were well differentiated, we hypothesize that
VEGF-D did not alter tumor cell invasive properties. These data indicate that VEGF-D
promotes regional and distant lymphogenous metastasis via the induction of tumor-associated
lymphatic vessels.
Human VEGF-D does not elicit an immune response in non-transgenic mice
In analogy to Rip1VEGF-D mice, the analysis of hematoxylin and eosin-stained
pancreatic sections of Rip1Tag2;Rip1VEGF-D mice revealed that 23% of tumor-associated
lymphatic lacunae (n=412, N=20) contained leucocyte accumulations, which consisted of the
same immune cell populations as mentioned above (Figure 12 and data not shown). In one
mouse, several small tumors were completely engulfed in a lymph node-like cluster of
leucocytes (Figure 12B). No immune cells were visible in the few tumor-associated lymphatic
vessels of Rip1Tag2 control mice (n=94, N=14).
Figure 12. Immune cell accumulations in lymphatic lacunae surrounding
Rip1Tag2;Rip1VEGF-D tumors
(A) Immunohistochemistry with anti-Podoplanin antibody (brown; counterstaining with
hematoxylin). Note that erythrocytes fill the lymphatic lacuna (B) Hematoxylin and eosin
staining. Asterisks indicate immune cell accumulations; dashed lines delineate tumors; A,
artery; Ex, exocrine tissue; Lv, lymphatic vessel; T, tumor; V, vein. Scale bars: 100 µm.
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Although the data from single transgenic Rip1VEGF-D mice did not support that peri-
insular immune cell accumulations resulted from an immune response of the mouse immune
system against human VEGF-D transgene, we wanted to further investigate whether hVEGF-
D may display immunogenic features. If so, we hypothesized that hVEGF-D-expressing
tumors would be more heavily infiltrated by immune cells than control tumors. Therefore, we
quantified intra-tumoral immune cells upon immunofluorescent labeling with an anti-CD45
antibody as well as immune markers for macrophages (F4/80), B lymphocytes (B220), T
helper lymphocytes (CD4), and cytotoxic T lymphocytes (CD8). In line with previous studies,
our analysis demonstrated that tumors of Rip1Tag2 control mice were extensively infiltrated
by CD45-positive immune cells [153], most of them being F4/80-positive macrophages.
However, to our surprise, tumors of double-transgenic mice contained significantly less
CD45-positive leucocytes and macrophages. The numbers of intra-tumoral cytotoxic T cells
was markedly reduced, yet not significantly. The amount of intra-tumoral T helper and B
lymphocytes was not affected (Table IV).
Table IV. Immune cells infiltrating Rip1Tag2 and Rip1Tag2;Rip1VEGF-D tumors
In a second experiment, we investigated whether hVEGF-D can elicit an immune
response in non-hVEGF-D transgenic mice by transplanting hVEGF-D-expressing cell lines
subcutaneously into Rip1Tag2 mice. Therefore, we established cell lines from Rip1Tag2 and
Rip1Tag2;Rip1VEGF-D tumors. As depicted in Figure 13, immunoblot analysis confirmed
expression of hVEGF-D in cell line C derived from a double transgenic tumor. In contrast,
control tumor cell line A did not produce detectable levels of VEGF-D. We injected
approximately 106 Rip1Tag2;Rip1VEGF-D or Rip1Tag2 tumor cells into each flank of a
given mouse according to the scheme in Figure 13 (mouse groups I-IV). We sacrificed
animals four weeks after tumor cell injection, harvested the tumors, measured tumor volumes
and stained tumor sections with antibodies against CD45 and F4/80 as described above. We
performed statistical analyses by comparing either mouse groups I and II (Rip1Tag2 mice
injected with control and VEGF-D-expressing cells, respectively) or mouse groups II and IV
(Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice injected with VEGF-D-expressing cells,
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respectively) As shown in Table V, Neither of the statistical results revealed any significant
differences in tumor volumes or the contents of immune cells (see below, and data not
shown).
Figure 13. Syngenic and allogenic
transplantation of tumor cell lines
derived from Rip1Tag2 and
Rip1Tag2;Rip1VEGF-D insulinomas
Immunoblotting analysis with
anti-VEGF-D antibody on lysates of
cell lines derived from Rip1Tag2 and
Rip1Tag2;Rip1VEGF-D tumors.
Staining with antibodies against actin
was used as loading control. Cell lines
A and C were used for subcutaneous
(s.c.) injection into Rip1Tag2 and
Rip1Tag2;Rip1VEGF-D mice as
schematically depicted.
The lack of an increase in immune cells associated with hVEGF-D-expressing tumors
as well as the absence of tumor cell destruction (reflected by comparable tumor volumes)
suggest that the immune system of a non-hVEGF-D transgenic mouse does not react against
hVEGF-D. Together with the fact that no destruction of β-cells occurred in Rip1VEGF-D
transgenic islets and that single transgenic mice were normoglycemic at any age, these
experiments exclude autoimmunity as cause for immune cell accumulations in peri-insular/-
tumoral lymphatics of transgenic mice. Notably however, ectopic insulinomas were not
surrounded by immune cell clusters as seen in orthotopic insulinomas (see also next section).
The tumor microenvironment modulates VEGF-D-elicited effects
Several biological effects of VEGF-D in Rip1Tag2;Rip1VEGF-D mice contrast with
results from previous mouse tumor studies. Notably, xenotransplantation experiments, in
which tumor cells producing hVEGF-D were engrafted into the skin of immunocompromized
mice, showed increased hVEGF-D-mediated intra- but not peri-tumoral lymphangiogenesis.
In addition, tumor angiogenesis and tumor growth were stimulated [100, 144]. To address
whether the function of VEGF-D may depend on the tumor microenvironment, we studied the
vascular phenotype of the previously described tumors grown upon subcutaneous
transplantation of insulinoma cells into transgenic mice. Based on the above-described results
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excluding autoimmunity to the transgene, mouse groups I and III (control cells injected into
Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice, respectively) as well as II and IV (hVEGF-D-
expressing cells injected into Rip1Tag2 and Rip1Tag2;Rip1VEGF-D mice, respectively) were
grouped into one respective category (hVEGF-D-negative and hVEGF-D-positive cell lines,
respectively). Lymphangiogenesis as well as angiogenesis associated with control and
hVEGF-D-expressing tumors were then compared upon immunofluorescence staining for
LYVE-1 and CD31.
The analysis of angiogenesis and lymphangiogenesis associated with ectopic tumors
revealed striking differences in comparison to the previously described orthotopic
insulinomas. As shown in Figure 14, expression of VEGF-D induced marked intra- but no
peri-tumoral lymphangiogenesis in 29% of subcutaneous Rip1Tag2;Rip1VEGF-D tumors
(n=7). No lymphatic vessels were found in or in close vicinity of Rip1Tag2 control tumors
(n=6). The intra-tumoral lymphatic vessels of ectopic Rip1Tag2;Rip1VEGF-D insulinomas
formed a dense lymphatic network, whereas intra-tumoral lymphatics found in orthotopic
insulinomas described above were more sparse (see also Figure 8D). Furthermore,
quantification of tumoral blood vessel densities demonstrated that in contrast to orthotopic
insulinomas, expression of VEGF-D had no effect on tumor angiogenesis in ectopic
Rip1Tag2;Rip1VEGF-D when compared to control tumors (Table V).
Figure 14. Angiogenesis and lympangiogenesis in ectopic subcutaneous Rip1Tag2 and
Rip1Tag2;Rip1VEGF-D insulinomas
Double immunofluorescence analysis with anti-CD31 (red) and anti-LYVE-1 antibody
(green). Nuclei are counterstained with DAPI (blue). Arrowheads indicate lymphatic vessels;
dashed lines delineate tumors; S, subcutis; T, tumor.
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Table V. Quantification of the blood vessel density of ectopic subcutaneous VEGF-D-
negative and –positive tumors
In conclusion, these observations demonstrate that VEGF-D modulates tumor growth,
lymphangiogenesis and angiogenesis differently depending on the encountered tumor
microenvironment. Therefore, the phenotypic differences between our transgenic mouse
model compared to previous xenotransplantation studies might – at least in part - be due to
the distint tumor microenvironment.
3.1.5. Discussion
In the recent years, tumor-associated lymphangiogenesis has gained increasing
attention as a metastasis-promoting factor. Here we addressed the effect of the
lymphangiogenic factor VEGF-D on tumor lymphangiogenesis, angiogenesis, and metastasis
in a well-characterized transgenic mouse model of pancreatic β-cell carcinogenesis
(Rip1Tag2).
We generated transgenic mice expressing human VEGF-D under the control of the
Rip1 promoter, which targets expression of the transgene specifically to β-cells of pancreatic
islets of Langerhans. The phenotypical characterization of Rip1VEGF-D mice revealed the
presence of lymphatic lacunae growing around (but not in) most islets, while islets of
wildtype littermate mice were only occasionally associated with lymphatic vessels. These
observations suggest that VEGF-D expression induced de novo lymphangiogenesis in
Rip1VEGF-D mice, which is in line with previous reports demonstrating a lymphangiogenic
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function of VEGF-D in K14-VEGF-D transgenic mice, xenotransplantation, and adenoviral
gene transfer experiments [135, 136, 138].
To investigate the impact of VEGF-D on tumor development and progression, we
crossed Rip1VEGF-D with Rip1Tag2 mice, a transgenic mouse model of poorly metastatic β-
cell carcinogenesis [124]. In line with previous studies, Rip1Tag2 control insulinomas were
only rarely associated with lymphatic vessels. Also, metastases were detected only
occasionally and exclusively in regional lymph nodes (15%). In contrast, transgenic
expression of VEGF-D in Rip1Tag2;Rip1VEGF-D mice resulted in extensive peri- and to
some extent also intra-tumoral lymphangiogenesis. The functionality of the newly formed
lymphatic vessels was indirectly demonstrated by tumor cell aggregates, which circulated in
lymphatics of the exocrine pancreatic tissue of double transgenic but not control mice.
Moreover, the increase in tumor-associated lymphangiogenesis was associated with the
frequent formation of regional lymph node (61%) and distant lung metastases (86%). Since
the first organ to be afflicted by hematogenous metastasis is the liver, the lack of hepatic
metastases in Rip1Tag2;Rip1VEGF-D mice suggests that also the lung metastases resulted
from primarily lymphogenous spread of tumor cells [154]. The metastatic cancer cells may
have reached the lungs either via lymphatic capillaries crossing the diaphragm or via the main
lymph-collecting duct (ductus thoracicus), which evacuates the lymph into the venous blood
stream that flows through the right ventricle of the heart into the pulmonary capillary bed.
VEGF-D expression did not affect the transition from benign adenomas to malignant
carcinomas. Also, metastases were well differentiated and still expressed insulin. Together
with the fact that Rip1Tag2 tumors can metastasize but do so only rarely, our observations
suggest that VEGF-D rather promotes passive metastasis by providing additional lymphatic
escape routes for tumor cells than altering tumor cell invasive and migratory properties. Yet,
since not all Rip1Tag2;Rip1VEGF-D mice exhibited metastases, such tumor cell properties
may be additionally required and may represent a rate-limiting step for the dissemination of
cancer cells. The data of Rip1Tag2;Rip1VEGF-D mice support the “bridgehead concept of
metastases”, which postulates that lymph node metastases form a reservoir of successfully
metastasized tumor cells. These may already possess many of the properties required for
further spread and may therefore metastasize more frequently to peripheral sites than cells
from the primary tumor [123].
Interestingly, while VEGF-D stimulated predominantly the formation of peri-insular
lymphatics in orthotopic insulinomas, ectopic tumors resulting from subcutaneous (s.c.)
injection of Rip1Tag2;Rip1VEGF-D cells displayed dense intra-tumoral lymphatic networks
but no peri-tumoral lymphangiogenesis. Although we cannot explain the molecular
mechanisms underlying the microenvironmental influence on VEGF-D-induced effects, we
demonstrate that such determination occurs and significantly alters the tumor phenotype.
Recent studies using intra-muscular adenoviral gene transfer and xenotransplantation
experiments have demonstrated a potent angiogenic activity of the fully processed form of
VEGF-D (VEGF-DΔNΔC) via activation of VEGFR-2 [100, 136]. In contrast, transgenic
expression of VEGF-D in the skin of K14-VEGF-D mice failed to promote angiogenesis
[135]. High levels of VEGF-DΔNΔC were detected in islets and tumors of Rip1VEGF-D and
Rip1Tag2;Rip1VEGF-D transgenic mice, respectively, while levels of circulating VEGF-D
was comparable to that of control mice, suggesting that secreted VEGF-D might become
sequestered to the extra-cellular matrix. However, despite pronounced insular and tumoral
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expression of VEGF-D, islet and tumor angiogenesis were significantly reduced in
comparison to control mice. In fact, most of the tumors of 9-week old Rip1Tag2;Rip1VEGF-
D mice were very small and lacked the typical reddish color of angiogenic Rip1Tag2 tumors,
suggesting that at that age, double transgenic tumors still represent hyperplastic islets in
which the angiogenic switch has not yet occurred. Thus, contradicting the previously
published angiogenic effects of VEGF-DΔNΔC, our results show that expression of VEGF-
DΔNΔC directly or indirectly inhibits angiogenesis in our mouse model. Interestingly
however, in ectopic s.c. Rip1Tag2;Rip1VEGF-D tumors, VEGF-D did not affect tumor
angiogenesis when compared with subcutaneous Rip1Tag2 control tumors. One possible
cause for the reduced MVD in orthotopic Rip1Tag2;Rip1VEGF-D insulinomas could be that
the peri-tumoral lymphatic lacunae form a physical barrier to vascular, peri-vascular or other
cells necessary for angiogenesis, which cannot be properly recruited from the exocrine
pancreas to newly forming tumor blood vessel sprouts. This would explain why in
subcutaneous tumors, which exhibit intra- but not peri-tumoral lymphangiogenesis,
angiogenesis is not affected. If this hypothesis holds true, the contribution of circulating
endothelial progenitor cells to the tumor vasculature would be insufficient for adequate tumor
angiogenesis. The mechanism of VEGF-D-mediated anti-angiogenic activity is currently
subject of further investigations.
32% of lymphatic lacunae surrounding Rip1VEGF-D islets and Rip1Tag2;Rip1VEGF-
D tumors contained erythrocytes or profuse hemorrhage. We demonstrated that in
Rip1VEGF-D mice, intra-lymphatic bleedings resulted from blood-lymphatic vessel shunts in
the vicinity of islets. It remains to be shown whether these shunts formed upon deregulated
VEGF-D-induced lymphangiogenesis or whether blood vessels heading from the exocrine
tissue through the lymphatic lacunae into islets or tumors were mechanically instable.
However, the design of future lymphangiogenic therapies for patients suffering from primary
or secondary lymphedema should consider that VEGF-D might induce similar unfavorable
side effects.
Furthermore, 23% of the newly formed islet- and tumor-associated lymphatic vessels
of Rip1VEGF-D and Rip1Tag2;Rip1VEGF-D mice contained immune cells, which formed
large clusters with increasing age of the mice. These clusters predominantly consisted of T
helper and B lymphocytes as well as macrophages, whereas cytotoxic T cells were only rarely
detected. Since the intra-lymphatic leucocyte accumulations are reminiscent of a lymph
congestion, one possible explanation would be that immune cell clusters resulted from a
malfunction of a few of the islet-/tumor-associated lymphatic vessels. In contrast, we found
no significant differences in the numbers of intra-tumoral lymphocytes but less intra-tumoral
macrophages in orthotopic Rip1Tag2;Rip1VEGF-D compared to control tumors. These
results were not reproducible in ectopic tumors, since a comparative analysis of s.c. VEGF-D-
positive and VEGF-D-negative insulinomas revealed equal numbers of tumor-associated
immune cells. Although currently, we cannot conclusively explain the reduction of intra-
tumoral macrophages in orthotopic tumors, we hypothesize that the reduced tumoral MVD
may restrict the number of monocytes accessing Rip1Tag2;Rip1VEGF-D tumors.
hVEGF-D is 48% identical to hVEGF-C, and both molecules display similar binding
properties for VEGFR-3 and VEGFR-2 (reviewed in [45]). Recently, VEGF-C has been
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studied in the Rip1Tag2 mouse model [146], which enabled us to directly compare biological
effects elicited by VEGF-D and VEGF-C. Similarly to VEGF-D, transgenic expression of
VEGF-C induced peri- but not intra-tumoral lymphangiogenesis in Rip1Tag2;Rip1VEGF-C
mice, thereby promoting the dissemination of tumor cells to regional lymph nodes. However,
neither this nor our study revealed lung metastases in Rip1Tag2;Rip1VEGF-C mice. Yet, a
systematic screen for such is still pending and the occurrence of lung metastases cannot be
conclusively excluded. Although also VEGF-C has been shown to promote angiogenesis, no
such activity could be evidenced in Rip1Tag2;Rip1VEGF-C tumors [155, 156]. Nevertheless,
in contrast to transgenic VEGF-D, expression of VEGF-C had no negative impact on tumor
angiogenesis and tumor growth. Also, no intra-lymphatic hemorrhages and no immune cell
clusters were found in Rip1Tag2;Rip1VEGF-C mice. The qualitative dissimilarity of VEGF-
D- and VEGF-C-elicited effects indicate that these factors may induce the formation of
lymphatic vessels that differ on the functional and molecular level. For example, it is possible
that endothelial cells of newly formed lymphatic vessels release distinct paracrine factors
depending on whether endothelial cells have been stimulated by VEGF-D or VEGF-C. These
paracrine factors may differently influence primary tumor and tumor endothelial cells,
facilitating lung metastasis and inhibiting angiogenesis in VEGF-D- but not VEGF-C-
transgenic mice, respectively. Future studies on Rip1Tag2;Rip1VEGF-D and
Rip1Tag2;Rip1VEGF-C mice as well as cultured primary endothelial cells from lymphatic
capillaries are required to identify distinct molecular alterations induced by VEGF-D and
VEGF-C.
In conclusion, our results support the notion that VEGF-D expressed by tumor cells
promotes metastasis to regional lymph nodes and the lungs by inducing peri-tumoral
lymphangiogenesis. In contrast, tumor angiogenesis is reduced. Furthermore, we demonstrate
that the tumor microenvironment critically modulates whether VEGF-D-induced
lymphangiogenesis occurs in the tumor parenchyma or at the tumor periphery and whether
expression of VEGF-D affects tumor angiogenesis.
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3.2. Activation of VEGFR-3 is sufficient to promote lymphogenous metastasis
Lucie Kopfstein1, Pascal Lorentz1, Tanja Veikkola2, Kari Alitalo2, Gerhard Christofori1
1Department of Clinical-Biological Sciences, Institute of Biochemistry and Genetics,
University of Basel, 4058 Basel, Switzerland
2Molecular/Cancer Biology Laboratory, Biomedicum, University of Helsinki, Helsinki 00014,
Finland
Running title: VEGF-C156S promotes metastasis
This work was supported by grants from the Swiss National Science Foundation, the Swiss
Cancer League, the Swiss Bridge Award, the Krebsliga Beider Basel, the EU-FP6 framework
programmes LYMPHANGIOGENOMICS LSHG-CT-2004-503573 and BRECOSM LSHC-
CT-2004-503224, and Novartis Pharma Inc.
Introduction VEGF-C156S
56
3.2.1. Abstract
In many human carcinomas, expression of the lymphangiogenic vascular endothelial
growth factor-C (VEGF-C) and VEGF-D correlates with increased tumor-associated
lymphangiogenesis and the emergence of regional lymph node metastases. Both factors can
activate VEGF receptor 3 (VEGFR-3), the expression of which is largely restricted to
lymphatic endothelium in the adult, and VEGFR-2, which is found on both blood and
lymphatic vessels. By employing a recently engineered selective ligand for VEGFR-3
(VEGF-C156S) we aimed to assess whether the stimulation of tumor lymphangiogenesis via
VEGFR-3 is sufficient to promote lymphogenous metastasis. Therefore, we generated
transgenic mice, expressing VEGF-C156S in β-cells of pancreatic islets of Langerhans.
Whereas wildtype islets were not associated with lymphatics, Rip1VEGF-C156S islets were
often surrounded by large lymphatic lacunae. These mice were crossed with Rip1Tag2 mice,
a transgenic model of poorly metastatic pancreatic β-cell carcinogenesis. While control mice
neither exhibited pronounced tumor-associated lymphangiogenesis nor metastases, tumors of
Rip1Tag2;Rip1VEGF-C156S mice were in close contact with newly-formed lymphatic
vessels and frequently developed regional lymph node metastases. Our results demonstrate
that VEGF-C156S-induced activation of VEGFR-3 is sufficient to promote tumor-associated
lymphangiogenesis and lymphogenous metastasis.
3.2.2. Introduction
The vascular endothelial growth factor (VEGF) family of glycoproteins and their
receptors (VEGFRs) are important players of physiological and pathological angiogenesis and
lymphangiogenesis. To date, five mammalian VEGF family members have been identified,
including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PlGF. VEGF-A, VEGF-B and PlGF
have been linked to angiogenic processes via activation of blood endothelial VEGFR-1 and
VEGFR-2. In contrast, VEGF-C and VEGF-D are the only identified natural ligands for
VEGFR-3, the expression of which is largely restricted to lymphatic endothelium. However,
the fully processed forms of VEGF-C and VEGF-D are able to also activate VEGFR-2.
Although predominantly expressed on blood endothelium, VEGFR-2 is also found on some
lymphatic vessels [67]. Therefore, mature VEGF-C and VEGF-D exhibit lymphangiogenic
activities via activation of both VEGFR-3 and VEGFR-2 and can promote angiogenesis via
VEGFR-2 [41, 53, 131, 132, 135, 155, 157]. Moreover, VEGF-C was shown to induce the
formation of VEGFR-2/VEGFR-3 heterodimers in vitro, which may modulate sensitivity to
VEGFR-2 signaling in vessels co-expressing the two receptors [158-162].
The fatality of cancer predominantly results from the formation of metastases rather
than from the primary tumor itself. Among many tumor cell-instrinsic alterations such as gain
of migratory and invasive properties of cancer cells, also processes in the tumor stroma
contribute to metastatic dissemination. These include lymphangiogenesis triggered by tumor-
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secreted soluble factors, such as VEGF-C and VEGF-D, resulting in an increase in the
number and size of lymphatic escape routes for metastatic tumor cells (reviewed in [89]).
Accordingly, a variety of human tumors express high levels of VEGF-C and VEGF-D, which
correlates with tumor-associated lymphangiogenesis and the emergence of regional lymph
node metastases (reviewed in [163]). Furthermore, experiments using xenotransplantation and
transgenic mouse models have demonstrated that VEGF-C and VEGF-D expressed by tumor
cells enhance lymphogenous metastasis via induction of tumor-associated lymphangiogenesis
[100, 144, 146]. However, several of these studies reported a simultaneous increase in tumor
angiogenesis, which suggests the parallel activation of VEGFR-2 [100]. Therefore, it is not
clear whether activation of VEGFR-3 is sufficient for tumor-associated lymphangiogenesis
and lymphogenous metastasis and to what extent VEGF-C- and VEGF-D-mediated induction
of VEGFR-2 signaling contributes to or even is required for these processes.
Recently, a mutant form of VEGF-C, VEGF-C156S, has been generated by replacing
the second of the eight conserved cysteine residues of the VEGF homology domain (VHD)
(Cys156) with a serine. In contrast to VEGF-C, VEGF-C156S is a selective agonist of
VEGFR-3 but not VEGFR-2 and has therefore enabled the study of VEGFR-3-intrinsic
biological functions [55]. A transgenic mouse model, in which VEGF-C156S is expressed in
basal keratinocytes of the skin, has demonstrated that VEGFR-3 activation by VEGF-C156S
promoted dermal lymphangiogenesis without influencing angiogenesis [135].
The present study addresses whether activation of VEGFR-3 is sufficient to promote
tumor lymphangiogenesis and thereby the spread of cancer cells to regional lymph nodes.
Therefore, we have generated transgenic mice, in which expression of VEGF-C156S is driven
by the rat insulin promoter (Rip1) and thereby is specifically targeted to β-cells of pancreatic
islets of Langerhans. These mice were subsequently crossed with Rip1Tag2 mice, a
transgenic mouse model of poorly metastatic β-cell carcinogenesis [124], and tumor
lymphangiogenesis, angiogenesis, and metastasis were analyzed. Furthermore, we aimed to
compare the investigated parameters with results obtained from a previous analysis of
Rip1Tag2;Rip1VEGF-C mice, which exhibited increased tumor-associated
lymphangiogenesis and lymphogenous metastasis [146].
3.2.3. Materials and Methods
Cloning of the Rip1VEGF-C156Sdel36 construct
The original Rip1VEGF-C156S construct was kindly provided by T. Veikkola
(Molecular/Cancer Biology Laboratory, Biomedicum, University of Helsinki, Helsinki,
Finland). This construct was generated by blunt ligation of the HindIII/NotI cDNA fragment
encoding the 1998 bp coding region of full length human VEGF-C156S (nucleotides 80 –
2076, Acc. No. NM_005429) between the 704 bp BamHI/XbaI fragment of the rat insulin
gene II promoter and a 436 bp fragment containing SV40 introns and polyadenylation signal
sequences of the HindIII/XbaI opened Rip1 vector (Rip1; [124]. To enable excision of the
Rip1VEGF-C156S transgene insert with BamHI for generation of transgenic mice, a third
BamHI restriction site located between the Rip1 and the hVEGF-C156S sequence was
eliminated by a double digest with XbaI and SpeI followed by blunt religation of the vector.
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Therefore, 10 µl of DNA was incubated for one hour at 37°C with 10 µl 10x Klenow buffer,
10 µl of 10 mM ATP, 2 µl of Klenow enzyme, and 1 µl of T4 DNA ligase adjusted with
sterile H20 to a 100 µl reaction volume (Klenow buffer: 0.5M Tris-HCl pH 7.5, 0.1 M MgCl2,
10 mM DTT, 0.5 mg/ml BSA, 200 µM dNTPs; Klenow enzyme and T4 DNA ligase from
Boehringer Mannheim/Roche, Mannheim, Germany). The new construct lacking 36 bp
between the Rip1 and the hVEGF-C156S sequence was named Rip1VEGF-C156Sdel36.
Generation of Rip1VEGF-C156S Transgenic Mice
50 µg of the Rip1VEGF-C156Sdel36 plasmid was digested with 10 µL BamHI in a
total volume of 155 µL for five hours and resolved on a 0.8% agarose gel. The ~ 3 kb band
containing the BamHI-cut Rip1VEGF-C156S transgene construct was excised from the gel
and purified once with the QIAEX II gel extraction kit (Qiagen, Hombrechtikon, Switzerland)
kit. The purified Rip1VEGF-C156Sdel36 DNA fragment was used for injection into fertilized
C57BL/6 oocytes to generate Rip1VEGF-C156S transgenic mice according to standard
procedures at the Transgenic Mouse Core Facility TMCF, Biozentrum, Basel [147].
Genotypes were confirmed by PCR analysis of standard toe genomic DNA
preparations using a primer pair specific for the transgene (forward primer located in the Rip1
sequence: 5'-TCC GGA CTC GAC CTC TCG GAC; reverse primer located in the VEGF-C
sequence: 5'-CCC CAC ATC TAT ACA CAC CTC C). PCR cycles were: 94°C, 5 min (x1);
94°C, 30 sec, 64°C, 30 sec, and 72°C, 1 min 30 sec (x34); and 72°C, 10 min (x1). PCR
products were analyzed in 1.5% agarose gels. Routine PCR screening of Rip1VEGF-C156S
heterozygotes was performed according to the same protocol.
For histopathological analysis, lectin perfusion, electron microscopy, and vascular
cast analysis refer to General Materials and Methods
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3.2.4. Results
Generation of Rip1VEGF-C156S transgenic mice
To generate transgenic mice specifically expressing human VEGF-C156S (hVEGF-
C156S) in β-cells of pancreatic islets of Langerhans, the hVEGF-C156S cDNA was cloned
between the rat insulin II gene promoter fragment (Rip) and the human growth hormone
introns and a polyadenylation signal (Rip1; [124]. The original Rip1VEGF-C156S construct
was generated by blunt ligation of a HindIII/NotI cDNA fragment encoding the 1998 bp
coding region of full length human VEGF-C156S to the XbaI/HindIII-opened Rip1 vector. To
prepare the Rip1VEGF-C156S construct for injection into fertilized mouse oocytes, the
Rip1VEGF-C156S transgene had to be excised from the vector by a BamHI restriction digest
(BamHI being the only suitable restriction site). Therefore, a third BamH1 restriction site
located in the multiple cloning site between the Rip1 and the hVEGF-C156S sequence was be
removed, which resulted in the Rip1VEGF-C156Sdel36 plasmid lacking 36 bp of the original
vector (Figure 1). Injection of the Rip1VEGF-C156S transgene construct into fertilized
C57BL/6 oocytes resulted in two viable and fertile founder lines exhibiting stable germline
transmission named Rip1VEGF-C156S-1 and Rip1VEGF-C156S-2.
Figure 1. Modification of the Rip1 VEGF-C156S construct for generation of Rip1VEGF-
C156S transgenic mice
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VEGF-C156S induces peri-insular lymphangiogenesis in Rip1VEGF-C156S transgenic
mice
To test whether the transgene was expressed, pancreatic sections from transgenic and
control littermate mice were stained with anti-VEGF-C antibody. For both transgenic
founderlines, immunofluorescence analysis revealed strong VEGF-C immunoreactivity in the
majority of islet cells as would be expected from the relative abundance of insulin-expressing
β-cells in islets (approximately 80%). In contrast, no VEGF-C expression was detectable in
islets of wildtype littermate mice (Figure 2A). To investigate morphological changes elicited
by transgenic expression of VEGF-C156S, we analyzed pancreata by histology,
immunohistochemistry and immunofluorescence. Hematoxylin and eosin stainings of
pancreata from Rip1VEGFC156S transgenic mice revealed that most islets were separated
from the surrounding exocrine tissue by large vascular structures. Based on immunoreactivity
for the lymphatic endothelium marker Podoplanin, these peri-insular structures were
identified as enlarged lymphatic capillaries. Using these methods, no lymphatic vessels were
detected in transgenic islets themselves or associated with islets of control littermate mice
(Figure 2A). Also on the ultra-structural level visualized using toluidine blue-stained semi-
thin sections, enlarged lymphatic vessels were frequently found in close proximity to islets of
Rip1VEGF-C156S but not C57BL/6 littermate control mice (Figure 2B). Importantly, no
impact of VEGF-C156S on blood vessels could be detected when comparing Rip1VEGF-
C156S with control mice (data not shown). Notably, the phenotype of Rip1VEGF-C156S was
identical to that previously described for Rip1VEGF-C mice, which displayed peri-insular
lymphangiogenesis without affecting angiogenesis [146].
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Figure 2. Phenotypical analysis of transgenic Rip1VEGF-C156S founder lines
(A, Upper panel) Immunofluorescent staining with anti-VEGF-C antibody (red). Nuclei are
counterstained with DAPI (A, middle panel) Hematoxylin and eosin staining of pancreatic
sections (A, lower panel) Immunofluorescent staining with anti-LYVE-1 antibody. Nuclei are
counterstained with DAPI. (B) Toluidine-blue-stained semithin sections from transgenic and
control pancreata as indicated. Dashed lines delineate islets; arrowheads indicate lymphatic
capillaries; C, capillary; Ex, exocrine tissue; Is, islet.  Scale bars: (A) 100 µm, (B) 50 µm.
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VEGF-C156S promotes peri- and intra-tumoral lymphangiogenesis
To assess the role of VEGF-C156S in tumor angiogenesis, lymphangiogenesis, and
metastasis, we crossed Rip1VEGF-C156S-2 with Rip1Tag2 mice, a transgenic mouse model
of pancreatic β-cell carcinogenesis [124]. Of note, β-cell tumors that develop in Rip1Tag2
mice are capable of local invasion, but metastasis is only rarely encountered. Rip1Tag2
control and Rip1Tag2;Rip1VEGF-C156S double transgenic mice were sacrificed between 12
and 14 weeks of age, a time-point, when these mice succumb to hypoglycemia caused by
excessive tumoral insulin production.
The analysis of Rip1Tag2;Rip1VEGF-C156S and control tumor mice revealed no
significant differences with regard to tumor incidence (defined as the number of tumors per
pancreas having a diameter >1 mm) and tumor volume (defined as the sum of all
macroscopically detectable tumors per pancreas having a diameter >1 mm and assuming that
the tumors are spherical). Since angiogenesis is predominantly mediated via VEGFR-1 and
VEGFR-2, we investigated whether VEGF-C156S as a selective ligand for VEGFR-3 had any
impact on tumor angiogenesis. To measure the tumor blood vessel density, we stained
pancreatic sections of the two genotypes using the blood endothelial marker CD31 and
counted intra-tumoral blood vessels. As expected, expression of the selective VEGFR-3
ligand had no effect on tumor angiogenesis, which was reflected by comparable tumor
microvessel densities in both mouse lines (Table 1).
Table I. Tumor incidence, volume, and microvessel density in Rip1Tag2;Rip1VEGF-
C156S mice
In contrast, analysis of pancreata by hematoxylin and eosin staining unveiled striking
morphological differences at the tumor periphery comparable to those observed in single
transgenic mice. Most double-transgenic tumors were separated from the exocrine tissue by
large endothelium-lined lacunae, which partially or completely enclosed the tumors. Based on
their immunoreactivity for the lymphatic endothelium markers Podoplanin and LYVE-1,
these lacunae were identified as lymphatic vessels.  In large tumors, lymphatic vessels were
also found in the tumor center. In agreement with recent publications, Rip1Tag2 tumors were
only rarely found in close association with lymphatic vessels (Figure 3A)[146, 150].
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Quantification of peri-tumoral lymphangiogenesis was performed by assessing the extent by
which LYVE-1-positive lymphatic vessels surrounded the tumor perimeter. Thereby we
confirmed that 74 % of insulinomas in double-transgenic animals had closely apposed
lymphatics encompassing most or all of the insulinoma circumference. In contrast, only 40 %
of Rip1Tag2 control tumors were to some extent associated with lymphatics (Figure 3B).
These results indicate that VEGF-C156S promotes tumor-associated lymphangiogenesis.
VEGF-C156S promotes regional lymph node metastasis
Evidence from clinical and experimental studies suggests that the close association of
tumors with lymphatic vessels might promote lymphogenous spread of tumor cells, which
may follow routes of natural drainage and subsequently form metastases in regional lymph
nodes [146]. To assess whether VEGF-C156S-induced peri-tumoral lymphangiogenesis
promotes the lymphogenous dissemination of cancer cells, hematoxylin and eosin-stained
pancreatic sections of Rip1Tag2 and Rip1Tag2;Rip1VEGF-C156S mice were screened for
metastatic insulinoma cells. Consistent with previous reports, β-cells were only occasionally
found to disseminate in lymphatic vessels of Rip1Tag2 pancreata, which may also account for
the fact that none of the investigated control mice displayed metastases in pancreatic lymph
nodes. In contrast, double-transgenic Rip1Tag2;Rip1VEGF-C156S mice frequently exhibited
tumor cell clusters circulating in lymphatic vessels located next to tumors and in the exocrine
pancreas (data not shown). Concomitantly, metastases were found at the afferent rim of at
least one lymph node on all pancreatic sections exhibiting lymph nodes (Figure 3C, Table II).
Tumor cells still retained their well-differentiated morphology, and no signs of anaplasia such
as an altered nucleus/cytoplasm ratio or nuclear atypia were observed. Furthermore, all
metastases were immunoreactive for insulin, confirming their derivation from primary β-cell
tumors (data not shown). A comparative analysis of tumor grades demonstrated that the
expression of VEGF-C156S did not affect the ratio of benign adenoma versus malignant
carcinoma (Table II). In summary, our data demonstrate that activation of VEGFR-3 alone
results in the formation of a dense tumor-associated lymphatic network and promotes the
formation of regional lymph node metastases.
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F i g u r e  3 .
Phenotypical analysis
o f  R i p 1 T a g 2 ;
Rip1VEGF-C156S
mice
(A ) Hematoxylin and
e o s i n  a n d
immunofluorescence
staining with anti-
Podoplanin antibody
(B ) Quantification of
peri-tumoral
lymphangiogenesis as
described in the text.
Results are indicated as
percentages of tumors
in a given class above
the bars. 113 tumors of
seven
Rip1Tag2;Rip1VEGF-
C156S mice and 170
tumors of six Rip1Tag2
mice were analyzed.
(C ) Hematoxylin and
eosin staining of a
regional lymph node
metastasis. Dashed
lines delineate tumors;
Ex, exocrine tissue; LN,
lymph node;  M,
metastasis; Tu, tumor.
Scale bars: 100 µm.
Table II. Analysis of tumor grades and metastasis in Rip1Tag2;Rip1VEGF-C156S and
control mice.
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3.2.5. Discussion
Here we have addressed whether selective activation of VEGFR-3 is sufficient to
promote tumor-associated lymphangiogenesis and metastasis by expressing the VEGFR-3-
selective ligand VEGF-C156S in tumors of Rip1Tag2 mice, a transgenic mouse model of
poorly metastatic multistep β-cell carcinogenesis [124]. For this purpose, we generated two
lines of Rip1VEGF-C156S transgenic mice, in which expression of VEGF-C156S is
specifically targeted to β-cells of the endocrine pancreas. While in control littermate mice,
small lymphatic capillaries were detected only rarely in the vicinity of islets and exclusively
upon visualization by electron microscopy, most islets of Rip1VEGF-C156S mice were
partially or completely encompassed by large endothelium-lined lacunae immuno-reactive for
the lymphatic vessel markers Podoplanin and LYVE-1. These observations demonstrate that
the selective activation of VEGFR-3 promotes lymphangiogenesis in Rip1VEGF-C156S
mice. Since our and previous studies of wildtype mice have revealed the presence of a few
lymphatic capillaries close to islets of Langerhans, we hypothesize that the enlarged peri-
insular lymphatic lacunae found in Rip1VEGF-C156S transgenic mice result from the
dilation and growth of pre-existing lymphatic capillaries [164]. In accordance with our
results, the analysis of K14-VEGF-C156S transgenic mice showed that expression of VEGF-
C156S in the skin stimulated the growth of dermal lymphatic vessels [135]. Interestingly, the
phenotype of Rip1VEGF-C156S mice is identical to that of the recently published
Rip1VEGF-C mice, which expressed wildtype VEGF-C in islets of Langerhans [146]. This
observation indicates that in the Rip1 model, all effects of transgenic VEGF-C expression are
mediated predominantly via VEGFR-3 and not VEGFR-2.
To assess whether activation of VEGFR-3 is sufficient to stimulate tumor
lymphangiogenesis and promote metastasis, we crossed Rip1VEGF-C156S with Rip1Tag2
mice, a transgenic mouse model of poorly metastatic multistep β-cell carcinogenesis [124]. In
line with previous reports, small lymphatic capillaries were detected in the vicinity of some
insulinomas of Rip1Tag2 control mice (40%), while the majority of tumors lacked any
contact with lymphatic vessels. In contrast, transgenic expression of VEGF-C156S and thus
activation of VEGFR-3 in double transgenic Rip1Tag2;Rip1VEGF-C156S mice resulted in
the growth of large lymphatic lacunae, which partially (40%) or completely (34%)
surrounded most tumors. These results demonstrate that activation of VEGFR-3 by a selective
ligand is sufficient to promote tumor-associated lymphangiogenesis.
Tumors of Rip1Tag2 mice are intrinsically metastatic but realize their metastatic
potential only rarely, which may be due to the early death of these mice resulting from
excessive tumoral insulin production and subsequent hypoglycemia [124]. In fact, most
reports studying the process of metastasis formation with use of the Rip1Tag2 model did not
find any metastases in these mice [146, 148, 150]. However, VEGF-C expressed in
Rip1Tag2;Rip1VEGF-C double transgenic mice promoted metastasis to regional lymph
nodes by stimulating tumor-associated lymphangiogenesis. To investigate, whether VEGF-
C156S-induced peri-tumoral lymphangiogenesis is sufficient to promote lymphogenous
metastasis, we screened lymph nodes of three Rip1Tag2;Rip1VEGF-C156S mice for
insulinoma metastases. Indeed, in every investigated double transgenic mouse, one or more
metastases were found in regional pancreatic lymph nodes. All metastases were well
differentiated and still express insulin. Furthermore, a comparative analysis of primary tumor
gradings demonstrated that expression of VEGF-C156S did not affect the ratio of benign
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adenoma versus malignant carcinoma, suggesting that VEGF-C156S does not promote
invasive and migratory capabilities of tumor cells. Together with the fact that Rip1Tag2
tumors can metastasize but do so only exceptionally, our observations suggest that VEGF-
C156S-induced activation of VEGFR-3 promotes lymphogenous metastasis by stimulating
tumor-associated lymphangiogenesis.
Although in the adult vasculature mainly restricted to lymphatic endothelium, recent
studies have evidenced that VEGFR-3 is to some extent expressed also on quiescent vascular
endothelial cells, primarily in fenestrated capillaries such as in pancreatic islets [158].
Moreover, VEGFR-3 was reported to become re-expressed on the blood vasculature of
tumors [146, 165]. Therefore, we investigated whether VEGF-C156S may promote tumor
angiogenesis and assessed the tumoral microvessel density using the specific blood
endothelial marker CD31. Statistical analyses revealed comparable tumor microvessel
densities in Rip1Tag2;Rip1VEGF-C156S and control mice, demonstrating that VEGF-C156S
has no effect on tumor angiogenesis and suggesting that a potential expression of VEGFR-3
on tumor blood endothelium may play only a subordinate role in these mice. Importantly, also
wildtype VEGF-C, which can activate both VEGFR-2 and VEGFR-3 and thereby promoted
angiogenesis in several experimental studies, exhibited no angiogenic activity in
Rip1Tag2;Rip1VEGF-C tumors [146, 155, 156]. However, the processing state of wildtype
VEGF-C in tumors of Rip1Tag2;Rip1VEGF-C mice remains to be elucidated, since the
angiogenic ability of VEGF-C is dependent on its proteolytic processing to the mature form
[131].
Taken together, our data demonstrate that activation of VEGFR-3 alone is sufficient to
promote the formation of a tumor-associated lymphatic network, which increases the contact
area between tumor cells and potential lymphatic escape routes, thereby promoting the
passive spread of cancer cells to regional lymph nodes. The comparison of
Rip1Tag2;Rip1VEGF-C156S and the previously published Rip1Tag2;Rip1VEGF-C mice
suggests that at least on the macro- and microscopic level, Rip1Tag2;Rip1VEGF-C156S
phenocopy Rip1Tag2;Rip1VEGF-C mice [146]. Future studies on cultured primary
endothelial cells deriving from lymphatic capillaries of both transgenic mouselines will
elucidate whether VEGF-C and VEGF-C156S induce distinct biological effects on the
molecular level. Furthermore, it will be interesting to investigate whether activation of
VEGFR-3 by VEGF-C156S can induce the formation of VEGFR-2/VEGFR-3 heterodimers
such as observed for VEGF-C. Nevertheless, our results suggest that the selective inhibition
of VEGFR-3 signaling may already significantly reduce the risk of further metastatic
dissemination of tumor cells.
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4. Generation and analysis of transgenic mice expressing angiogenic VEGF
family members during Rip1Tag2 tumorigenesis
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4.1.1. Abstract
Placental growth factor (PlGF) belongs to the vascular endothelial growth factor
(VEGF) family of ligands, which are important players of angiogenesis and
lymphangiogenesis. In contrast to VEGF-A, PlGF is not critical for vascular development but
may be a critical regulator of VEGF-A-dependent pathological angiogenesis. In many human
carcinomas, expression of PlGF correlates with increased tumor angiogenesis and growth.
However, the formation of inactive PlGF-1/VEGF-A heterodimers has been recently
described, suggesting that PlGF-1 might also act as an antagonist of VEGF-A-mediated tumor
angiogenesis. To assess the dual role of PlGF-1 in tumor angiogenesis, we generated
Rip1PlGF-1 transgenic mice, which express human PlGF-1 in β-cells of pancreatic islets of
Langerhans. In comparison to the islet vasculature of control mice, the blood capillaries of
transgenic islets are dramatically dilated thereby increasing the islet area occupied by blood
vessels. In contrast, PlGF-1 does not affect the number of islet blood vessels. By crossing
Rip1PlGF-1 with Rip1Tag2 mice, a transgenic model of pancreatic β-cell carcinogenesis,
double-transgenic mice have been generated that express PlGF-1 in tumor cells. Transgenic
expression of PlGF-1 during Rip1Tag2 tumorigenesis significantly reduces the tumor
microvessel density as well as the tumor burden in comparison to control mice, which
suggests that PlGF-1 acts as an antagonist of VEGF-A-mediated tumor angiogenesis.
4.1.2. Introduction
Placental growth factor (PlGF) is a member of the vascular endothelial growth factor
(VEGF) family of ligands that control blood and lymphatic vessel development [45].
Originally identified in human placenta, PlGF is also expressed in heart, lung, thyroid gland,
and skeletal muscle [166]. Alternative splicing of the human PlGF gene generates at least four
isoforms, which differ in size and receptor binding properties. While PlGF-1 and PlGF-3 are
freely diffusible, PlGF-2 and PlGF-4 are mostly sequestered by heparan sulfates of the
extracellular matrix [167-171]. In the mouse, only the PlGF-2 homolog is expressed [172].
VEGF-A, the best-studied angiogenic VEGF family member to date, binds to VEGFR-1,
VEGFR-2, and the co-receptors NP-1 and NP-2, which are expressed on blood vessel
endothelium. Notably, the angiogenic effects of VEGF-A are mainly mediated via VEGFR-2.
In contrast, all PlGFs are selective ligands for VEGFR-1, and PlGF-2 in addition binds to NP-
1 and NP-2 [167].
Although VEGFR-1 has only low tyrosine kinase activity and deletion of its tyrosine
kinase domain does not affect vascular development, intrinsic signaling of VEGFR-1 may
mediate some of the PlGF-induced biological effects [14, 44]. PlGF-2 is more potent than
PlGF-1 in inducing proliferation of endothelial cells and angiogenesis, which may be due to
its ability to also activate NP receptors [79, 173, 174]. However, there is evidence that
VEGFR-1 also acts as a decoy receptor for VEGF-A, and VEGFR-1-selective ligands such as
PlGF might indirectly potentiate effects of VEGF-A by displacing it from VEGFR-1 and
increasing its availability for activation of VEGFR-2 [60, 170, 175]. Recently, adenoviral
gene transfer of PlGF-2 has been shown to upregulate expression of VEGF-A [176].
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Furthermore, PlGF-1-induced activation of VEGFR-1 resulted in transphosphorylation of
VEGFR-2 and thereby amplification of VEGF-A-driven angiogenesis via VEGFR-2 [44,
177]. Alternatively, when both factors are produced in the same cell, PlGF-1 can form
inactive heterodimers with VEGF-A and inhibit VEGF-A-induced angiogenenic responses in
vitro and in vivo [52, 178]. Thus, PlGF-induced signaling pathways and biologic activities
may depend on the spatial expression as well as alternative splicing of PlGF, and in particular
PlGF-1 appears to play a dual role during angiogenesis.
Studies of PlGF-deficient mice have revealed that PlGF is not critical for the
development and the maintenance of the physiologic vasculature. Yet, these mice show
impaired angiogenesis, plasma extravasation, and collateral vessel growth in ischemic retina,
limb and heart, wounded or inflamed skin, and cancer, suggesting that PlGF might be
involved in pathological angiogenesis [68, 101, 179]. The analysis of transgenic mice
expressing PlGF-2 in the skin has demonstrated increased blood vessel permeability
responses and monocyte recruitment [180, 181]. In contrast, adenoviral delivery of PlGF-1 or
PlGF-2 into skin, ischemic myocardium or limb induced the formation of impermeable blood
vessels by stimulating their coverage with smooth muscle cells [179].
The precise role of PlGF in tumorigenesis is not fully understood. PlGF is expressed
in a variety of human malignancies, including hemangioblastoma, meningioma, brain tumors,
melanoma, as well as renal cell, breast, non-small cell lung, gastric, and colorectal carcinoma
[96-98, 182-187]. Three of these reports correlated increased PlGF expression levels with
pronounced tumor angiogenesis and growth [97, 183, 186]. Similarly, a study using PlGF-2-
overexpressing Lewis Lung Carcinoma cell lines reported a PlGF-2-mediated increase in
tumor angiogenesis and growth [101]. In contrast, transplantation experiments with PlGF-1-
transfected mouse fibrosarcoma cells demonstrated impaired tumor growth resulting from the
formation of inactive PlGF-1/VEGF-A heterodimers [178].
This study aimed to address the dual role of PlGF-1 on tumor angiogenesis in a well-
characterized transgenic mouse tumor model of multistep β-cell carcinogenesis [124]. We
have generated Rip1PlGF-1 transgenic mice, in which expression of human PlGF-1 is driven
by the rat insulin promoter (Rip1) and thereby specifically targeted to β-cells of pancreatic
islets of Langerhans. Rip1PlGF-1 mice are currently being crossed with Rip1Tag2 tumor
mice, thereby generating Rip1Tag2;Rip1PlGF-1 mice. Rip1Tag2 and Rip1Tag2;Rip1PlGF-1
mice are being analyzed for tumor angiogenesis, the recruitment of smooth muscle and
inflammatory cells to the tumor vasculature, and tumor growth. In addition, these mice will
enable future studies of the in vivo formation of PlGF-1/VEGF-A heterodimers.
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4.1.3. Methods
Cloning of the Rip1PlGF-1 construct
Total RNA was isolated from freshly snap frozen human placental tissue using
TRIzol Reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.
Subsequently, placental RNA was reverse transcribed into cDNA using reverse transcriptase
and random hexamers from Sigma Chemical Co., St. Louis, MO according to standard
procedures. The 450 bp sequence of human PlGF-1 (hPlGF-1, gene accession number
X54936, nucleotides 322-771) was amplified from the cDNA by PCR using the forward
primer 5’- GCT CTA GAG ACG TCT GAG AAG ATG CCG GT (XbaI site underlined) and
the reverse primer 5’- CCC AAG CTT GGT GGG TTA CCT CCG GGG (HindIII site
underlined). PCR cycles were: 94°C, 5 min (x1); 94°C, 30 sec, 60°C, 30 sec, and 72°C, 1min
30 sec (x10); and 72°C, 7 min (x1). The band appearing at the expected size of PlGF-1 was
extracted from the gel with the QIAEX II gel extraction kit (Qiagen, Hombrechtikon,
Switzerland) and subcloned into the pBluescript SK+ vector (Sigma Chemical Co., St. Louis,
MO using XbaI and HindIII. After verification by sequencing, the PlGF-1 cDNA was
subcloned into the Rip1 vector between the 704 bp rat insulin II promoter and a 436 bp
stretch containing SV40 small T intron and polyadenylation signal sequences using XbaI and
Hind III (Rip1; [124].
Generation of Rip1PlGF-1 transgenic mice
100 µg of the Rip1PlGF-1 plasmid were digested with 10 µL BamHI in a total
volume of 400 µL for five hours and resolved on a 0.8% agarose gel. The ~ 1.5 kb transgene
construct comprising Rip1, full length hPlGF-1, and the SV40 small T intron and
polyadenylation signal sequences was extracted from the gel and purified once with the
QIAEX II gel extraction kit. The purified Rip1PlGF-1 fragment was used for injection into
the pronucleus of fertilized C57BL/6 oocytes at the Transgenic Mouse Core Facility (TMCF,
Biozentrum, Basel) according to standard procedures.
Genotypes were confirmed by PCR analysis using a primer pair specific for the
transgene (forward primer located in the Rip1 sequence: 5'-TAA TGG GAC AAA CAG CAA
AG; reverse primer located in the human PlGF-1 sequence: 5'-CCA CAC TTC CTG GAA
GGG), starting from standard toe genomic DNA preparations. PCR cycles were: 94°C, 5 min
(x1); 94°C, 30 sec, 57°C, 30 sec, and 72°C, 30 sec (x34); and 72°C, 7 min (x1). PCR products
were analyzed in 1.5% agarose gels. Routine PCR screening of Rip1VEGF-PlGF-1
heterozygotes was performed according to the same protocol.
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RT-PCR analysis of PlGF-1 expression
Mice were sacrificed at 3-4 weeks because of the higher ratio of endocrine to
exocrine pancreas in young mice. Half of the pancreas was homogenized in TRIzol reagent
for RNA isolation according to the manufacturer’s protocol (Sigma Chemical Co., St. Louis,
MO). 500 ng of total RNA was reverse transcribed using reverse transcriptase and random
hexamers from Sigma Chemical Co., St. Louis, MO. The cDNA was screened for PLGF-1 by
PCR using the forward primer 5’- GCT CAG AGA CGT CCT GAG AAG ATG CCG GT and
the reverse primer 5’- CCC AAG CTT GGT GGG TTA CCT CCG GGG. PCR cycles were:
94°C, 5 min (x1); 94°C, 30 sec, 60°C, 30 sec, and 72°C, 1 min 30 sec (x10); and 72°C, 7 min
(x1). PCR products were analyzed in 1.5% agarose gels.
For histopathological analysis, lectin perfusion, electron microscopy, and vascular
cast analysis refer to General Materials and Methods
4.1.4. Results
Generation of Rip1PlGF-1 transgenic mice
To generate transgenic mice expressing human PlGF-1 specifically in β-cells of
pancreatic islets of Langerhans, the 450 bp coding sequence of PlGF-1 was amplified from
human placental tissue by RT-PCR. The cDNA fragment was subseqently cloned between the
rat insulin II gene promoter fragment (Rip) and the human growth hormone introns and
polyadenylation signals of the Rip1 vector using XbaI and HindIII (Figure 1). Injection of the
transgene into fertilized C57BL/6 oocytes resulted in two viable and fertile founder lines
exhibiting stable germline transmission termed Rip1PlGF-1-1 and Rip1PlGF-1-2.
Figure 1. Cloning of
t h e  R i p 1 P l G F - 1
construct
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Dilated islet blood vessels in Rip1PlGF-1 transgenic mice
Since expression of the transgene was difficult to assess by immunohistochemical
and immunofluorescence analysis due to the lack of suitable antibodies, we performed RT-
PCR for PlGF-1 on RNA extracted from pancreata of the two transgenic founderlines. Using
this technique, the founderline Rip1PlGF-1-2 was found to express PlGF-1, whereas no PlGF-
1 expression was detected in pancreata of line Rip1PlGF-1-1 (Figure 2). Thus, all
experiments were continued with the founderline Rip1PlGF-1-2. If not indicated otherwise,
Rip1PlGF-1 denotes the Rip1PlGF-1-2 mouseline.
Figure 2. RT-PCR analysis of transgenic PlGF-1
expression
Pancreatic RNA from Rip1PlGF-1-1 and Rip1PlGF-1-
2 mice was tested for expression of PlGF-1. Placental
RNA served as positive control, RNA from C57BL/6
pancreata and H2O as negative controls. + indicates
with, - without the addition of reverse transcriptase
To investigate morphological changes induced by the expression of PlGF-1, we
analyzed pancreata of Rip1PlGF-1 and littermate control mice by histology,
immunohistochemistry and immunofluorescence. Hematoxylin and eosin stainings as well as
toluidine blue-stained semi-thin sections of pancreata revealed dramatically dilated vascular
structures containing erythrocytes in islets of Rip1PlGF-1-2 mice. Based on immunoreactivity
for the blood endothelial marker CD31, these structures were identified as blood capillaries.
In contrast, islets of non-expressing Rip1PlGF-1-1 and control littermate mice exhibited small
blood vessels with hardly detectable lumina (Figure 3). To determine, whether the enlarged
islet blood vessels of Rip1PlGF-1-2 mice allowed a physiological blood flow, a fluorophore-
labeled lectin was injected into the teil vein of anaesthetized mice. The employed tomato-
derived lectin is a natural glycoprotein that interacts with carbohydrates of blood
endothelium. Using this technique, only the functional blood vessels are labeled and can be
detected using immunofluorescence microscopy. As shown in the lower panels of Figure 3B,
the injected lectin visualized the entire pancreatic blood vascular network of both control and
transgenic mice, thereby revealing that the dilated insular capillaries of Rip1PlGF-1-2 mice
were functional and readily perfused (Figure 3).
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Figure 3. Morphology of Rip1PlGF-1 transgenic islets
(A) Hematoxylin and eosin stainings and immunohistochemical analysis of C57BL/6,
Rip1PlGF-1-1, and Rip1PlGF-1-2 transgenic mice with anti-CD31 antibody as indicated (B,
upper panel) Toluidine blue-stained semi-thin sections of control and transgenic islets (B,
lower panel) Lectin (yellow)-perfused C57BL/6 and PlGF-1-2 transgenic mice. Islets have
been stained with anti-insulin antibody (red). Nuclei are counterstained with DAPI. Scale
bars: 100 µm
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Several studies have demonstrated angiogenic activities of PlGF-1, which appears to
be limited to pathological conditions (reviewed in [72]). To assess whether PlGF-1 promoted
the growth of blood vessels in islets of Rip1PlGF-1 transgenic mice, we stained pancreatic
sections with anti-CD31 antibody and quantified the islet microvessel density by computer-
assisted morphometric analysis. As depicted in Figure 4A, overexpression of PlGF-1 had no
significant effect on the number of intra-insular blood capillaries. However, the increase in
vessel diameter resulted in a significant increase of CD31-positive islet area when compared
to control mice (p = 0.0239, two-tailed Student’s t test). We hypothesized that PlGF-1 might
stimulate blood endothelial cells to proliferate but might not induce sprouting angiogenesis,
which would explain that blood vessel numbers were unchanged but the vessel diameter was
increased in Rip1PlGF-1 mice. To assess a proliferative effect of PlGF-1 on endothelial cells,
we performed an in vitro angiogenesis assay, in which isolated islets of Rip1PlGF-1 mice
were co-cultured with human umbilical vein endothelial cells (HUVECs) in a three-
dimensional collagen gel matrix as described previously [127, 148]. HUVECs respond by
chemotactic migration, proliferation, and tube formation when co-cultured with islets or
tumors that are actively undergoing angiogenesis, whereas in the case of a non-angiogenic
islet, endothelial cells do not respond. It is known from the literature that wildtype islets do
not induce angiogenic responses in this assay, while VEGF-A165-expressing islets derived
from Rip1VEGF-A transgenic mice as well as Rip1Tag2 tumors exhibit pronounced
angiogenic activity, resulting in proliferation of HUVECs and formation of tubule-like
structures [148]. In our assay, a representative rate of 74% of Rip1Tag2 tumors stimulated in
vitro angiogenesis, whereas Rip1PlGF-1 transgenic islets did not induce proliferation and
tube formation of endothelial cells and thus were completely non-angiogenic (Figure 4B).
These results indicate that in our assays, PlGF-1 has no effect on endothelial cell
proliferation.
A previous study has demonstrated that a significant reduction of pericytes leads to
the dilation of blood vessels [188]. Since PlGF-1 did not induce proliferation of endothelial
cells in our assays, we hypothesized that the hyperdilation phenotype of islet capillaries of
Rip1PlGF-1 mice might result from inappropriate pericyte-coating of blood capillaries. To
address this question, we stained pancreatic sections of Rip1PlGF-1 and control mice with the
pericyte marker NG-2. Statistical evaluation demonstrated that the number of pericyte-coated
blood capillaries per transgenic islet was comparable to that of control islets. However, the
percentage of NG-2-positive islet area was significantly reduced in transgenic compared to
control mice (p = 0.0306, two-tailed Student’s t test). These data suggest that blood vessels in
PlGF-1-expressing islets are less well stabilized by pericytes than islet that of control mice,
which may account for the hyperdilation phenotype of Rip1PlGF-1 islet capillaries (Figure
4C).
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Figure 4. Analysis of islet angiogenesis and arteriogenesis in Rip1PlGF-1 mice
(A, left panel) Islet blood vessel density upon immunofluorescent staining with anti-CD31
antibody (Rip1PlGF-1, n=13: 22.6±9.7, C57BL/6, n=9: 25.9±15.3, p=0.5454, unpaired
Student’s t test) (A, right panel) Percentage of islet area occupied by CD31-positive
structures (Rip1PlGF-1, n= 12: 12.6±3.8, C57 BL/6, n =9: 8.8±3, p=0.0239, unpaired
Student’s t test) (B) Islets and tumors derived from 9 week-old Rip1PlGF-1 (n=16, N=2) and
Rip1Tag2 control mice (n=35, N=4), respectively. Examples of angiogenic and non-
angiogenic islets are shown in insets. Results are indicated as % of islets or tumors in the
respective angiogenesis class above bars (C, left panel) Number of islet blood vessels coated
with NG-2-positive pericytes (Rip1PlGF-1, n=12: 17.8±11.6, C57 BL/6, n=9: 23.3±27.3,
p=0.5825, unpaired Student’s t test with Welch correction) (C, right panel) Percentage of
islet area occupied by NG-2-positive structures (Rip1PlGF-1, n=12: 6.5±2, C57BL/6, n=9:
8.9± 2.8, p=0.0306, unpaired Student’s t test).
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Transgenic PlGF-1 represses tumor growth in Rip1Tag2;Rip1PlGF-1 mice
To assess the impact of PlGF-1 on tumor angiogenesis and growth, we crossed
Rip1PlGF-1 mice with Rip1Tag2 mice, a well-characterized model of multistep β-cell
carcinogenesis [124]. Rip1Tag2 control and Rip1Tag2;Rip1PlGF-1 double transgenic mice
were sacrificed between 12 and 14 weeks of age, a time-point, when these mice succumb to
hypoglycemia caused by excessive tumoral insulin production. To assess the state of
endogenous PlGF expression in Rip1Tag2 control tumors, lysates of 12 week-old control
tumors were analyzed by immunoblotting with anti-PlGF antibody. Interestingly, this
experiment revealed that some of the control tumors upregulated endogenous mouse PlGF-2,
suggesting that this factor may play a role during Rip1Tag2 tumorigenesis (Figure 5A).
Figure 5. Expression of PlGF
in control tumors and
phenotype of Rip1Tag2 and
Rip1Tag2; Rip1PlGF-1
tumors
(A ) Immunoblot analysis of
Rip1Tag2 tumors with anti-
PlGF antibody.  Mouse
placenta served as positive
control (B) Hematoxylin and
eosin staining of tumors as
indicated. Scale bars: 100 µm.
The analysis of hematoxylin and eosin-stained pancreatic sections is currently
ongoing. Our preliminary evaluation showed that Rip1Tag2;Rip1PlGF-1 tumors appeared
more invasive and often developed important hemorrhage, yet these findings require further
examination (Figure 5B). To investigate the impact of PlGF-1 on tumor angiogenesis, we
assessed the microvessel density of tumors from both genotypes upon immunofluorescence
staining with anti-CD31 antibody. Thereby we found that the number of blood vessels in
Rip1Tag2;Rip1PlGF-1 tumors was significantly smaller than that in control tumors,
suggesting that expression of PlGF-1 couneracted tumor angiogenesis (Table I). Since
repressed tumor angiogenesis might negatively influence tumor growth, we also quantified
the tumor burden. In line with this hypothesis, the tumor volumes of Rip1Tag2;Rip1PlGF-1
mice were significantly reduced when compared to control mice, while the tumor incidence
was unaffected by transgenic expression of PlGF-1 (Table I). Together, these data imply that
expression of PlGF-1 counteracts tumor angiogenesis and thereby represses tumor growth in
Rip1Tag2;Rip1PlGF-1 mice.
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Table I. Tumor incidence, volume and tumoral blood vessel density in
Rip1Tag2;Rip1PlGF-1 mice
4.1.5. Discussion
Here we report the establishment of a transgenic mouse model to study the effect of
PlGF-1 on angiogenesis under physiological conditions as well as during tumorigenesis. One
mouseline was generated expressing human PlGF-1 under the control of the rat insulin
promoter (Rip1, [124]), which targets expression of the transgene specifically to β-cells of
pancreatic islets of Langerhans. Analysis of the islet blood vasculature revealed no
quantitative differences with regard to the islet blood vessel density when comparing
Rip1PlGF-1 and littermate control mice. Furthermore, isolated islets did not stimulate the
proliferation and tube formation of co-cultured endothelial cells in an in vitro angiogenesis
assay, whereas control tumors induced a potent angiogenic response. Two previous studies
analyzing the biological effect of PlGF-1 in a mouse cornea assay reported conflicting results,
demonstrating either a potent or no angiogenic activity of the PlGF-1 homodimer [174, 178].
Our data underline that PlGF-1 neither promotes angiogenesis under physiological conditions
in vivo nor elicits angiogenic responses in vitro. Notably, a recent study of Rip1VEGF-A165
mice similarly reported that transgenic expression of the prototype angiogenic VEGF family
member VEGF-A165 in the endocrine pancreas did not increase the blood vessel density of
transgenic islets. However, 50% of Rip1VEGF-A165 islets induced an angiogenic response in
the collagen gel assay, demonstrating that the collagen gel assay is a sensitive tool to assess
angiogenic activity of growth factors even when no such effect can be observed in transgenic
islets in vivo [148].
While transgenic PlGF-1 had no effect on the blood vessel quantity, striking
qualitative differences were found when comparing the morphology of the islet vasculature of
Rip1PlGF-1 with that of wildtype littermate mice. Analysis of pancreata by common
histology as well as by electron microscopy revealed that in comparison to control islets, all
intra- but not extra-insular blood vessels of transgenic mice are dramatically enlarged,
resulting in a significant increase of islet area occupied by CD31-positive structures. As
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demonstrated by i.v. injection of lectin, these blood vessels are functional and readily
perfused. Since PlGF-1 did not stimulate the proliferation of blood endothelial cells, we
hypothesized that the enlargement of the blood capillary diameters may result from
insufficient pericyte stabilization. Pericytes are important components of the vessel wall,
conferring scaffolding stability to the endothelial tube and modulating the process of
angiogenesis in a paracrine cross-talk with endothelial cells [3]. The essential function of
pericytes was previously demonstrated with use of genetically modified mice, in which
reduced amounts of pericytes caused microaneurysms as well as hemorrhages [188].
Therefore, we assessed the pericyte recruitment to CD31-positive blood vessels in Rip1PlGF-
1 transgenic and control islets with use of the pericyte marker NG-2. Indeed, although the
number of pericyte-coated blood vessels is unaffected by the expression of PlGF-1, the
percentage of islet area occupied by NG-2-positive structures is significantly reduced in
transgenic compared to control islets. These results indicate that the blood capillaries of
Rip1PlGF-1 transgenic islets are less well coated with pericytes than that of control islets,
which might – at least in part - account for the capillary hyperdilation phenotype.
Interestingly, PlGF-2 expressed in basal keratinocytes of K14-PlGF-2 transgenic mice
similarly induced a strong enlargement of dermal vessels. However, in addition, both an
increase in total and pericyte-coated blood vessel numbers was documented, implying that
PlGF-2 is involved in promoting angiogenesis and arteriogenesis [180]. Thus, PlGF-1 and
PlGF-2 may have opposing functions, either destabilizing blood vessels or promoting
pericyte-recruitment, angiogenesis, and arteriogenesis respectively.
To investigate the effect of PlGF-1 on tumor angiogenesis and tumor growth,
Rip1PlGF-1 mice have been crossed with Rip1Tag2 mice, a transgenic mouse model of
multistep β-cell carcinogenesis [124, 127]. Tumor growth in Rip1Tag2 mice is critically
dependent on an angiogenic switch occurring at about six weeks of age, which involves the
onset of VEGF-A expression [189]. Since PlGF-1 has been proposed to critically modulate
VEGF-A-mediated pathological angiogenesis, the Rip1Tag2 tumor model is well suited to
analyze such effects. Notably, RT-PCR analysis of tumor lysates revealed that many
Rip1Tag2 control tumors expressed endogenous mouse PlGF-2. Although not further
investigated during our analysis, this finding suggests that PlGF-2 plays a critical role during
Rip1Tag2 tumorigenesis. Our preliminary analysis of Rip1Tag2;Rip1PlGF-1 and control
mice revealed that transgenic expression of PlGF-1 does not affect tumor incidence but
significantly reduces the tumor volume. Concomitantly, the tumor blood vessel density is
significantly decreased in Rip1Tag2;Rip1PlGF-1 mice, suggesting that expression of PlGF-1
counteracts angiogenesis and thereby tumor growth. Two previous studies have reported that
PlGF-1 can heterodimerize with VEGF-A, thereby antagonizing the binding of VEGF-A to
VEGFR-2 and inhibiting VEGF-A-induced angiogenic responses [52, 178]. Since in
Rip1Tag2;Rip1PlGF-1 tumors PlGF-1 and VEGF-A are expressed in the same cell, such
heterodimerization could be one mechanism underlying repressed tumor angiogenesis in
Rip1Tag2;Rip1PlGF-1 mice. Furthermore, as seen in Rip1PlGF-1 single transgenic mice,
nascent blood vessels of Rip1Tag2;Rip1PlGF-1 tumors may be destabilized by inappropriate
pericyte recruitment. It is known that in comparison to the normal vasculature, tumor blood
vessels are disorganized and leaky. Thus, a further aggravation of an already poor tumor
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blood vessel quality by repressed pericyte coverage may result in vessel regression and thus
reduced numbers of CD31-positive tumor blood vessels. In line with this hypothesis, the
histologic examination of tumors insinuates that Rip1Tag2;Rip1PlGF-1 exhibit more
hemorrhages than control tumors, yet, this finding is still preliminary and the subject of
ongoing analyses. Also the significance of our observation that Rip1Tag2;Rip1PlGF-1 tumors
appear more invasive than control tumors remains to be confirmed by detailed investigation.
In summary, our preliminary observations suggest that the presence of PlGF-1
counteracts adequate pericyte coating of blood capillaries, resulting in the hyperdilation of
blood capillaries. No angiogenic or arteriogenic activity was detected. Moreover, during
tumorigenesis, expression of PlGF-1 significantly reduces tumor angiogenesis and therewith
tumor growth. The establishment of Rip1PlGF-1 single transgenic and Rip1Tag2;Rip1PlGF-1
tumor-bearing mice will now also enable studies of other known or proposed activities of
PlGF-1 in vivo, including the recruitment of hematopoietic stem cells and inflammatory cells.
Furthermore, we have recently generated Rip1PlGF-2 transgenic mice and are in the process
of generating double-transgenic Rip1Tag2;Rip1PlGF-2 mice, which will allow a direct
comparison of biological effects of PlGF-1 and PlGF-2 in the same experimental setting.
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4.2.1. Abstract
Vascular endothelial growth factor (VEGF)-B is a member of the VEGF family of
cytokines regulating blood and lymphatic vessel development. Accumulating evidence
suggests that VEGF-B may be involved in mediating tumor angiogenesis and may promote
epithelial-to-mesenchymal transition (EMT) and thus invasiveness of cancer cells. To assess
the effect of tumoral VEGF-B expression on tumor angiogenesis and invasiveness, we have
generated Rip1VEGF-B167 transgenic mice, in which expression of the transgene is targeted to
β-cells of pancreatic islets of Langerhans. Four healthy and fertile founderlines were
obtained, which exhibited slightly more and dilated capillaries in the islet periphery.
Currently, Rip1VEGF-B167 mice are being crossed with Rip1Tag2 mice, a well-characterized
transgenic model of multistep β-cell carcinogenesis. Our preliminary analysis demonstrates
that tumoral expression of VEGF-B167 significantly promotes tumor angiogenesis, while the
tumor volume and tumor invasiveness remain unaffected. Unexpectedly, the tumor incidence
is significantly reduced in these mice. The phenotypic characterization of Rip1VEGF-B167 and
Rip1Tag2;Rip1VEGF-B167 mice with regard to these parameters as well as to the recruitment
of pericytes and hematopoietic stem cells is the subject of ongoing investigations.
4.2.2. Introduction
VEGF-B belongs to the VEGF family of ligands, which are involved in physiological
and pathological blood vessel angiogenesis and lymphangiogenesis. Alternative splicing gives
rise to the two isoforms VEGF-B167 and VEGF-B189, VEGF-B167 being the predominant form
in vivo and most abundantly detected in heart, skeletal muscle, central nervous system,
pancreas, and prostate, showing overlapping tissue distribution with VEGF-A [94, 190-192].
While VEGF-B167 binds heparan-sulfate proteoglycans and is therefore mostly sequestered on
the cell surface or in the extracellular matrix, VEGF-B189 is freely diffusible. When produced
in the same cell, both VEGF-B isoforms can form heterodimers with VEGF-A in vitro [191].
VEGF-A is a ligand for VEGFR-1, VEGFR-2, and the co-receptors NP-1 and NP-2,
mediating angiogenic effects predominantly via VEGFR-2. In contrast, VEGF-B only binds
to VEGFR-1 and NP-1. Similarly to VEGFR-2, VEGFR-1 is predominantly expressed on
blood endothelial cells. Moreover, it is found on many non-endothelial cells including
monocytes/macrophages, hematopoietic stem cells, pericytes, and tumor cells. The signaling
pathways induced by VEGF-B-mediated VEGFR-1 activation are not yet conclusively
elucidated. Although VEGFR-1 has only weak tyrosine kinase activity, it may display
intrinsic signaling functions [101]. Other reports claim that VEGFR-1 might act as a decoy
receptor for VEGF-A and that VEGFR-1-selective ligands such as VEGF-B might indirectly
stimulate VEGF-A signaling by displacing VEGF-A from VEGFR-1, thereby increasing the
VEGFR-2-activating fraction of VEGF-A [60, 170, 175]. Alternatively, heterodimerization of
VEGF-B with VEGF-A may alter the receptor specificity of VEGF-A [191].
Studies of VEGF-B-deficient mice have unveiled that VEGF-B plays a role during
cardiac and cerebral development [193-195]. Furthermore, these mice show impaired
recovery following myocardial or cerebral ischaemic insults, reduced angiogenic responses in
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collagen-induced arthritis and fail to develop pulmonary hypertension in response to hypoxia
[193, 196-198]. Thus, although VEGF-B is not critical during systemic vascular development,
it may be involved in pathological vascular remodeling. These observations are in line with
the fact that endothelial cells of pathologic vasculature upregulate VEGFR-1 expression [44,
68]. Experiments using VEGF-B-releasing Matrigel plugs and electrotransfer of plasmids
expressing VEGF-B have demonstrated that VEGF-B can exert angiogenic effects in vivo
[199]. Furthermore, transgenic mice expressing VEGF-B in endothelial cells display
enhanced vascular growth in an in vivo Matrigel assay and during cutaneous wound healing.
Notably, no vascular permeability-promoting activity, such as the one known for VEGF-A,
was observed [200].
The role of the VEGF-B/VEGFR-1 system in tumorigenesis has been recently
addressed in several clinical and experimental studies. VEGF-B is expressed in a variety of
human cancers, including melanoma, meningioma, fibrosarcoma, breast, squamous cell, renal
cell and head and neck carcinoma [94, 96, 201]. In oral squamous cell carcinoma, elevated
VEGF-B expression correlates with increased tumor microvessel density, suggesting that
VEGF-B might be involved in the process of tumor angiogenesis [95]. One mechanism by
which VEGF-B may support tumor neo-angiogenesis is the recruitment of VEGFR-1-positive
hematopoietic stem cells and pericytes [202]. Furthermore, two in vitro studies show that
VEGF-B can stimulate migration and invasion but not proliferation of different pancreatic
and colorectal cancer cells via activation of VEGFR-1 [203, 204]. Consistent with these
reports, VEGF-B has been shown to induce epithelial-to-mesenchymal (EMT) transition via
VEGFR-1 in a pancreatic cancer cell line [205].
To investigate the effect of VEGF-B on tumor angiogenesis and tumor progression,
we have generated Rip1VEGF-B167 transgenic mice, in which the expression of human
VEGF-B167 is driven by the rat insulin promoter (Rip1) and thereby is targeted to β-cells of
pancreatic islets of Langerhans. Rip1VEGF-B167 mice were crossed with Rip1Tag2 tumor
mice, a transgenic mouse model of β-cell carcinogenesis [124]. Here we report the
preliminary data of analyses performed on single transgenic Rip1VEGF-B167 and double
transgenic Rip1Tag2;Rip1VEGF-B167 mice with regard to islet and tumor angiogenesis as
well as tumor growth. Since Rip1Tag2 tumor cells may express VEGFR-1, we also
investigated whether expression of VEGF-B167 promotes invasiveness in vivo as a correlate to
its previously described ability to induce EMT in vitro.
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4.2.3. Materials and Methods
Generation of Rip1VEGF-B167 transgenic Mice
The Rip1VEGF-B167 vector was kindly provided by M. Jeltsch (Molecular/Cancer
Biology Laboratory, Biomedicum, University of Helsinki, Helsinki, Finland). The construct
comprises a 704 bp BamHI/XbaI fragment of the rat insulin gene II promoter, the cDNA
fragment encoding the 565 bp coding region of full length human VEGF-B167 (nucleotides 1-
565, Accession number EMBL:U43369), and a 436 bp stretch containing SV40 introns and
polyadenylation signal sequences (Rip1; [124]. 100 µg of the Rip1VEGF-B167 plasmid were
digested with 10 µL BamHI in a total volume of 450 µL for five hours and resolved on a
0.8% agarose gel. The ~ 1.7 kb band comprising the Rip1, the human VEGF-B167, and the
SV40 small T intron and polyadenylation signal sequences was excised from the gel and
purified once with the GENECLEAN SPIN kit (QBiogene, Luzern, Switzerland). The
purified Rip1VEGF-B167 fragment was used for injection into the male pronucleus of
fertilized C57BL/6 oocytes according to standard procedures at the Transgenic Mouse Core
Facility TMCF, Biozentrum, Basel [147].
Genotypes were confirmed by PCR analysis of standard toe genomic DNA
preparations using a primer pair specific for the transgene (forward primer located in the Rip1
sequence: 5'-TAA TGG GAC AAA CAG CAA AG; reverse primer located in the
Rip1VEGF-B167 sequence: 5'-CGC GAG TAT ACA CAT CTA TCC). PCR cycles were:
94°C, 5 min (x1); 94°C, 30 sec, 57°C, 30 sec, and 72°C, 30 sec (x34); and 72°C, 10 min (x1).
Routine PCR screening of Rip1VEGF-B167 heterozygotes was performed according to the
same protocol.
For histopathological analysis, tumor grading, lectin perfusion, and electron
microscopy refer to General Materials and Methods
4.2.4. Results
Generation of Rip1VEGF-B167 transgenic mice
To generate transgenic mice expressing VEGF-B167 specifically in β-cells of
pancreatic islets of Langerhans, a cDNA containing the full-length coding sequence of human
VEGF-B167 was cloned between the rat insulin II gene promoter fragment (Rip) and the SV40
small t antigen intron and polyadenylation signal (Figure 1). Injection of the transgene into
fertilized C57BL/6 oocytes resulted in four viable, healthy, and fertile founderlines exhibiting
stable germline transmission (Rip1VEGF-B1 to Rip1VEGF-B4).
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Figure  1 .  The
Rip1VEGF-B167
transgene construct
The XbaI/HindIII
fragment containing
human VEGF-B167 was
l igated into the
XbaI/HindIII-opened
Rip1 vector. The
r e s t r i c t i o n  s i t e s
located in the 5’ and
3’ multiple cloning
sites acquired from the
previous vector are
indicated.
Transgenic founder lines were tested for β-cell-specific expression of VEGF-B by
immunofluorescence analysis using an anti-VEGF-B antibody. Thereby, founderlines
Rip1VEGF-B1, -B2, and -B3 were shown to express the transgene, whereas islets of
Rip1VEGF-B4 and control littermate mice did not exhibit any detectable levels of VEGF-B
in several experiments (Figure 2 and data not shown). The founderline Rip1VEGF-B1 was
selected for phenotypical analysis in most experiments, thus in the following, Rip1VEGF-B167
refers to the Rip1VEGF-B1 founderline if not noted otherwise.
The islet blood vessel architecture of Rip1VEGF-B167 transgenic mice
In order to characterize morphological alterations induced by transgenic expression of
VEGF-B167, we analyzed pancreata of Rip1VEGF-B167 and littermate control mice by
histology and immunofluorescence. Inspection of hematoxylin and eosin-stained sections
revealed that Rip1VEGF-B1 transgenic islets were frequently located next to large blood
vessels, whereas control islets were mainly found in the deeper parenchyma of the exocrine
tissue. A statistical evaluation of this finding is currently underway (Figure 2). In other
respects, no distinct phenotype of transgenic islets was apparent. To visualize the islet blood
vasculature, we performed immunofluorescence stainings using anti-CD31 antibody and
injected a fluorophore-coupled tomato-derived lectin into the tail vein of anaesthetized mice.
This naturally occurring glycoprotein associates with high affinity with sugar chains of blood
endothelium. As shown in Figure 2, both control and VEGF-B167-expressing islets exhibited a
comparably dense and well-perfused network of blood capillaries. In contrast, in comparison
to control islets, we detected more CD31-positive capillaries in the periphery of transgenic
islets (arrows).
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Figure 2. Histological analysis of Rip1 VEGF-B167 islets
Pancreatic sections from Rip1VEGF-B1, –B3 and control littermate mice were analyzed by
immunofluorescence staining with anti-VEGF-B antibody (red), hematoxylin and eosin
staining, and immunofluorescence staining with anti-CD31 antibody (red) as indicated. I.v.
injected lectin was detected by immunofluorescence (yellow), islets were visualized using
anti-insulin antibody (red). Nuclei were couterstained with DAPI. Dashed lines demarcate
islets, arrows indicate peripheral islet capillaries. Scale bars: 100 µm
To unveil phenotypic alterations on the ultra-structural level, we prepared toluidine
blue-stained semithin-sections of a Rip1VEGF-B3 and a C57BL/6 control mouse. As shown
in Figure 3, capillaries located in the rim of transgenic islets were slightly dilated in
comparison to peripheral capillaries of control islets (Figure 3, asterisks). Furthermore, the
islet microvessel density appeared increased in VEGF-B167-expressing islets. Both
observations are currently being analyzed to allow statistical evaluation.
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Figure 3. Ultra-structural analysis of Rip1VEGF-B167 transgenic islets
40x and 100x magnifications of toluidine blue-stained semi-thin sections of C57BL/6 control
and Rip1VEGF-B167 transgenic mice as indicated. Ex, exocrine tissue; asterisks indicate
blood capillaries. Scale bars: 50 µm
The lack of more striking structural or organizational alterations of islet blood vessels
in Rip1VEGF-B167 transgenic mice may indicate that at least in the absence of a pathological
challenge such as hypoxia or inflammation, VEGF-B167 does not significantly modulate
angiogenesis in Rip1VEGF-B167 transgenic mice.
Transgenic VEGF-B167 promotes tumor angiogenesis but not tumor growth in
Rip1Tag2;Rip1VEGF-B167 mice (preliminary data)
Accumulating evidence from the literature implies a particular involvement of
VEGF-B and its receptor VEGFR-1 in pathological angiogenesis [179, 193]. To assess the
impact of overexpressed VEGF-B on tumor angiogenesis and tumor progression, we crossed
Rip1VEGF-B167 with Rip1Tag2 transgenic mice, a well-established model of multistep β-cell
carcinogenesis [124]. As revealed by immunofluorescence staining with anti-VEGF-B
antibody, the majority of RipTag2 control tumors did not express VEGF-B. Interestingly
however, we detected immunoreactivity for VEGF-B in sharply demarcated areas of some
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control tumors (Figure 4). In contrast, all insulinomas of Rip1Tag2;Rip1VEGF-B167 mice
expressed large amounts of VEGF-B167 (Figure 4).
To measure tumor angiogenesis, we quantified the microvessel density of tumors by
immunohistochemical staining of pancreatic sections with anti-CD31 antibody and
subsequent counting of intra-tumoral CD31-immunoreactive vascular structures (Figure 4).
Double transgenic tumors exhibited significantly more blood vessels than tumors of control
mice, suggesting that transgenic expression of VEGF-B167 promoted tumor angiogenesis (p =
0.0004, two-tailed Student’s t test, Table I). Furthermore, based on the above described
finding that islets of Rip1VEGF-B167 mice appeared to be frequently located next to large
blood vessels, we investigated such correlation in Rip1Tag2;Rip1VEGF-B167 mice. However,
as shown in Table I, equal percentages of double transgenic and Rip1Tag2 control tumors
were detected in the vicinity of large vessels.
Figure 4. Tumoral expression of VEGF-B and tumor blood vasculature in control and
Rip1Tag2; Rip1 VEGF-B167 mice
Immunofluorescence analysis of twelve week-old Rip1Tag2 and Rip1Tag2;Rip1 VEGF-B167
mice using anti-VEGF-B and anti-CD31 antibody. Note that some Rip1Tag2 control tumors
upregulate expres-sion of VEGF-B. Ex, exocrine tisse, T, tumor. Scale bars: 100 µm.
Next, we reasoned that an increase in tumor angiogenesis might also accelerate tumor
growth. However, Rip1Tag2;Rip1VEGF-B167 mice did not die earlier than Rip1Tag2 control
mice, suggesting that tumor growth was not significantly promoted in double transgenic mice.
Moreover, quantitative analyses of the tumor burden unveiled that both the tumor incidence
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and the tumor volume were reduced in Rip1Tag2;Rip1VEGF-B167 compared to control mice,
whereby only the reduction in tumor incidence was statistically significant  (p = 0.0452, two-
tailed Student’s t test with Welch correction and p = 0.0751, two-tailed Student’s t test,
respectively; Table I). In contrast, neither tumor cell proliferation nor apoptosis were affected
by transgenic expression of VEGF-B167, which suggests that the enhancement of tumor
angiogenesis upon transgenic expression of VEGF-B167 had no direct effect on the cancer
cells as such. The decrease in tumor incidence and tumor growth of Rip1Tag2;Rip1VEGF-
B167 mice cannot be explained so far. However, the analysis of tumor-bearing mice is still
ongoing and the presented results have to be considered preliminary.
Table I. Tumor burden and tumor microvessel density in Rip1Tag2;Rip1VEGF-B167transgenic mice
Expression of VEGFB167 does not affect tumor invasiveness in Rip1Tag2;Rip1VEGF-
B167 mice (preliminary data)
As a consequence of conflicting data it is not fully established whether β tumor cells
express VEGFR-1 [206-208]. Despite this uncertainty, results from very recent studies
demonstrating that VEGF-B-induced activation of VEGFR-1 might be involved in epithelial-
to-mesenchymal transition of cancer cells motivated us to investigate such activity of VEGF-
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B167 in Rip1Tag2;Rip1VEGF-B167 mice [203-205]. Therefore, we are currently assessing the
malignant phenotype of Rip1Tag2;Rip1VEGF-B167 and control tumors by histological
grading upon hematoxylin and eosin staining. As shown in Table II, the preliminary statistical
analyses indicate only minor changes in the ratio of benign versus malignant tumors.
However, the still small number of control mice does not yet allow an appropriate and
conclusive interpretation of these results.
Table II. Tumor grading of Rip1Tag2;Rip1VEGF-B167 versus control mice
In summary, the analysis of Rip1Tag2;Rip1VEGF-B167 mice demonstrated that
tumoral expression of VEGF-B167 promotes tumor angiogenesis. However, no impact on the
tumor cells themselves was observed to date, in particular, tumor volume, tumor incidence,
and invasiveness were not increased during Rip1Tag2 tumorigenesis.
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4.2.5. Discussion
We have generated Rip1VEGF-B167 transgenic mice, which over-express human
VEGF-B167 specifically in β-cells of pancreatic islets of Langerhans. In comparison to age-
matched control mice, which do not exhibit any detectable levels of VEGF-B167 protein in
islets, our observations indicate only a minor impact of VEGF-B167 expression on the islet
blood vasculature of transgenic mice. VEGF-B167-expressing islets exhibited slightly more
and dilated blood capillaries in the islet periphery, indicating a weak pro-angiogenic effect of
VEGF-B167. Also, transgenic islets were frequently observed to be located next to large blood
vessels. However, as a result of the distinct endocrine pancreatic development, islets of
Langerhans are known to be closely associated with the vascular system of the organ, and
ongoing statistical analysis has yet to prove the significance of this finding. The observation
that VEGF-B167 did not critically influence blood vessel growth in transgenic islets is
consistent with studies of VEGF-B-deficient mice, which demonstrated that this growth factor
is not required for systemic angiogenesis under physiological conditions but is particularly
involved in mediating pathological angiogenesis [193, 196-198]. Yet, it has to be mentioned
that a previous study of RipVEGF-A165 transgenic mice similarly reported no major
qualitative or quantitative changes in islet vasculature induced by β-specific overexpression
of VEGF-A165 [148]. However, in an in vitro angiogenesis assay, isolated RipVEGF-A165
transgenic islets promoted angiogenic responses in co-cultured endothelial cells, while
wildtype islets did not induce such angiogenic effects. Thus, it is possible that in vivo, islets
of Langerhans are not a permissible environment for the induction of pronounced
angiogenesis even by potent angiogenic factors such as VEGF-A165. Therefore, we are
currently performing collagen gel assay experiments with islets from Rip1VEGF-B167 mice to
unveil a potentially latent angiogenic effect of VEGF-B167 in vitro.
 Using the Rip1Tag2 mouse model of pancreatic β-cell carcinogenesis, we have
assessed the influence of tumoral overexpression of VEGF-B167 on tumor angiogenesis,
growth and progression. Rip1Tag2 transgenic mice express the SV40 large T antigen (Tag)
under the control of the rat insulin gene promoter (Rip), which elicits the sequential
development of β-cell tumors over a period of 12–14 weeks [124]. The tumor growth in
Rip1Tag2 mice is critically dependent on an angiogenic switch occurring at about six weeks
of age, which involves the onset of VEGF-A expression [189]. Of note, a previous study
demonstrated that injection of a soluble VEGFR-1 into Rip1Tag2 mice repressed tumor
growth, which might result from the concomitant sequestration of all three VEGFR-1 ligands,
VEGF-A, PlGF, and VEGF-B [209]. During our analysis, we found that a small subset of
control tumors expressed VEGF-B in a well-demarcated tumor area, indeed suggesting a role
of this growth factor in Rip1Tag2 tumorigenesis. In contrast, all tumors of
Rip1Tag2;Rip1VEGF-B167 mice expressed high amounts of VEGF-B, enabling a comparative
study of the two genotypes. First, we investigated the impact of VEGF-B167 on tumor
angiogenesis. Quantification of the tumor microvessel density using the blood endothelium-
specific marker CD31 revealed a significant increase blood vessels per tumor area in
Rip1Tag2;Rip1VEGF-B167 mice when compared to age-matched control mice, strongly
suggesting that VEGF-B167 promotes tumor angiogenesis. This result is in line with a recent
clinical study of oral squamous cell carcinoma, which correlated elevated VEGF-B
expression with increased tumor microvessel density [95]. It was reported that one
mechanism by which VEGF-B may support tumor neo-angiogenesis is the recruitment of
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VEGFR-1-positive hematopoietic stem cells and pericytes [202]. Also, VEGF-A-induced
angiogenesis might be modulated by the formation of VEGF-B/VEGF-A heterodimers in case
both growth factors are produced in the same cell. Since VEGF-A is naturally upregulated
during Rip1Tag2 tumorigenesis, such heterodimers might indeed be formed. The pericyte and
hematopoietic stem cell recruitment as well as possible VEGF-B/VEGF-A heterodimerization
are the subject of ongoing analyses of Rip1Tag2;Rip1VEGF-B167 mice.
It has been demonstrated that an increase in tumor angiogenesis promotes tumor
growth and thereby negatively influences the outcome of tumor-bearing animals as well as
cancer patients (reviewed in [210]). However, double transgenic Rip1Tag2;Rip1VEGF-B167
mice neither succumbed earlier to insulinoma nor exhibited increased tumor burden in
comparison to control mice. Rather, both tumor incidence and tumor volume were reduced in
Rip1Tag2;Rip1VEGF-B167 mice. In contrast, tumor cell proliferation and apoptosis were
unaffected by the expression of VEGF-B167, which indicates that VEGF-B167-mediated
stimulation of angiogenesis had no effect on the tumor cells as such. Interestingly, a previous
study of Rip1Tag2;Rip1VEGF-A165 mice reported an accelerated induction of tumor
angiogenesis and subsequently tumor growth and mortality, while the tumor microvessel
density of fully developed tumors was not increased by the expression of VEGF-A165 in
comparison to control tumors. The observed phenotypic differences of Rip1Tag2;Rip1VEGF-
B167 and Rip1Tag2;Rip1VEGF-A165 mice indicate that the two overexpressed growth factors
trigger distinct signaling pathways. Thus, VEGF- B167 may not only indirectly mediate
angiogenesis by potentiating VEGF-A-signaling via VEGFR-2 but may induce intrinsic
angiogenic signaling via VEGFR-1.
Based on our observations from single transgenic Rip1VEGF-B167 mice we
investigated whether we could detect any correlation with regard to the localization of
Rip1Tag2;Rip1VEGF-B167 tumors next to large blood vessels. However, no such relation was
found when comparing double transgenic and control tumors. One possibility is that the
Rip1Tag2;Rip1VEGF-B167 tumors may have overgrown and incorporated such blood vessels.
This hypothesis is currently being addressed by a quantitative analysis of intra-tumoral large
blood vessels in double transgenic and control tumors.
Recently, several studies using pancreatic and colorectal cancer cell lines reported that
VEGF-B stimulated tumor cell migration, invasion, and epithelial-to-mesenchymal (EMT)
transition but not proliferation via activation of VEGFR-1 [203-205]. During EMT, cells
progressively redistribute or down-regulate apical and basolateral epithelial-specific proteins,
such as tight and adherens junction proteins, and re-express mesenchymal molecules,
resulting in the abrogation of cell-cell contacts and the gain of motility (reviewed in [211]).
Although still heavily debated, EMT may represent the in vitro correlate to invasiveness and
metastasis. Since a subset of Rip1Tag2 control tumors expressed VEGF-B in specific areas
that could represent invasive tumor edges, we investigated a potential effect of VEGFB167 on
the invasiveness of tumors in vivo and assessed the malignant phenotype of tumors of
Rip1Tag2;Rip1VEGF-B167 and control mice by histological grading. Thus far, we were not
able to detect significant differences of tumor grades when comparing double transgenic and
control tumors. However, the analysis is still ongoing and the numbers of analyzed mice is
not yet sufficient to draw reliable conclusions. Yet, it has to be considered that expression of
VEGFR-1 has not been verified yet in β-cells of islets and insulinomas in vivo, although it is
commonly detected in islet and Rip1Tag2 tumor capillaries as well as in insulinoma cell lines
[206-208].
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Taken together, our preliminary data demonstrate that transgenic expression of
VEGF-B167 only moderately affects physiological angiogenesis, yet significantly promotes
tumor angiogenesis. Our ongoing detailed analyses of Rip1Tag2;Rip1VEGF-B167 mice will
shed more light on the mechanisms of VEGF-B-mediated angiogenesis and its impact on
tumor progression.
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4.3.1. Abstract
Members of the vascular endothelial growth factor (VEGF) family and their receptors
(VEGFR) are important regulators of blood and lymphatic vessel development. VEGFR-1
and VEGFR-2 are predominantly expressed on blood endothelium and mediate angiogenesis
upon activation by their ligands. VEGF-A is the only known mammalian ligand for VEGFR-2
but binds and activates also VEGFR-1. The identification of the VEGFR-2-selective VEGF-
E, a viral homolog of VEGF-A, has enabled the study of distinct biological functions of
VEGFR-2. Here we report the generation of three independent transgenic mice expressing
VEGF-ED1701 specifically in β-cells of pancreatic islets of Langerhans (Rip1VEGF-ED1701).
These mice represent a new tool for investigating the role of activated VEGFR-2 in blood
vessels of adult animals. Moreover, Rip1VEGF-ED1701 mice are currently being crossed with
Rip1Tag2 transgenic mice, a well characterized model of multistage β-cell tumorigenesis.
Future studies of double-transgenic mice will further our understanding of the importance of
VEGFR-2 signaling for tumor angiogenesis, tumor progression, and metastasis.
4.3.2. Introduction
Vascular endothelial growth factor receptor-2 (VEGFR-2/flk-1/KDR) is one of the
three transmembrane VEGFR tyrosine kinases, which are involved in vasculogenesis,
angiogenesis, and lymphangiogenesis. While in the adult, expression of VEGFR-3 (flt-4) is
largely restricted to lymphatic endothelium, VEGFR-1 (flt-1) and VEGFR-2 are
predominantly expressed on blood endothelial cells. However, VEGFR-2 is also expressed on
other cells including lymphatic endothelial, hematopoietic stem, and tumor cells [212].
Furthermore, a soluble form of VEGFR-2 has been discovered in mouse and human serum
[61]. VEGFR-2 is a high-affinity receptor for VEGF-A as well as the processed forms of
VEGF-C and VEGF-D [47]. Studies of knockout mice suggest that during embryogenesis,
VEGFR-2 is the main signal transducer of vasculogenesis and angiogenesis, whereas
VEGFR-1 acts as a negative regulator [10, 13]. Also in the adult, VEGFR-2 is the major
mediator of mitogenic and survival signals in endothelial cells and of VEGF-A-induced
angiogenesis. While signaling via VEGFR-2 has been demonstrated to be crucial for the
recruitment of hematopoietic precursor cells to the developing vasculature, its role has not yet
been conclusively elucidated in the adult tissue [10, 47]. In contrast, distinct interactions
between VEGFR-2 and NP-1, integrin αVβ3 and VE-cadherin have been shown to be critical
for mediating angiogenesis, vascular permeability, and lymphangiogenesis [213-217].
Furthermore, several recent studies indicate that activation of VEGFR-2 also promotes
lymphangiogenesis [217, 218].
During tumorigenesis, VEGF-A-mediated activation of VEGFR-2 significantly
contributes to angiogenesis and thereby promotes tumor growth [90, 219]. Moreover, recent
evidence suggests a primary role of VEGFR-2 in mediating VEGF-A-induced adhesion,
migration, and invasion of tumor cells in vitro, in part via activation of integrins [220, 221].
However, since VEGF-A binds and activates both VEGFR-1 and VEGFR-2, the distinct
contribution of VEGFR-2 signaling to observed biological effects was difficult to assess. The
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discovery of VEGF-E, a viral homolog of VEGF-A and selective ligand for VEGFR-2, has
enabled a more precise dissection of the role of this receptor during physiological and
pathological angiogenesis. VEGF-E is the collective term for the five variants identified in the
genome of the parapoxviruses Orf virus and Pseudocowpox virus, namely VEGF-ENZ-2,
VEGF-ENZ-7, VEGF-ENZ-10, VEGF-ED1701, and VEGF-EVR634 [222-226]. Parapoxviruses infect
sheep, goats, cattle, and humans, and induce skin lesions characterized by extensive
vasodilation, dermal edema, and proliferation of endothelial cells [227-229]. Although
VEGF-E variants show only 16 to 29% amino acid identity with VEGF-A165, they display
almost the same affinity for VEGFR-2 as VEGF-A165. The variants VEGF-ENZ-2, VEGF-ENZ-
10, and VEGF-ED1701 also bind NP-1, a co-receptor of VEGF-A, VEGF-B, and PlGF-2, which
may be particularly important in mediating vascular permeability [223-225]. The ability of
these VEGF-E variants to bind NP-1 is surprising given their lack of conservation of the
heparin-binding domain implicated in the binding of VEGF-A, VEGF-B, and PlGF-2 to NP-1
[171, 216, 230]. Moreover, VEGF-ENZ-2 was reported to display heparin-binding activity, yet
the amino acid stretch mediating this action is not yet identified [226]. Although differing in
their amino acid sequence and receptor binding affinities, all VEGF-E variants possess
similar activities as described for VEGF-A, such as induction of tissue-factor expression,
chemotaxis, proliferation, and sprouting of cultured endothelial cells in vitro as well as
induction of angiogenesis and vascular permeability in vivo [223-226].
The aim of the present study was to establish a transgenic mouse expressing VEGF-E
under the control of the rat insulin promoter (Rip1), thereby targeting expression of the
transgene to pancreatic islets of Langerhans. Future crossings of these mice with Rip1Tag2
transgenic mice, a well-characterized insulinoma model, will enable the study of the specific
role of VEGFR-2 activation in tumor angiogenesis, including the recruitment of
hematopoietic progenitor cells. Moreover, a potential involvement of VEGFR-2 in the
promotion of tumor invasiveness and metastasis can be addressed.
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4.3.3. Materials and Methods
Cloning of the Rip1VEGF-ED1701 construct
VEGF-ED1701 cDNA was amplified by PCR from the pCD379-VEGF-ED1701 vector
construct kindly provided by Prof. C. Dehio (Division of Molecular Microbiology,
Biozentrum,Basel, Switzerland) using the forward primer 5’- GCT CTA GAG CCA CCA
TGA AGT TTC TCG TCG GC containing a 5’-XbaI restriction site (underlined) and the
reverse primer 5’-CCC AAG CTT CTA GCG GCG TCT TCT GGG CGG containing a 5’-
HindIII restriction site (underlined). PCR cycles were: 94°C, 2 min (x1); 94°C, 15 sec, 65°C,
30 sec, and 72°C, 45 sec (x30); and 72°C, 7 min (x1). PCR products were resolved on a 1%
agarose gel and extracted with the QIAEXII Gel Extraction kit. Constructs were sequenced at
Synergene Biotech (Schlieren, Switzerland), using the forward primer located in the Rip1
sequence: 5'-TAA TGG GAC AAACAG CAA AG and the reverse primer comprising the
stop codon of VEGF-E 5’-CCC AAG CTT CTA GCG GCG TCT TCT GGG CGG.
Generation of Rip1VEGF-ED1701 transgenic mice
100 µg of the Rip1VEGF-ED1701 plasmid were digested with 10 µL BamHI in a total
volume of 450 µL for five hours and resolved on a 0.8% agarose gel. The ~ 1.5 kb transgene
construct was extracted from the gel and purified once with the GENECLEAN SPIN kit
(QBiogene, Luzern, Switzerland). The purified RipVEGF-ED1701 DNA fragment was used for
generation of RipVEGF-ED1701 transgenic mice according to standard procedures at the
Transgenic Mouse Core Facility TMCF, Biozentrum, Basel [147]. Screening for founders and
of RipVEGF-ED1701 heterozygotes was performed by PCR using a forward primer located in
the Rip1 sequence: 5'-TAA TGG GAC AAA CAG CAA AG and a reverse primer located in
the VEGF-E sequence: 5'-CCA TGT TTT CGT GCT GTC CG), starting from standard toe or
tail genomic DNA preparations. PCR cycles were: 94°C, 5 min (x1); 94°C, 30 sec, 55°C, 30
sec, and 72°C, 30 sec (x34); and 72°C, 7 min (x1).
RT-PCR analysis of of Rip1VEGF-ED1701 transgenic mice for VEGF-E expression
Pancreata were homogenized in TRIzol reagent for RNA isolation according to the
manufacturer’s protocol (Sigma Chemical Co., St. Louis, MO). 500 ng of total RNA was
reverse transcribed using reverse transcriptase and random hexamers from Sigma Chemical
Co., St. Louis, MO. The cDNA was screened for VEGF-E by temperature gradient PCR using
the forward primer 5’- AGC CAA GGC CGA TGG TCT TTC and the reverse primer 5’-CCA
TGT TTT CGT GCT GTC CG (both located in the VEGF-E sequence). PCR cycles were
94°C, 5 min (x1); 94°C, 30 sec, 54-66°C, 30 sec, and 72°C, 30 sec (x29); and 72°C, 7 min
(x1).
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4.3.4. Results
Generation of Rip1VEGF-ED1701 transgenic mice
To generate transgenic mice specifically expressing VEGF-E in β-cells of pancreatic
islets of Langerhans, the cDNA encoding the 399 bp of full length VEGF- ED1701 deriving
from Orf virus strain D1701 was amplified by PCR from the pCD379-VEGF-ED1701 vector
construct. The VEGF- ED1701 cDNA was subsequently cloned between the 704 bp rat insulin II
promoter and a 436 bp stretch containing SV40 small T intron and polyadenylation signal
sequences of the Rip1 vector using XbaI and HindIII (Rip1; [124] (Figure 1). The
Rip1VEGF-ED1701 construct was tested for insertion of VEGF- ED1701 by restriction digests
using XbaI/HindIII as well as with BamHI. Both digests revealed inserts of the expected size
of approximately 400 bp and 1.5 kb, respectively. To exclude mutations, which might have
been induced during PCR and cloning procedures, the Rip1VEGF-ED1701 construct was
sequenced using primers encompassing the entire VEGF-ED1701 insert and a small stretch of
the Rip1 sequence. Thereby, the appropriate insertion into the vector as well as the correct
sequence of VEGF-ED1701 were verified.
Figure 1. Map of the
Rip1VEGF-ED1701
construct
For injection of the transgene into fertilized C57BL/6 oocytes, the Rip1VEGF-ED1701
construct was digested with BamHI. The insert comprising the rat insulin promotor (Rip1),
the VEGF-ED1701 and the SV40 small T intron and polyadenylation signal sequences was used
for generation of transgenic mice. However, only one Rip1VEGF-ED1701 founderline was
obtained. To exclude transgene integration effects during future analyses we repeated oocyte
injections, which resulted in four additional Rip1VEGF-ED1701 transgenic founders. All
founderlines exhibited stable germline transmission and were healthy and fertile.
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Analysis of transgenic VEGF-ED170 expression
A first attempt to assess transgenic expression of VEGF-E by immunohistochemistry
and immunofluorescence analysis with specific rabbit sera revealed unspecific binding of
antibodies to β-cells of control mice (data not shown). Since no purified antibodies were
commercially available, the five transgenic founderlines were tested for expression of VEGF-
E by RT-PCR performed on pancreatic RNA. Considering the high ratio of endocrine to
exocrine pancreas in young mice, pancreata were isolated from 3-4 week-old animals. As
shown in Figure 2, the founderlines Rip1VEGF-ED1701-3, Rip1VEGF-ED1701-4, and
Rip1VEGF-ED1701-5 expressed VEGF-E in pancreata, whereas no VEGF-E mRNA could be
detected in pancreata of Rip1VEGF-ED1701-1 and Rip1VEGF-ED1701-2 mice.
Figure 2. RT-PCR analysis of transgenic VEGF-E expression
Pancreatic RNA from the five Rip1VEGF-ED1701 founderlines was tested for expression of
VEGF-E. Rip1VEGF-ED1701 plasmid served as positive, H2O as negative control. β-actin
primers were used to monitor quality of cDNA. VE1, founderline Rip1VEGF-ED1701-1, VE2,
founderline Rip1VEGF-ED1701-2, VE3, founderline Rip1VEGF-ED1701-3, VE4, founderline
Rip1VEGF-ED1701-4, VE5, founderline Rip1VEGF-ED1701-5; + indicates with, - without reverse
transcriptase.
The phenotypical characterization of the three expressing founderlines is currently
ongoing. Furthermore, these mice are being crossed with Rip1Tag2 transgenic mice, a well-
established mouse model of multistage β-cell carcinogenesis, and will be analyzed to dissect
the specific role of activated VEGFR-2 in tumor angiogenesis and tumor progression [124].
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4.3.5. Discussion
Here we report the establishment of Rip1VEGF-ED1701 transgenic mice, in which
expression of the variant VEGF-ED1701 is targeted specifically to β-cells of pancreatic islets of
Langerhans. Three independent healthy and fertile founderlines were generated exhibiting
stable germline transmission as well as transgene expression in the pancreas, enabling the
exclusion of transgene integration artifacts as cause of potential phenotypical observations.
Members of the vascular endothelial growth factor (VEGF) family and their receptors
are important regulators of physiological and pathological angiogenesis. VEGFR-1 and
VEGFR-2 are mainly involved in angiogenic processes, whereas VEGFR-3 is an important
signal transducer during lymphangiogenesis [45]. Since VEGFR-2-deficient mice are
embryonically lethal and VEGF-A as the only mammalian ligand for VEGFR-2 also activates
VEGFR-1, the specific contribution of VEGFR-2 to VEGF-A-induced processes in adult
animals has been difficult to assess. The discovery of the viral VEGF-E family members,
which display selective affinity for VEGFR-2, has represented an important step towards
elucidating distinct VEGFR-2-mediated signaling and biological effects. All VEGF-E
variants characterized to date display almost the same affinity for VEGFR-2 as VEGF-A165,
and VEGF-ENZ-2, VEGF-ENZ-10, and VEGF-ED1701 can also bind the co-receptor NP-1 [223-
226]. Although differing in their amino acid sequence and receptor binding affinities, all
VEGF-E variants possess similar activities as described for VEGF-A, including induction of
endothelial cell proliferation in vitro and angiogenesis in vivo (reviewed in [46]). Recent
studies have demonstrated that VEGFR-1, which is a negative modulator during vascular
development, becomes again important in pathological angiogenesis of the adult, such as
occurring in cancer [179]. Although its importance is undisputed, the specific role of
VEGFR-2 during tumor angiogenesis has only recently become clearer due to studies using
VEGF-E [46, 67, 231]. Furthermore, VEGFR-2 has been shown to contribute to tumor cell
migration and invasion in vitro and may therefore also be involved in metastasis in vivo [220,
221].
The generation of Rip1VEGF-ED1701 transgenic mice represents a new tool to study
biological effects of activated VEGFR-2 in the adult vasculature. Furthermore, these mice are
currently being crossed with Rip1Tag2 mice, a well-characterized model of poorly-metastatic
β-cell carcinogenesis [124]. The analysis of double transgenic Rip1Tag2;Rip1VEGF-ED1701
mice will contribute to our understanding of the role of VEGFR-2 in tumor angiogenesis,
tumor progression, and metastasis.
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5. Conclusion and Outlook
The VEGF family of ligands and their receptors have emerged as central players of
blood and lymphatic vessel development and play a critical role during malignancy. The
objective of this study was to investigate and to compare side-by-side the biological effects
elicited by the different VEGF family members in vivo under physiological conditions as well
as during carcinogenesis. The here established transgenic mouselines expressing either
VEGF-B167, PlGF-1, VEGF-ED1701, VEGF-C156S or VEGF-D under the control of the same
promoter represent valuable biological models that allow such comparative analysis of
VEGFs and VEGFRs.
VEGF family members involved in lymphangiogenesis
The distinct phenotypes of transgenic mouselines expressing either VEGF-C or VEGF-
D suggest that although displaying the same receptor binding capacity for VEGFR-3 and -2,
these growth factors exert different functions. In contrast, selective activation of VEGFR-3 by
transgenic expression of VEGF-C156S results in the identical phenotype as described for
VEGF-C. The observations presented in this thesis underline the value of these mouse models
for the identification of distinct functions of VEGF-C, -C156S, and –D and may serve as
basis for future in vitro and in vivo studies of lymphangiogenesis and metastasis employing
these mouselines. For instance, cultured primary endothelial cells derived from tumor-
associated lymphatic vessels may serve to elucidate distinct molecular alterations as well as
signaling pathways induced by VEGF-C, -C156S, and –D. Also, the hypothesis of
lymphangioblast precursors that may directly contribute to the de novo formation of
lymphatic vessels can be addressed in vivo. Furthermore, a potential molecular cross-talk
between VEGFR-2 and –3 as well as its significance can be studied. Finally, these mice may
also be used to test the efficacy of anti-metastatic therapies.
VEGF family members involved in angiogenesis
In the past ten years, the critical involvement of VEGF-A in normal as well as tumor
angiogenesis has overshadowed the interest in elucidating the biological significance of the
other ligands for VEGFR-1 and –2. The generation as well as ongoing characterization of
transgenic mice expressing VEGF-B167, PlGF-1, or VEGF-ED1701 under the Rip1 promoter
may contribute to our understanding of the role of these growth factors under physiological
conditions as well as during malignancy. At present, we have identified VEGF-B167 and
PlGF-1 as a promoter and inhibitor of tumor angiogenesis, respectively. Hence, although
binding to the same receptor, these growth factors elicit opposing effects on the tumor blood
vasculature, which might be considered when designing inhibitors of angiogenesis involving
VEGFR-1. Whether VEGF-B167 and PlGF-1 act predominantly via intrinsic activation of
VEGFR-1 or whether they are only modulators of VEGF-A-mediated angiogenesis – possibly
via heterodimerization with VEGF-A - will be one of many interesting issues that can be
addressed with use of these mice. Also the ability of VEGF-B167 and PlGF-1 to recruit
VEGFR-1-positive hematopoietic stem cells, immune cells, and pericytes will be tested in the
future. The phenotypical analysis of VEGF-ED1701-expressing mice is currently underway and
will help to elucidate the specific role of VEGFR-2 signaling during tumorigenesis.
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